

American Dental Association

**ADACommons**

---

[ADA News](#)

[ADA Products and Publications](#)

---

10-2-2000

## ADA News - 10/02/2000

American Dental Association, Publishing Division

Follow this and additional works at: <https://commons.ada.org/adanews>



Part of the [Business and Corporate Communications Commons](#), [Dentistry Commons](#), and the [History of Science, Technology, and Medicine Commons](#)

---

### Recommended Citation

American Dental Association, Publishing Division, "ADA News - 10/02/2000" (2000). *ADA News*. 29.  
<https://commons.ada.org/adanews/29>

This News Article is brought to you for free and open access by the ADA Products and Publications at ADACommons. It has been accepted for inclusion in ADA News by an authorized administrator of ADACommons. For more information, please contact [commons@ada.org](mailto:commons@ada.org).

AMERICAN DENTAL ASSOCIATION  
**News**<sup>®</sup>  
**ADA**

OCTOBER 2, 2000

www.ada.org

VOLUME 31, NO. 18

**BRIEFS**

**ADA's first Webcast ready to premiere**

The ADA kicks off the 141st annual session with its first Webcast, "Get Connected to a New Smile," with a cosmetic dental procedure performed live Oct. 12 on the Internet.

Dr. Paul Landman, a general dentist, will perform the procedure from his office at the Manus Northwestern Oral Health Center in Chicago, followed by a question-and-answer session addressing patient inquiries.

ADA members are advised to encourage patients to tune in for the Webcast by visiting ADA.org from 11 a.m. to 1 p.m. (CDT) on Oct. 12. Those watching the Webcast must download



RealPlayer software or upgrade their browsers. ADA.org will provide a link for free downloads.

The original Webcast procedure and question-and-answer session will be repeated from 7-9 p.m. that same day and archived on ADA.org for the following 30 days. The Discovery Channel's Web site, "www.discovery.com", will carry the Webcast, too.

For more information, contact the ADA's Division of Communications at Ext. 2806. ■

# Data bank bill stalled

## Rep. Norwood: Opening it won't improve patient care

BY CRAIG PALMER

Washington—The House Commerce Committee convened hearings Sept. 20 on proposed legislation to give the public access to confidential disciplinary information on physicians and dentists stored in the National Practitioner Data Bank.

"This legislation is about protecting patients, not targeting doctors," said the committee chair, Rep. Thomas J. Bliley Jr., a Virginia Republican who has single-handedly in the 106th Congress pushed public access to the adverse action and malpractice payment reports on

**Patients' rights bill pushed in ads, page eight**

physicians, dentists and other practitioners stored in the data bank. "Let patients check out their doctors," he said. "Americans have a right to view

this information."

The proposed legislation, HR 5122, would make National Practitioner Data Bank information "available to the public, without charge, through the telecommunications medium known as the World Wide Web." See DATA BANK, page nine



**Welcome home, ADA:** Chicago, home to the American Dental Association, awaits this year's annual session. Must-know details about session begin on page 23.

# Delegates head to Chicago

## Renovation, new district proposed

BY KAREN FOX

Major decisions affecting the future of the ADA await the 2000 House of Delegates later this month.

As of press time, more than 60 resolutions were set for the delegates' debate in Chicago Oct. 14-18.

The resolutions up for consideration cover renovation of the ADA headquarters building to a proposed new trustee district and the dentist's right to administer anesthesia.

The proposed American Dental Association policies will be considered by 427 delegates. The following list highlights major resolutions filed

See DELEGATES, page 32



**INSIDE**



**New look**

ADA.org debuts its redesign this month. Story, page 34.

**PROFILE**

# Dr. Meskin to step down

## JADA editor to depart after next year

BY JAMES BERRY

In mid-September, staffers with The Journal of the American Dental Association received a personal letter from JADA Editor Lawrence H. Meskin.

"For 10 years, I have enjoyed working with you, the JADA crew, in producing a journal that has no equal," wrote Dr. Meskin. "Your

**Excerpts of his editorials, page 40**

success has been my success. I will miss being part of the team."

No matter that those who got the letter included a production assistant who'd been with ADA Publishing for

just two years. ("Ten years ago, I was a senior in high school," she said.) This was vintage Larry Meskin.

Small, human gestures that acknowledge the feelings and contributions of others are a trademark. It's just like him to fret over how secretaries and copy editors and relatively new production assistants would

See DR. MESKIN, page 41



**Fond farewell:** Dr. Meskin, at a podium last year, will leave the JADA editorship Dec. 31, 2001.





# ADAHF announces new publication for donors

## Learn how the foundation works

The ADA Health Foundation announces the publication of Contributor, the foundation's new biannual newsletter.

Designed to provide information to current donors about how their contributions are helping make clinical dentistry better, Contributor also aims to encourage support for the foundation's research, education and access programs.

The ADA Health Foundation, the charitable

arm of the American Dental Association, is the nation's premier non-profit organization dedicated to enhancing clinical dentistry for dentists and their patients. Grant applications are considered by its board of directors in support of research, education and access programs.

For more information or to receive a copy of contributor, contact the ADAHF by phone at 1-312-440-2547; by fax at 1-312-440-3526 or by e-mail at "adahf@ada.org". ■



(ISSN 0895-2930)

OCTOBER 2, 2000 VOLUME 31, NUMBER 18

Published semimonthly except for July and December by ADA Publishing, a division of ADA Business Enterprises, Inc. at 211 E. Chicago Ave., Chicago, Ill. 60611, 1-312-440-2500, e-mail: "ADANews@ada.org" and distributed to members of the Association as a direct benefit of membership. Statements of opinion in the ADA News are not necessarily endorsed by ADA Publishing, the American Dental Association, or any of its subsidiaries, councils, commissions or agencies. Printed in U.S.A. Periodical postage paid at Chicago and additional mailing office.

POSTMASTER: Send address changes to the American Dental Association, ADA News, 211 E. Chicago Ave., Chicago, Ill. 60611. © 2000 American Dental Association. All rights reserved.

**ADA.org**  
"www.ada.org"



When the icon at left appears with an ADA News article, turn to our counterpart on the World Wide Web—the ADA News Daily—for related news and information via ADA.org.

**PUBLISHER:** Laura A. Kosden  
**EDITOR:** Dr. Lawrence H. Meskin  
**ASSOCIATE PUBLISHER, EDITORIAL:** James H. Berry  
**ASSOCIATE PUBLISHER, MARKETING AND OPERATIONS:** Gabriela Radulescu  
**NEWS EDITOR:** Judy Jakush  
**ASSISTANT NEWS EDITOR:** Arlene Furlong  
**WASHINGTON EDITOR:** Craig Palmer  
**SENIOR EDITORS:** Clayton Luz, Karen Fox, Mark Berthold  
**EDITORIAL ASSISTANT:** Chrestine Johnson  
**CREATIVE DIRECTOR:** Peter Solarz  
**TECHNOLOGY COORDINATOR:** David Buehrens  
**PRODUCTION:** Susan Chauvet, Angie R. Miller, Sheila Cassella, Jeanie Yu  
**NATIONAL SALES MANAGER:** Bud McKeon  
**DIRECTOR OF PRODUCTION:** Elizabeth Cox  
**PRODUCTION ASSISTANT:** Katrina Collins  
**ADVERTISING SALES MANAGER:** Carol J. Krause  
**MARKETING MANAGER:** Jill Philbin  
**CIRCULATION CUSTOMER SERVICE REP:** Wanda Welch, Gwen Johnson

**ADVERTISING POLICY:** All advertising appearing in this publication must comply with official published advertising standards of the American Dental Association. The publication of an advertisement is not to be construed as an endorsement or approval by ADA Publishing, the American Dental Association, or any of its subsidiaries, councils, commissions or agencies of the product or service being offered in the advertisement unless the advertisement specifically includes an authorized statement that such approval or endorsement has been granted. A copy of the advertising standards of the American Dental Association is available upon request.

**ADVERTISING OFFICES:** 211 E. Chicago Ave., Chicago, Ill. 60611. Phone 1-312-440-2740. Eastern representative: Vince Lagana, PO Box 6, Pocono Pines, PA, 18350; phone 1-570-646-7861. Central representative: Robert J. Greco, Hilltop Executive Center, 1580 S. Milwaukee Avenue, Suite 404, Libertyville, Ill. 60048; phone 1-847-522-7560. Western representative: Audrey Jehorek, 8 Hexham, Irvine, Calif. 92612; phone 1-949-854-8022.

**SUBSCRIPTIONS:** Nonmember Subscription Department 1-312-440-2867. Rates—for members \$8 (dues allocation); for nonmembers—United States, U.S. possessions and Mexico, individual \$52; institution \$74 per year. Foreign individual, \$72; institution \$93 per year. Canada individual, \$62; institution \$84 per year. Single copy U.S. \$7, outside U.S. \$9. For all Japanese subscription orders, please contact Maruzen Co. Ltd. 3-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103 Japan. ADDRESS OTHER COMMUNICATIONS AND MANUSCRIPTS TO: ADA News Editor, Suite 2010, 211 E. Chicago Ave., Chicago, Ill. 60611.

**ADA HEADQUARTERS:** The central telephone number is 1-312-440-2500. The ADA's toll-free phone number can be found on the back of your membership card.



Look for the ADA Seal of Acceptance as your assurance that the product meets ADA guidelines for safety and effectiveness.


Taking great impressions  
isn't just black and white.



e.mix for every clinical indication!

There's more than one way to take a great impression. Many doctors choose both polyether and polyvinyl siloxane impression materials, depending on the clinical situation. Whatever material you choose, the Pentamix 2 e.mix system makes it easy to obtain homogeneous, void-free impressions with the push of a button.

- Dimension Penta polyvinyl siloxane is unmatched for the tray/syringe technique
- Impregum Penta polyether provides natural hydrophilicity and unsurpassed



**Pentamix<sup>®</sup> 2**  
The Electronic Mixing System™

©2000 ESPE America, Inc.

See us at the ADA Annual Session (booth 1631) and the Greater New York Dental Meeting (booth 411)



# AT PRESSTIME

## 'Invisalign' attracts press, public attention

You may have seen their television ads. Two sisters greet each other, apparently after a long absence. One wears full orthodontic braces. The other appears to have a Hollywood smile. "Hey, I thought we were going to do this together," says the sister with braces. "We did," says her sibling.

Turns out the sister without the brackets and wires is wearing a clear plastic tooth "aligner" from the Invisalign system, which uses "cutting-edge 3-D computer graphics technology to design and manufacture" the mouthguard-like aligners, according to the company's Web site, "www.invisalign.com".

Invisalign is the brand name of Align Technology Inc., of Sunnyvale, Calif. Founded in March 1997, the company promotes its system as "an alternative to conventional wire-and-bracket technology," which it acknowledges is "not designed to treat patients with mixed dentition and/or growing palates, and therefore is not appropriate for children."

The company says it uses its computer technology to create from 12 to 48 plastic aligners, depending on the orthodontist's judgment of patient need. Each aligner is worn for about two weeks in succession and removed only for

**■ "The company acknowledges that the Invisalign system 'is not appropriate for children.' "**

eating, brushing and flossing. Costs of Invisalign reportedly run much higher than conventional orthodontics. USA Today reported Sept. 26 that "Invisalign is expected to be 20 percent to 50 percent more expensive than traditional braces, which typically cost \$3,500 to \$5,000."

Align Technology says it has trained more than 1,000 orthodontists to use its system, which it says is being studied through clinical trials at the University of the Pacific School of Dentistry and in 26 private orthodontic practices across the country.

The company says it also is "conducting a research project with the orthodontic and engineering departments at Indiana University and will soon start a second university-based clinical study at the University of Washington."

Ronald S. Moen, executive director of the American Association of Orthodontists, said the AAO takes "no official position, pro or con," on any particular orthodontic technique. "That is a decision best left to the orthodontist in consultation with the patient," he said.

Dr. Robert Waxler, an orthodontist in Manchester, Mo., said he's been using Invisalign for about a year and has roughly 40 patients at various stages of treatment.

"It's a very good additional tool," he said of the Invisalign system. "But there are many, many problems it can't handle and never will be able to handle. It certainly doesn't replace braces." ■

—Reported by James Berry


**All ears:** The American Association of Endodontists convened a meeting July 26 of its dental specialty group task force at ADA headquarters. The AAE invited the ADA Council on Government Affairs, the ADA Health Foundation and ADA Council on Dental Education and Licensure to listen in as AAE board members discussed issues related to faculty recruitment and retention.



# Why Not Do More Porcelain Restorations?

Use stronger Rembrandt® Cerinate® Porcelain.

Patients are more receptive if you don't cut their teeth.



1, 2, Research available.

**"Rembrandt Cerinate Porcelain Laminates have taken my office by storm. They are unbreakable and guarantee 100% Patient Satisfaction."**

## No Tooth Preparation! No

\*Of Course Rembrandt Cerinate Porcelains can also



No Preparation on #8, Minimal Preparation on #9 and Crown Preparation on #10. All beautiful with

Call (800) 445-0345 for more information or visit us at

**DenMat**  
ISO 9001 CERTIFIED  
©2000 Den-Mat Corp. 801126710-A 9/00 ADA  
U.S. Patent 5,009,709. Others Pending.

**Den-Mat.com**

Order a complimentary technique tape (Multiple Laminates Placement), or



# VIEWPOINT

Snapshots OF AMERICAN DENTISTRY

LAURA A. KOSDEN, *Publisher*

DR. LAWRENCE H. MESKIN, *Editor*

JAMES H. BERRY, *Associate Publisher,*  
*Editorial*

JUDY JAKUSH, *ADA News*  
*Editor*

## MYVIEW

# Reunited: oral health and the body

It was quite an achievement—as monumental as getting a male patient to become a regular flosser. After 10 years and three billion dollars, the Human Genome Project recently announced success in solving the human genetic code. Enthusiastic observers can see prevention and even cure of inherited diseases just around the corner. They see us repairing or regenerating our own failed body parts.

Dentistry has long been a profession that readily adopts technological advances. For example, X-rays had been discovered only six months before the first dental radiograph was taken. Putting knowledge of the human genetic code to work will provide our patients with more ways to maintain or restore good oral health. Already scientists have grown a tooth on the adrenal gland of a rat. This experiment may lack clinical applications now, but it lets us imagine what the future may hold for our profession and patients.



Richard J. Mielke, D.M.D.

Knowing where to find a gene on the twisting strands of our DNA is not the same as understanding how our genes work together. Although there are genes that control the development of our dentition and supporting structures, no one has pointed to a DNA strand and identified it as the “dental section.” The long-standing artificial division in health care between the oral cavity and the rest of the body may finally be swept away. Health care could become much more integrated in the future. Medicine and dentistry are destined

to become cross-linked, like the strands of DNA.

The move in this direction began before the completion of the genome mapping. The effects of systemic disease upon dental health has long been appreciated by our profession. Recently the reverse has been shown to be true as well, when periodontal disease was postulated as a causative factor in heart disease, diabetes and other conditions. Ongoing research continues to explore this relationship. In a study just completed at Oregon Health Sciences University, for example, diabetics who went on a rigid oral hygiene program reduced their blood sugar levels.

With the integration of health care knowledge, vigilance by our profession is essential. As the oral cavity becomes reunited with the rest of the body, dental practice and dental education may change. The challenge for dentistry is to maintain and strengthen its identity as the profession with the most expertise in the oral cavity. We do not want to become simply the cleaning and repair people of the mouth, even if we can also provide winning smiles.


Even as we watch for new information on disease inter-relationships and

See MY VIEW, page five

## Dental income

A relationship may exist between dentists' net income and preferred provider organization or capitation plan involvement. Dentists with the highest net income reported the lowest level of involvement with such plans.

Percentage of private practitioners who reported participating in PPO or capitation dental plans by net income



Source: American Dental Association, Survey Center, 1998 Survey of Capitation and Preferred Provider Dental Plans  
(Data should not be assumed to be statistically significant)

## LETTERS

### Credentialing

I had browsed the article in the Aug. 7 ADA News titled, “Credentials Verification Surveys,” and it sparked curiosity about credentialing services.

Earlier this year I had signed on with a dental plan. About two months after receiving plan approval, I got a letter from a credential firm hired by health care organizations to re-verify licensure and blah, blah, blah. The letter states, “Regulatory guidelines require a periodic credentialing process. All documents must be collected and verified within a limited time frame. Any delays could force us to ask you for the same information again.” Which regulatory guidelines? What period? What time frame? And what about this alleged use of “force”? Gosh, I hope I have not “forced” them to do anything. I was not aware I had these hidden powers of “force.”

Then there is the letter from another company that states, “Information about your practice and credentials is available to the public on the Internet. In some cases this information may be derogatory to reflect consumer complaints or state board actions. Your reputation is valuable and we encour-

age you to take a few minutes to check your record for accuracy and completeness.”

I’m not sure who these people are, but I’m glad I have their encouragement, and I commend them on their usage of the words “some” and “may.”

As a practicing dentist, I am accredited by the state board, my accredita-

### British anesthesiology

As one who is both a dentist anesthesiologist and an oral and maxillofacial surgeon, I have completed thousands of cases as an anesthesiologist and also as a single operator anesthesiologist.

I have viewed with great interest the machinations of various factions within the ADA over the past several years with regard to questions about the proper place of anesthesia in dentistry.

Historically, since the time of Horace Wells, dentists have enjoyed cutting-edge positions from the seminal development

of the science to being in the vanguard of those perfecting outpatient anesthesia techniques currently employed in most areas of the country for surgical procedures of all types.

As evidenced by the article in the Sept. 4 ADA News (England to Prohibit General Anesthesia Use in Dental Offices”), it is ironic that dentists, who have an unsurpassed safety record, be they dentist anesthesiologists or oral and maxillofacial surgeons, relative to any other type of provider in any setting, are in very real

See LETTERS, page five

### LETTERS POLICY

ADA News reserves the right to edit all communications and requires that all letters be signed. The views expressed are those of the letter writer and do not necessarily reflect the opinions or official policies of the Association or its subsidiaries. ADA readers are invited to contribute their views on topics of interest in dentistry. Brevity is appreciated. For those wishing to fax their letters, the number is 1-312-440-3538; email to “ADANews@ada.org”.



tion credentials are then credentialized by accreditation credentializing organizations that are accredited by another organization. SOME people MIGHT think that interpreting credentials is a tedious and complex process, much akin to nuclear physics. Others MAY feel that organizations associated with credential verification have created yet another business niche providing a useless service at the expense of everyone else.

May the “force” be with you.

Patrick R. Cone, D.D.S.  
Corpus Christi, Texas



# LETTERS

*Continued from page four*

danger of legislatively losing pain relief options, that is, general anesthesia, they have enjoyed for over 150 years.

The loss of office anesthesia will not be because of any relative danger in the provision of anesthesia services by dentists, but because of the politics of numbers (dentists anesthesiologists and OMS provider numbers are dwarfed by the M.D./D.O./C.R.N.A. provider numbers).

The second reason dentistry will lose office anesthesia is because of the in-fighting prevalent between various ADA factions. The defeats of anesthesiology as a specialty within dentistry were short sighted and will be seen to be Pyrrhic victories in the near future.

The ADA will soon begin to understand that any imagined detriment stemming from approval of the specialty would have been inconsequential compared to the loss of office anesthesia from the real foes, uninformed or opportunistic legislators and competing anesthesia providers outside the dental ranks.

It is obvious that the incorporation of anesthesiology as a specialty of dentistry is long overdue and would have done much more to preserve our rich heritage in anesthesiology than any other vacuous solution proffered, including the three resolutions going before the House of Delegates this year.

Finally, it is indeed tragic that in the future our patients will have severely limited access to anything more than traditional local anesthesia in the office setting. Those who need or want more than local anesthesia will have to pay significantly higher fees for services in a less optimal environment, if they can be shoehorned into already overcrowded operating rooms at all.

Perhaps it's not too late to preserve our anesthesia heritage and provide services our patients want and deserve. Does the ADA even care?

Daniel L. Orr II, D.D.S., Ph.D., J.D.  
Anesthesia coordinator  
Nevada Society of Oral  
and Maxillofacial Surgeons  
Clinical professor of surgery  
University of Nevada Medical School

# MYVIEW

*Continued from page four*

genetic information to come forth in the future, the genome mapping may begin to have unanticipated results. Health insurers may want to run a genetic analysis on applicants for insurance. Rates for coverage may vary from one person to another like airline ticket prices today. Some really bad genotypes may be denied coverage altogether.

In addition, after preaching responsibility for one's own health maintenance, we may see a regression in response, as people begin to take a fatalistic view of their future health, based on their genes. Anticipating this reaction, the prestigious New England Journal of Medicine included an article in its July 13 issue warning that lifestyle still has a great effect on health, despite all the hoopla about genetic determinants.

It would be ironic if dentistry's great success in reducing the incidence of dental disease by making people participants in their own health maintenance were stalled by a development holding such promise for further prevention benefits. We may never get those men to floss.

Dr. Mielke is editor of the WSDA News, the publication of the Washington State Dental Association. His comments, reprinted here with permission, originally appeared in the August issue of the WSDA News.

**Editor's note:** The 1999 House of Delegates rejected a resolution proposing specialty status for dental anesthesiology.

## Wake-up call?

The article regarding British general anesthesia regulation changes should serve as a wake-up call to the profession. Though this scenario may be unlikely in the United States, we should be concerned. It has always been the contention of our medical colleagues that the administration of general anesthesia is the practice of medicine. With this in mind and after reading the complete report on the Web site given, I felt a few important issues had been overlooked.

It wasn't clear in the ADA News article that physician specialists were responsible for all

three recent pediatric anesthesia-related deaths and that most general anesthetics in British dental offices after release of the 1990 Poswillo Report were administered by physician specialists. These latest three pediatric deaths occurred in the hospital (one patient) and office venues (two patients). All three tragedies were deemed preventable for a variety of reasons. The recent July 2000 British Department of Health report indicated physician training programs had placed a "low priority" on "the training of specialists in general anaesthesia for dental treatment." As a remedy, the report suggested "that all anaesthetists in training ... must be able to demonstrate that they have devoted an appropriate part of their professional training to cases involving dental treatment and ... should be able to resolve any problems associated with sharing a patient's

airway with a dentist." To ensure the adequacy of qualified physician anesthetists to meet future "demand" for general anesthesia for dental procedures, the report included the following recommendation: "There is a need to monitor and ensure the future provision of anaesthetists with adequate training and experience of general anaesthesia for dental treatment."

Shouldn't organized dentistry in the United States develop educational opportunities to ensure proficiency training in the administration of general anesthesia by dentists, not just our oral and maxillofacial surgeon colleagues?

Additionally, the July 2000 British report's Executive Summary includes the following important conclusions:

See LETTERS, page six

# Captek®

*World's most experienced Captek lab*

- 151,319 Captek based PFM units fabricated thru July 2000
- Captek bridges are Laser welded to ensure passive seating & precision fit
- 7-year guarantee against breakage provides you & your patients with complete confidence

**\$109**  
per unit with  
"IPS d.SIGN®"  
Glass Ceramic

**FREE Laminated  
Chairside Guide**

**"Due to its beautiful esthetics and strength, Captek is my restoration of choice when a metallic based porcelain restoration is needed."**

*Dr. Jorge Pinero  
Private Practice/Fracine, WI  
Lecturer, The Midwest Institute of Laser and Esthetic Dentistry*

**"... (Captek) also demonstrated anti-microbial effects in the neighboring tissues as a result of the bacteriostatic surface energy."**

*Dr. Robert Zena  
Assoc. Professor, Postgraduate Programs  
University of Louisville Dental School*

**"Excellent esthetics, possibly even superior to all-ceramic crowns."**

*Dr. Alvin Filastre, Lakeland, FL*

IPS d.SIGN, a glass ceramic, is fused to Captek copings, which are high noble with 88.2% Au, 9% Pt group metals and 2.8% Ag.

**Call for Free PFM Guide**  
**800.922.7835**  
Video lab tour at [www.glidewell-lab.com](http://www.glidewell-lab.com)

**GLIDEWELL LABORATORIES**  
Serving Dentistry Since 1970

See us at the ADA Annual Session, Booth # 1903



## LETTERS

*Continued from page five*

● Despite a large number of expert reports that have been aimed at improving such standards, it seems that patients are still vulnerable to unexpected death or non-fatal complications occurring outside hospital in circumstances that seem to be avoidable.

● It is unlikely that further attempts to refine general anaesthesia in dental practice outside hospitals through guidance, inspection and enforcement will provide sufficient assurance.

Clearly, our British medical and dental colleagues have realized that standards of care for the administration of general anesthesia cannot be mandated or legislated for the dental profes-

sion. This applies to state regulation of sedation and general anesthesia in the United States as well. Unfortunately, the British solution was extreme and will negatively impact patient access to dental care. Little, if any, consideration was given to improving postdoctoral general anesthesia training within dentistry.

The best way to raise the standards of care in general anesthesia for dentistry is through improved postdoctoral education. This is true of any health care discipline. This is best achieved with development of Standards for Advanced Education in General Anesthesia to improve clinical and didactic training through an accreditation process.

Unfortunately, the Commission on Dental Accreditation's accreditation process is linked to specialty recognition. Shouldn't organized dentistry in the United States take a more proactive

approach to improving postdoctoral education in general anesthesia for all dentists? Wouldn't accreditation (even if it takes specialty recognition) do more to improve standards of care and provide academicians for future predoctoral and postdoctoral education in sedation and general anesthesia? In my view, there seems to be something vital missing from organized dentistry's plans to improve standards of care in deep sedation/general anesthesia and improve access to care for a large subset of patients.

*James W. Chancellor, D.D.S.*

*Past president,*

*American Society of*

*Dentist Anesthesiologists*

**Editor's note:** The ADA Guidelines for Teaching the Comprehensive Control of Anxiety and Pain in Dentistry (Part Two) are intended to

provide direction for "education programs in anxiety and pain control offered at the advanced level (graduate or postgraduate)." Association policy supports the right of dentists who are appropriately trained to use conscious sedation, deep sedation and general anesthesia, and is committed to ensuring their safe and effective use.

### The struggle continues

Let me preface this by saying that I realize the organization wouldn't dare print this, but here goes:

Anesthesia—the struggle continues; It came as no surprise to me when I read of the infighting within American Academy of Oral and Maxillofacial Surgeons regarding their own double-degreed (M.D., D.D.S.) people. Mind you, this is the same organization that stands to block the doorway of anesthesiology becoming a specialty within dentistry.

It has been stated many times before that a prime reason that so much of the population refuses to seek dental care is their perception of fear associated with routine dental treatment. The answer to this dilemma is and has been at hand for many years: adequate training in advanced pain control.

As a dentist anesthesiologist, many of the patients I treat are those who have been traumatized at one time or another by someone attempting to treat them by conventional means.

Also, many practitioners often query me about how they can receive training in intravenous sedation or general anesthesia techniques.

Sadly, I have to tell them that the training they desire is virtually non-existent. That the avenue to bring more patients into the fold is closed largely because of the efforts of "our own" special interest group who desire to keep this skill in their own vest pocket. A prime example of dentistry again shooting itself in the foot.

And we wonder aloud at the media frenzy over TV shows like "20/20" and "60 Minutes" regarding issues like mortality (read as death) in the dental office.

We have lost and are rapidly losing the capability of being responsible for our own training in anesthesiology because oral surgeons want to ensure that they are the only dentists capable of performing this modality.

So to conclude, I'm not surprised that they are fighting within themselves over the issue of the double-degree. They have also fought other things that would definitely be of benefit to dentistry and the public at large.

*Albert R. Conley, D.D.S.*

*Takoma Park, Md.*

## UIC dental school to offer tours during session

The University of Illinois at Chicago College of Dentistry will host a gallery reception and tour of the college Oct. 15, coinciding with the ADA 141st annual session.

The college tour and open house reception of the Kottemann Gallery of Dentistry is scheduled from 5-6:30 p.m.

Shuttle buses will depart McCormick Place, site of the ADA annual session, between 4:30-5 p.m. and return to ADA session hotels between 6-6:30 p.m.

Parking will be available for those who wish to drive.

For more information, contact Bill Bike at 1-312-996-8495; by e-mail "billbike@uic.edu". ■

# Opalescence<sup>®</sup> 10%

The first ADA Accepted,  
syringe delivered, tooth whiten-

**Whitens**  
in 10 days or less

**Patented**  
bleaching  
systems

**Dentis**  
dispensed



Patented, comfortable  
custom tray, sustained  
release, sticky viscous  
gel.



© Copyright 2000 Ultradent Products, Inc. All Rights Reserved.U.S.  
Patent Nos: 5,098,303; 5,234,342;5,376,006; 5,409,631;  
5,725,843; 5,746,598; 5,759,037; 5,759,038; 5,770,105 and  
5,770,182. European Patent No. 0522087.Other U.S. Patents Pending  
and International Patents Granted and Pending.

**Opalescence<sup>®</sup>**  
tooth whitening sys-

**For your free sample or more info call 800.496.8334**



## Government

# Health care groups tell Congress

## It's time to "get serious and pass a real patients' bill of rights"

BY CRAIG PALMER

Washington—Physicians, dentists and other health care and patient groups urge the U.S. Senate in new television ads "to get serious and

pass a real patients' bill of rights" before Congress adjourns.

Advertisements began airing Sept. 14 in selected states with appeals to viewers of popu-

lar TV news and talk shows to lean on senators running for re-election to vote for patients' rights legislation before Congress adjourns next month for the fall elections.

Legislation—which is supported by the American Dental Association, American Medical Association and more than 60 health care and patient groups—is stalled as Congress heads into its final weeks of business.

"U.S. Senate: Time is now for patients rights," says the TV ad unveiled at a Sept. 13 AMA news conference. "Call your senator," the ad urges viewers as a toll-free "800" number appears on the screen.

The new ad campaign is supported by the AMA and a 67-organization Patient Access Coalition, whose members include the American Dental Association. The ads will appear initially in Michigan, Missouri, Pennsylvania, Delaware, Washington state and the Washington, D.C., metropolitan area.

"We are within one vote of victory in the Senate," said AMA Board Chairman D. Ted Lewers, M.D. "Time is running short and the Senate needs to put patients first and give them the protections they need and deserve. Today's ad is aimed at securing at least one extra vote. We'll keep the pressure up even into this election. It will be an election issue."

The American Dental Association separately pressed the Senate, in letters to each senator, to

## Come home from the Convention with a "wealth" of knowledge...

### and a great plan for your future!



It will be *worth your while* to stop by the ADA Members Retirement Program Booth #4706, for two reasons:

First of all, we'll give you *Feathering Your Nest: The Retirement Planner* — absolutely FREE! This indispensable book offers 461 pages of tips on preparing for a financially secure retirement. And it's yours, with our compliments — as a reminder that planning for your future is essential.

Which brings us to the *other* great reason to stop by our booth, for FREE information on the ADA Members Retirement Program, offered by The Equitable Life Assurance Society of the United States and established by the American Dental Association. You'll learn how you can custom-tailor a retirement plan to your specific needs — with eleven investment options, automatic tax compliance, toll-free professional assistance and account balance information.

**So stop by our booth, and walk away with a wealth of knowledge.**



**YOURS FREE...  
Just for stopping  
by our booth!  
(#4706)**

### Free Convention Seminar

You are cordially invited to attend our free seminar, "Maximize Your Future... Invest for the Long Term" on Sunday, October 15th, 9:00 a.m. – 11:30 a.m., at the Convention.

**For more information call toll-free  
1-800-523-1125, ext. 7255**

### Yes! TELL ME MORE!

I'm unable to stop at your booth or attend your seminar, but I'd still like FREE information on the ADA Members Retirement Program.

Name \_\_\_\_\_

Practice Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Practice Telephone (\_\_\_\_) \_\_\_\_\_

Number of Employees \_\_\_\_\_

Mail To: The ADA Members Retirement Program  
Information Distribution Center  
P.O. Box 2011  
Secaucus, NJ 07096-9807

ADAD7255

**■ "Dental patients deserve the same recourse as medical patients when a plan improperly denies a claim, regardless of whether the denial occurs before or after the patient receives treatment," said the ADA.**

cover freestanding dental plans in patient rights legislation. "Dental patients deserve the same recourse as medical patients when a plan improperly denies a claim, regardless of whether the denial occurs before or after the patient receives treatment," said Sept. 7 letters signed by ADA President Richard F. Mascola and Executive Director John S. Zapp.

"The patient bill of rights would eliminate the confusing patchwork of state rules, providing medical patients with the same baseline of protections against managed care abuses, regardless of where they live," the ADA officials said. "Dental patients should receive no less."

House-Senate negotiations on a compromise bill are stalled and the clock is running out on the 106th Congress, which is aiming for an Oct. 6 adjournment.

The chief sponsors of bipartisan legislation passed overwhelmingly by the House of Representatives last year say they have revised their measure to address the concerns of Senate members who oppose or support narrower patient rights legislation. But a draft of the compromise legislation came under immediate fire from business groups opposed to patient rights legislation. ■



## Government

### Data bank

*Continued from page one*  
Wide Web of the Internet.”

Rep. Bliley has announced his retirement, and his bill is unlikely to move in the few remaining weeks of the 106th Congress. The very idea of opening the data bank to public scrutiny prompted bipartisan protest from Commerce Committee members and health provider organizations.

The American Dental Association, American Medical Association and American Hospital Association are among organizations opposing public access to the data bank.

“Simply opening the National Practitioner Data Bank is a bad idea that will do nothing to improve patient care,” said dentist/Rep. Charlie Norwood (R-Ga.).

Physician/Rep. Tom Coburn (R-Okla.), who is also retiring from Congress, said, “Patients ought to be choosing their doctors on the basis of recommendations by other patients and no other way.”

However, the bill picked up the support of patients, consumer and employer groups who argued passionately for “lifting the veil” on data bank files. The National Association of Manufacturers said it “strongly supports” passage of legislation, if not in the current Congress, the next.

“The chairman’s bill seeks to give consumers a powerful tool with which to evaluate individual physicians by providing access to the National Practitioner Data Bank, a taxpayer-funded entity,” said Patrick Cleary, NAM vice president for human resources policy.

The Clinton administration, which manages the data bank, took a neutral stance on the bill, offering to “work with Congress on any legislative proposal that

improves the data bank” and recommending continuation of the bank’s authority to collect fees for providing information. The administration witness, Thomas Croft of the Health Resources and Services Administration, said the bank is financed not by taxpayers but by user fees.

But even among congressional opponents, including some who charged that the legislation was politically motivated—a charge Rep. Bliley rejected—there were acknowledged seeds of “consensus” and “common ground” toward giving the public more information about sanctions taken against health practitioners, perhaps with legislation in the next Congress.

“I believe there is consensus for getting better information out to the public,” said Republican Rep. Greg Ganske, an Iowa

physician who opposes public access to the practitioner data bank.

“I have no problem with state boards of licensure information being gathered and made available.” Several committee members said there might be “common ground” on legislation giving the public access to data bank files that are peer-reviewed before release.

Other committee members said it was appropriate and necessary to raise questions about the data bank and public access.

“This bill may or may not be the solution to a problem but it is certainly a start,” said Rep. Ed Bryant (R-Tenn.).

“It is most appropriate to consider this legislation,” added Rep. Bill Luther (D-Minn.). ■

### Dental coverage expanded for military retirees

BY CRAIG PALMER

*Sacramento, Calif.*—Expanded dental coverage for an estimated 4.2 million eligible military retirees and family members takes effect Oct. 1, the contractor, Delta Dental Plan of California, and military officials announced jointly.

“This is a dramatic benefit expansion that responds directly to input received from Uniformed Services retirees on what dental benefits they want and are willing to pay for,” said Navy Capt. Lawrence McKinley, Tricare Management Activity senior consultant for dentistry.

Enrollment in the expanded Tricare Retiree Dental Program began Sept. 1. The plan is voluntary and funded by enrollee premiums without government subsidy.

The new plan covers all basic benefits currently offered plus coverage for cast crowns, onlays, bridges, partials/dentures, orthodontics, dental accidents, certain diagnostic and preventive services and an allowance toward tooth-colored fillings in the back teeth, a non-covered procedure called posterior composites, said an announcement that was posted at “www.ddpdelta.org”.

Current enrollees will be given a choice of upgrading to the new coverage or remaining in the basic plan on a month-to-month basis after completing their initial 24-month enrollment period.

Delta said it will continue to administer the basic plan, which covers some 525,000 retirees and family members, but will no longer accept new enrollees.

Congress authorized military retiree coverage in 1997 legislation and since then has extended eligibility to Public Health Service and National Oceanic and Atmospheric Administration retirees, surviving spouses and dependents of deceased active duty members and dependents of certain military retirees who do not themselves enroll for coverage. ■

## Expect less from your patients.



### Better plaque removal at home

#### Cleans like no other brush in the world.

The Braun Oral-B 3D is the only power toothbrush that combines two distinct brushing motions: gentle in-and-out pulsations to loosen plaque from deep

between the teeth and below the gum-line, and side-to-side oscillations to sweep it away.



#### The better way to better results.

In a long-term practice-based study involving more than 16,000 patients, participating dentists reported that more than 80% of patients using a Braun Oral-B Plaque Remover\* had noticeable improvement in oral health.<sup>1</sup>

#### The right recommendation.

No other toothbrush in the world cleans like the Braun Oral-B 3D, which is why there’s no better brushing method to recommend to your patients. The Braun



# BRAUN

## Oral-B®

For more information, or to order yours at a professional trial price, please call 1-800-765-2959 or write Oral-B Laboratories, Dept. P, 600 Clipper Drive, Suite 200, Belmont, California 94002. Visit our web sites at [www.braun.com](http://www.braun.com) and [www.oralb.com](http://www.oralb.com). In Canada, please call 1-800-268-5217.

\*Braun Oral-B Ultra.

References: 1. Warren ER, et al. JADA 2000;131:389-394.



# Coverage and cost

## Health care reform weighs heavy with voters

BY CRAIG PALMER

Washington—Health reform remains “a very important issue” for Congress and this year’s presidential election with coverage and cost the two issues Americans most want addressed, said a study of health policy attitudes reported Aug. 30.

Health care is one of the issues the public most wants to know about when candidates articulate their positions, said the non-partisan Center on Policy Attitudes.

The study, including a nationwide poll, a

review of other health policy polls and feedback from Richmond, Va., and Cleveland, Ohio, focus groups, is posted at “www.policyattitudes.org”.

Education was seen as the most important issue in the upcoming elections with health care a “very close” second followed by social security and foreign policy and defense.

The COPA study finds “strong public support” for both a patient bill of rights and a government mandate requiring employers to provide health insurance for their employees.

“Health insurance for children may be the public’s single most important priority for health care reform.” Patient rights and children’s insurance legislation is pending in Congress but employer mandates have not been on the legislative front-burner in recent Congresses.

Each time the question of children’s coverage comes up in public opinion polls, an overwhelming majority, more than 80 percent, favors the general idea of the federal government providing health insurance for uninsured children.

“First, the backbone of health care coverage

would be a government requirement that all employers provide health insurance to their employees,” the COPA concluded.

“Beyond that, majorities seem ready to have the government directly provide insurance to limited and specific vulnerable populations including the unemployed, children, those approaching retirement age and those with low incomes.”

The other big public concern, according to the study, is the question of health care costs. A strong majority believes health costs are rising.

“In most cases, this concern is not derived from unhappiness with the level of their current health care costs but uneasiness that at some point in the future they will have trouble meeting rising costs,” the study said.

But Americans “are more conflicted about how to deal with costs,” the COPA reported.

“The consensus in the early to mid-1990s in favor of managed care as a way to control costs has broken down. Clearly, many Americans feel that through managed care the health care industry has diminished the quality of care and imposed limits on Americans’ access. It is diffi-

■ **“Clearly, many Americans feel that through managed care the health care industry has diminished the quality of care and imposed limits on Americans’ access,” the Center on Policy Attitudes reported.**

cult for Americans to accept any such limits.”

Furthermore, the public does not see the limits imposed by managed care as significantly reducing health care costs, the study concluded.

“If anything, Americans seem prone to try to regain some of the ground they feel they have given up in the movement to managed care. Thus there is strong support for a patients’ bill of rights.”

The Washington-based COPA is an independent non-profit organization of social science researchers created to give greater voice to the American public and to promote a better understanding of public attitudes.

The study was supported with grants from the Benton, Rockefeller and Tides foundations. ■

**Examine This...**

**ONLY TRIDENT ADVANTAGE™ and TRIDENT® For Kids deliver the remineralization benefits of RECALDENT™\***

In-situ clinical studies demonstrated significant remineralization for subjects chewing sugarless gum with RECALDENT™

**before treatment**

Actual microdiagram from a clinical study showing a demineralized subsurface area which has lost calcium and phosphate. Normally when combined, calcium and phosphate form insoluble crystals which cannot penetrate tooth enamel.

**after RECALDENT™**

When chewed regularly, sugarless gum with RECALDENT™ can replenish up to 4 times more calcium in tooth enamel compared to not chewing at all.

RECALDENT™ is a milk derived lactose-free ingredient, maintains calcium and phosphate in an amorphous, penetrable state, allowing for subsurface remineralization.

RECALDENT™ is a trademark of Amstar Foods Limited.

**FREE SAMPLES** of TRIDENT ADVANTAGE™ and TRIDENT® For Kids for your office! 1-800-TRI-0013

From TRIDENT®, the makers of the #1 Dentist recommended gum. Questions or comments? Call 1-800-524-2854. Visit our Web site at [www.tridentgum.com](http://www.tridentgum.com)

WARNER-LAMBERT ADAMS

## Williams lecture scheduled at Baylor

Dallas—Dr. David E. Frost is the Baylor College of Dentistry’s guest lecturer for the 3rd Annual Dr. P. Earle Williams Lectureship in Oral and Maxillofacial Surgery.

The lecture is slated for Jan. 20, 2001.

Dr. Frost—a clinical associate professor at the University of North Carolina and Case Western Reserve University—will speak on:

- “Oral and Maxillofacial Surgery in the Developing World: What You Have to Teach and What You Will Learn”;

- “Arthrocentesis: Clinically Effective Management of Pain and Mobility Problems.”

The lecture is presented in memory of Dr. Williams, a 1926 BCD alumnus and past president of the American Association of Oral and Maxillofacial Surgeons.

Tuition is free; voluntary contributions are accepted. For more information, call 1-214-828-8981. ■



# Social Security to review dental resident coverage

BY CRAIG PALMER

Washington—The Social Security Administration may seek “legislative intervention” to assure that 270,000 medical and dental residents pay Social Security taxes, SSA Commissioner Kenneth S. Apfel told Congress.

“We are exploring legislation amending the Social Security Act to clarify that medical residents are covered for Social Security purposes,” Mr. Apfel said in an Aug. 22 letter to the U.S. General Accounting Office, Congress’ auditing agency.

“We estimate that without legislative intervention, 270,000 medical residents who otherwise would be covered will lose some Social Security coverage over the next 10 years,” he wrote. A Social Security Administration spokeswoman said the estimate includes 15,501 dental residents.

“We believe that treating medical and dental residents as students will have adverse consequences for those residents, leading to the loss of Social Security earnings credits and the benefits that derive from these credits,” the Social Security chief told Congress.

“Moreover, this loss of coverage will result in a significant loss of revenues to the Old Age, Survivors and Disability Insurance trust funds, \$3.9 billion over 10 years” and could have a deleterious effect on the long-range solvency of the OASDI program, Mr. Apfel told Congress.

The GAO, investigating the impact of a 1998 court ruling for the House Ways and Means Committee, attached the Social Security letter and a statement from IRS Commissioner Charles O. Rossotti to its Aug. 31 report to Congress posted at the GAO Web site.

“You asked us to provide information about how IRS and SSA are proceeding since the court decision and what decisions IRS has made about refunding taxes for Social Security paid by medical residents and their employers and the effect of those decisions on the Social Security Trust Funds,” congressional auditors said in their report to Rep. E. Clay Shaw Jr. (R-Fla.) who chairs the Ways and Means social security subcommittee.

A federal court ruled that the University of Minnesota was not liable for Social Security contributions for wages paid to certain residents as part of their training in accredited residency programs, often at teaching hospitals. The ruling in part said some residents met certain criteria to be considered “students” and qualified for an exception from Social Security taxes under the Federal Insurance Contributions Act.

Some tax consultants have since advised clients that residents might qualify for a student exception, and some residents and employers are submitting claims to the IRS for refunds, the GAO said.

The IRS is treating refund applications “on a case by case basis,” which puts Social Security and the tax collectors at odds, the GAO told Congress. Social Security officials take the view that making decisions on a case by case basis “raises a question of fairness” for resi-

dents not affiliated with a school or university and unable to qualify as students, said the GAO report. The IRS has primary responsibility for determining FICA liability, collecting social security taxes and issuing refunds. The SSA maintains records on individual workers’ reported wages subject to FICA taxes and disburses benefits based on reported wages.

No federal law provides that residents are uniformly subject to or exempt from paying the FICA tax, the GAO reported. “However, federal law contains provisions under which medical residents could potentially be exempt,” the agency said.

The GAO is a congressional agency charged with auditing government programs to determine if public money is being spent efficiently and legislation implemented as Congress intended. ■

## Stabident SYSTEM

Intraosseous Anesthesia for the New Century



**Anesthetizing the attached gingiva**

Bevel of injection-needle is slid beneath the surface of the attached gingiva at a point mid-way between two adjacent teeth and about 2 mm. apical to the gingival margin. Blanched area appears after one or two drops of anesthetic have been injected



**Perforating the cortical bone**

The perforator is a solid 27G needle with a sharp beveled end. It is mounted in a latching-type contra-angle handpiece and held perpendicularly to the cortical plate. Within 2 secs. of drilling time there will be a feeling of “give” or “breakthrough” in passing from the hard cortical to the softer cancellous bone.



**Injecting the anesthetic**

The 27G injection-needle (“modified” or “regular”) is used. A surgical suction tip can be employed to reduce to tiny size the blood spot appearing on the gingiva or alternatively use GENTIAN-VIOLET DYE (see Tips Section on our website). Not more than one carpule of anesthetic with or without epinephrine should be used per patient per visit. Inject slowly and gently.

Whenever a block injection does not provide adequate anesthesia, **IT’S TIME TO TURN TO THE STABIDENT INTRAOSSEOUS SYSTEM – Complete and profound anesthesia is then assured!**

**The “MODIFIED” injection-needle rides into the drilled hole with special ease.**

Because in the “modified” injection-needle the sharp tip on the bevel has been smoothed away, a dif-



“Modified”

After gaining experience in using Stabident as a supplement to block injections, you may choose to use it on its own, as the primary anesthesia system. Deep anesthesia in less than 30 seconds after injecting!

**The “Regular” needle** is beveled to a sharp point, can be used both for the initial localized anesthetizing of the attached gingiva and for the final



“Regular” Needle

Standard Kit - 20 perforators, 20 needles (with “modified” or “regular” injection-needles).....	<b>\$27.00</b>
Economy Kit - 100 perforators, 100 needles (with “modified” or “regular” injection-needles).....	<b>\$104.75</b>

### Fairfax Dental

To place an order, please call  
**1-800-233-2305**

e-mail your order to  
**fairfax@stabident.com**

or write to: Fairfax Dental Inc.  
2601 S. Bayshore Drive, Suite 875,  
Miami, FL 33133.

VISIT OUR CONSTANTLY UPDATED WEBSITE [WWW.STABIDENT.COM](http://WWW.STABIDENT.COM)

USA Pat. Nos. 5057013 and 5173050. — EUROP. Pat. No. 292252.

FFD10-ADA0009-1



## President-elect Interview

# One man's viewpoint

## Dr. Anderton cites goals for the year

This is the second and final installment of a two-part interview with Dr. Robert M. Anderton, president-elect of the American Dental Association. The first segment appeared in the Sept. 18 ADA News. Dr. Anderton was inter-

viewed in August by ADA News Editor Judy Jakush about his objectives for the coming year. Dr. Anderton will be installed as the 137th president of the Association during ceremonies in Chicago Oct. 18 during annual session.

**ADA News:** What is the future of dentists' autonomy? Will private practice fee-for-service dentistry continue as the majority model; will it be



**Dr. Anderton:** The Surgeon General's Report on Oral Health 'was very favorable to dentistry overall.'

replaced by managed care models; or will it develop into a hybrid? And, ultimately, what will or should the Association's role in this be?

**Dr. Anderton:** The future of dentists' autonomy is very, very good. What a lot of these companies have found is that dentistry doesn't fit into the same mold that medicine does. I think we're being treated differently and I hope we can continue in that process. I think fee for service will continue to be the majority model.

There will be a greater mix of reimbursement models, but I see the preferred provider organizer having more impact than the capitation model. Dentistry is not a good fit with the capitation model.

Ultimately, the Association's role in this is to keep our members informed of what's going on. It will always be a member's individual choice as to whether he or she wants to participate in a particular type of plan. The ADA has to represent all its members—whether they participate in fee for service only or in managed care such as PPOs, health maintenance organizations or anything else. The ADA, in order to serve our members and the public, has to remain neutral. Our role is to inform the public and our members of the various aspects of these reimbursement models. I think we do a good job at that.

**ADA News:** The Association is doing more and more to reach members through technology like the Internet and to provide access to e-commerce solutions. What is viable for the ADA to offer?

**Dr. Anderton:** The ADA soon will be offering continuing education on the Internet, which is really one of the things we can do best. We've put an incredible amount of information on our Web site and there is more involving interactions to come. It's an exciting tool. Members will see significant benefits from the improvement in services.

Part of our electronic communications services include processing insurance claims electronically through the endorsement of WebMD/Envoy and Trojan by ADA Business Enterprises, Inc.—our for-profit subsidiary.


The latest development is the government's adoption of the ADA's CDT—Current Dental Terminology, the Code on Dental Procedures and Nomenclature—as the basis for electronic dental claims transactions under the 1996 Health Insurance Portability and Accountability Act—HIPAA. The ADA is at the forefront in this area and will continue to play that role. By the fall of 2002, the U.S. Department of Health and Human Services reports that it will be requiring all electronic dental claims transactions to use the currently valid version of CDT.

**ADA News:** Fluoridation is once again in the news this year as local communities consider ballots for community fluoridation. There was also recent activity in Congress, and the ADA urged Congress to be wary of "pseudo-scientific literature" about fluoridation. Is the ADA approach appropriate? Should the ADA be doing more?

**Dr. Anderton:** I had the opportunity to testify

## Introducing New Crest Whitestrips

DENTAL WHITENING SYSTEM



Help your patients wear their way  
to whiter teeth in just 14 days.

Revolutionary Crest Whitestrips get your patients' teeth a white they'll really want to take care of.

### Simple

- The thin, clear strips are applied directly to teeth.
- They're worn for just 30 minutes, twice a day for 2 weeks.

### Safe and Effective

- They deliver controlled, low-dose bleaching with hydrogen peroxide.
- The peroxide in the gel dissipates considerably after 30 minutes.

Your patients will notice significantly whiter teeth in 14 days, and you may notice an improvement in how they care for them.



## Recommend New Crest Whitestrips

HELP YOUR PATIENTS REVEAL A WHITER SMILE.

To order or request additional information, please call 1-800-543-2577

or visit [www.dentalcare.com](http://www.dentalcare.com)



before the Appropriations subcommittee in Washington for increased funding for the Centers for Disease Control and Prevention in support of community water fluoridation. Some 62 percent of U.S. communities are fluoridated, so we're offering help to those communities that are not. The ADA is, and will continue to, do what we can to support fluoridation of community water supplies.

This may be the most significant public service we have provided and it has helped to increase our professional image in the eyes of the public. It began in the 1960s when community water fluoridation was taking hold across the country. Once implemented, in a very short period of time, we began to see a dramatic decrease in the incidence of childhood dental caries. In fact we began to get the reputation at that time as a profession putting itself out of business. We continue to enjoy that reputation.

**ADA News:** Speaking of the profession that was putting itself out of business, it seems that didn't happen. While the childhood caries rate still remains an issue for those children highlighted in the Surgeon General's Report—the preschoolers who lack access to dental care—most Americans are seeking other services from dentists. What does this trend spell for the future? Could it mean more differentiation in training of dentists?

**Dr. Anderton:** The awareness and knowledge regarding systemic and oral diseases will continue to grow. There is obviously more and more of an emphasis today on cosmetic and esthetics. I don't believe it will mean any split in how dentists are trained or what the general dentist will be treating. There may be dentists who concentrate on restorative more than other aspects of dental care, but all oral health care is so interrelated that I don't believe it's an issue.

I do believe we will continue to see an increase in demand for dental services. To meet these demands, we may have to change our methods of

**■ "I wish every member could go to Washington and follow one of our staff members around. I've never spoken to a representative or a senator who did not speak very highly about our D.C. staff. Our presence is felt very strongly."**

practice a bit. That could mean increasing the number and type of personnel who work under the doctor's supervision.

**ADA News:** How do you assess the ADA Washington presence? What should members understand about what the Association does in D.C.? About our grassroots organizational efforts and successes?

**Dr. Anderton:** We can always use more grassroots support for our legislative efforts. Our Washington staff is very efficient and well trained; and they do an excellent job. I wish every member could go to Washington and follow one of our staff members around. I've never spoken to a representative or a senator who did not speak very highly about our D.C. staff. Our presence is felt very strongly. Our American Dental Political Action Committee and Council on Government Affairs do an excellent job as well. But they need more money, they need more support—the ADA could do more legislatively if we had more funds.

For the past several years, one of the top issues for our members has been advocacy. I hope all of our members realize what we are accomplishing in this area. I had the opportunity to review sever-

al bills on access issues in the past three or four months and to make comments on them. Many of my comments were accepted and incorporated. So we, the members of the ADA, do have a tremendous input into the legislative process. Every dollar we spend on advocacy is a dollar well spent.

**ADA News:** The efforts for licensure by credentials and standardization of clinical examinations have been under way for a number of years. What has the Association achieved so far and what would you like to see happen next?

**Dr. Anderton:** I and the other officers of the Association are well aware that licensure continues to be the No. 1 issue for students and young dentists. There is much that needs to be done, so we have scheduled a meeting next March inviting all licensure bodies to discuss the issues.

ADA policy supports licensure by credentials and I believe for now that's the most effective

thing the ADA can do. No matter what we do, it will still be up to each individual state—the legislatures and the state boards of dental examiners—to make that type of decision. The most effective action we can take—and it's what we are already doing—is to encourage them to allow licensure by credentials. Fortunately, there are only a few states left that do not allow licensure by credentials and we will continue to encourage them to do so.

We are also continuing efforts with the licensing bodies to see if agreement can be reached on standardization of clinical examinations for licensure. Even though progress appears slow, we are moving forward. Bringing the communities of interest to the table was the key in starting this process a few years ago, and it continues to be the essential center of the effort.

**ADA News:** What do you think about evidence-based dental care? What does this mean for


the profession?

**Dr. Anderton:** I think the real issue for dentistry here is this question: Whose evidence is dental care going to be based on? We have to keep a close watch on how standards are set and used. In the courtroom, we are seeing a trend that requires expert witnesses to base their testimony on some kind of documentable evidence—and not base testimony just on anecdotal or clinical experience alone.

We will have to keep a close watch to be sure the data supporting any effort at evidenced-based care is credible.

**ADA News:** In May, the government released the first-ever Surgeon General's Report on Oral Health. Did the contents surprise you?

**Dr. Anderton:** I was somewhat surprised because overall the report was even more favorable. *See DR. ANDERTON, page 14*



Better results from every




From the most advanced manual toothbrush ever designed come the most extraordinary results ever seen.\*

Unprecedented research and development. The Oral-B® CrossAction® is the result of extensive scientific research into every aspect of toothbrushing. Every feature of the CrossAction—from the unique CrissCross™ bristles to the easy-grip ergonomic handle—has but one purpose: to help patients do a better job brushing.

Unmatched efficacy. In over 80 head-to-head laboratory comparisons and 16 clinical studies, the cleaning ability of CrossAction was consistently superior to every other toothbrush tested.\*

Unbeatable recommendation. When you recommend the Oral-B CrossAction, you're not only recommending the most advanced manual toothbrush in the world today—you're giving your patients the ability to significantly improve their oral hygiene. To receive a clinical summary on the Oral-B CrossAction, please write: Oral-B Laboratories, 600 Clipper Drive, Belmont, CA 94002. Details are also available on our website at [www.oralb.com/labs](http://www.oralb.com/labs)



CrissCross bristles are angled to penetrate deep between teeth to lift and sweep away plaque.

**Oral-B®**

**CROSSACTION®**



## President-elect Interview

## Dr. Anderton

Continued from page 13

able to dentistry than I thought it would be. I believe that some of the data that the Surgeon General's Report was based on could have been more accurate and up to date, but overall, the significant issue it brought to light is that there appears to be a significant amount of untreated caries in underprivileged preschool-aged children. We knew that already and have been working on that issue on an ongoing basis. We continue to address it through access programs and the legislative changes we are supporting. Other than that, the surgeon general pointed out that 25 per-

cent of children have 80 percent of the disease. We should point with pride to the 75 percent who have so dramatically improved.

Dental care is obviously not the only aspect of underprivileged children's health that needs addressing. The interesting part of the SG report is the most critical numbers are based on preschool-aged children. As soon as the children reach school age, those numbers begin to change dramatically for the better.

**ADA News:** In an effort to reduce dependence on dues dollars, the ADA is continually developing new avenues for non-dues revenue. How much reliance should the ADA put in its for-profit and non-dues revenue efforts?

**Dr. Anderton:** Realistically, it's unlikely that we could totally replace dues with non-dues revenue, but we are increasing our efforts in this area. We have a close watch on our investments, but we

are more or less dependent on what happens on Wall Street with many of these issues. We did go through a restructuring of our for-profit endeavors last year and this should bring us very positive results.

**ADA News:** In its 2001 budget proposal, the Board of Trustees is recommending an operating budget of \$70 million that would decrease dues by \$3 to \$392. It is also proposing a six-year special assessment of \$45 annually per member to pay for a proposed \$28.7 million renovation of ADA-occupied space in the Association's Chicago headquarters building (giving a net increase of \$42 to the dues/assessment paid to the ADA). What do you see as the strengths and weaknesses of the 2001 budget proposal the Board of Trustees is sending to the House of Delegates?

**Dr. Anderton:** The people I've talked to have looked at it and seem to like it. I believe everyone


understands it is a bare-bones budget and we are getting close to determining what our true costs are. The weakness is, and I'd like everyone to understand this, is that we are jeopardizing our reserves. Under our current structure, we don't have a way to replenish our reserves, and the next several years are going to be critical regarding these funds. The House has asked to keep our reserve levels at 30 percent of operating budget. We will have a difficult time maintaining them at this level without some way of replenishing them, whether through dues or other contributory factors.

The budget-making process was solid this year. It is based on previous actual expenditures with allowances for inflationary factors. It was a much simpler process than what has been used in the past and it should be easier for the House to work with.

**ADA News:** And the proposed renovation of ADA-occupied space? What message do you feel is the most important one to give to members on that proposal?

**Dr. Anderton:** I would hope that the House will approve this and the members will accept it. It's something that will be absolutely necessary at some point and now is as good a time as any to do it. And the way the Board has proposed to pay for it—over a six-year period—is a reasonable approach. I hope that the House will see that this is a good way to protect our assets here in the building. Some members feel we are creating a luxury office, so I encourage everyone attending annual session to come to 211 E. Chicago. They will be surprised and pleased by the building and its location, but we must put the money in the building to protect our investment. It's 35 years old and without the renovation the building is just not marketable. It's ironic: when we built it, it was

# The moon is made of cheese.



# Elvis is working at a gas station in Iowa.




# Metal posts are stronger than fiber posts.



Forget what you've heard about fiber vs. metal posts. The truth is, in lab tests and clinical use, fiber offers greater flexural strength than stainless steel, titanium or zirconia. Fiber is so strong, it's used in Formula

One race cars and the B-2 Stealth Bomber.

Unlike metal posts, fiber posts respect tooth structure and virtually eliminate root fractures by absorbing, rather than transmitting, stress.



99% CLINICAL SUCCESS RATE			
University	# of Cases	Root Fractures	Post Fractures
Park H	400	0	0
Nice III	137	0	1
Toulouse II	158	0	0
Heinrich II/III	323	0	0
Hagens I	438	0	0
Siena I	1,114	0	0
Karlsruhe II	216	0	0
Rice I	451	0	0
<b>Total</b>	<b>3,477</b>	<b>0</b>	<b>1</b>

Fiber posts are guaranteed for six years. To order, or to learn more about our full line of white and translucent fiber posts, call BISCO today, or visit us on the Internet at [www.bisco.com](http://www.bisco.com).

Fiber integrates completely with adhesives and core build-up composite, can be removed in minutes without trauma, and never corrodes. And because fiber is stronger than metal, our



[ 1 . 8 0 0 . B I S C O . D E N T ]

**“It will be interesting to see where our focus takes us and a challenge to make sure our resources follow the priorities we've set for where we want the ADA to go. In order to be financially sound and fiscally responsible, in the future I believe we may have to refocus our attention to be sure we're getting the most out of our financial resources.”**

required to have asbestos in it. Now we have to take it out—as well as update its infrastructure and office space—all in order for the building to be more functional and to have proper value in the market place.

**ADA News:** The ADA Health Foundation continues to grow and is one of the Association's long-term success stories. What is its role in the new century?

**Dr. Anderton:** I don't think enough members are aware of the health foundation and the research it supports through the ADAHF Paffenbarger Research Center, which is located on the National Institute of Standards and Technology in Maryland.

I would like every member to know that Paffenbarger does a tremendous amount of research on dental materials. I'd like every member to know that the high-speed dental handpiece



was developed through PRC. Not just the hand-piece, but other important equipment and material that makes modern patient care a reality, such as the panoramic X-ray, composite resins and calcium phosphate cements for remineralization. More than 60 patents generate nearly \$1 million in revenue annually. That money of course goes back into the research. PRC is one of the best assets of the health foundation and every member should support it. I hope the role of the health foundation will continue in education and research. That's where we've had the biggest impact.

The Research Institute is also part of the foundation, and RI activities include the Health Screening Program at annual session. The ADAHF board is an excellent one and very active in pursuing ADAHF goals. I encourage every member of the ADA to support the ADA Health Foundation.

**ADA News:** How do you assess the public image of the profession?

**Dr. Anderton:** The public holds the profession in very high esteem. The ADA Strategic Plan calls for efforts to be made to maintain the image of the profession. We've been in the top five in public opinion polls, and moved down a bit in the recent Gallup survey, but they revised the questions they ask in that survey and added some categories. Overall, our image has not changed and I believe it will remain high as long as we maintain our ethical standards and continue to serve the public in the future as we have in the past.

We have many ongoing public campaigns that help patients learn more about oral health, such as National Children's Dental Health Month and the Adult Oral Health Awareness promotion. I think we're headed in the right direction. With what we're doing now and what we're planning with access and Medicaid issues as well as our ongoing community water fluoridation efforts, we will continue to hold the public's high regard.

**ADA News:** What progress is the ADA making in promoting direct reimbursement to benefits purchasers?

**Dr. Anderton:** Direct reimbursement continues to be very popular with members—it's very effective. The Board has recommended we continue dedicating \$2.5 million of the ADA operating budget for promotion of DR. This level of campaign was first launched in 1997 and we've seen continued progress, though it has been slow. We don't have the resources the insurance industry has in reaching benefits purchasers, but what we've done has shown results: since 1997, the number of employees newly covered by DR has grown from about 15,000 to 180,000. I think for some people it's difficult to understand that there's a factor that is not measurable—because we promote DR—how much good we do in supporting fee-for-service as an alternative.

**ADA News:** The Association's Future of Dentistry Project is one year away from completion. What will its value be to the profession?

**Dr. Anderton:** I've heard only positive feedback on the progress made in gathering the data by bringing together experts in all aspects of dental care. There are many agencies outside the Association awaiting its completion. The level of input from outside organizations in the process is outstanding. I think it will be completed on time and within budget. I believe it will be a report that members will be very proud of. It will be our document, owned by the profession.

**ADA News:** A new trustee district is being proposed for the Association, to make Florida the 17th district in response to the increased dentist population: 6,313 active, life and retired members, more than the 6,000 required for a state or group to petition the House of Delegates for reapportionment of trustee districts. What do you think about the prospect of an additional trustee on the Board?

**Dr. Anderton:** If we have a new trustee, I believe it will be very positive for the Association as a whole, not just for Florida. It will mean greater representation for Florida dentists and greater representation for the other states in the current 5th District: Alabama, Georgia and Mississippi. I realize that recently opposition has

arisen, but the petition appears to meet all the qualifications to become a trustee district.

We went through this in 1985 when Texas became the 15th District—which was a good thing for Texas, the 12th District and the ADA. It resulted in more representation for the membership.

**ADA News:** Any other matters you would like to discuss?

**Dr. Anderton:** I worked this past year on updating the ADA Strategic Plan, which is a report to the 2000 House. I intend to start the December Board of Trustees meeting with that new strategic plan. We're going to take recommendations from the House and prioritize the programs of



**Proud to serve:** Dr. Anderton thanks the 1999 House for its support.

ADA and carry this forward to the budget process to make sure the budget reflects the priorities of the Association as reflected in the Strategic Plan. This will continue with the work we did this year in creating a priority-based budget process.


It will be interesting to see where our focus takes us and a challenge to make sure our resources follow the priorities we've set for where we want the Association to go. In order to be financially sound and fiscally responsible, in the future I believe we may have to refocus our attention to be sure we're getting the most out of our financial resources.

Using the Strategic Plan this way I hope will bring the Strategic Plan more into focus, to make our members more aware of what the American Dental Association does, what it can do and how it can be more reflective of what the members want it to be. ■

# Core Value

## Premier® CompCore™

Economical composite resin core build-up material



### Ideal Handling - Saves Time

Premier® CompCore™, available in white and natural shades, is easily syringed, permitting precise placement without slumping and self-cures in only 3 minutes to save chair time.

### Inner Strength - Saves Tooth Structure

CompCore is radiopaque. Its advanced composite formulation provides outstanding compressive (255 MPa) and tensile strength (50 MPa) yet easily trims like dentin. When you chemically bond CompCore, with Premier IntegraBond™, you save tooth structure while creating a strong, unitary core with fluoride.

### Outstanding Value - Saves Money

★ If not completely satisfied, return CompCore for full refund and keep the FREE IntegraBond Professional Starter Kit. ★★ Limited to 3 kits per dentist.

**NEW!**  
Dual Shade Kit!  
28 gram Kit (3001403)

**FREE \$95 Value**  
IntegraBond™ & Auto-Cure  
Activator Professional  
Starter Kit Attached!

Order through your authorized dealer.





# Health & Science

## Ergonomics and dentistry The ADA seeks objective information

BY ARLENE FURLONG

You spend the majority of your day with your head cocked at a strange angle, looking with indirect vision into a 3-inch wide cylindrical cavity.

How can ergonomics—the science that seeks

to adapt working conditions to the worker—apply to such a scenario?

The ADA intends to find out.

Dental Ergonomics Summit 2000, sponsored by the councils on Dental Practice and

Scientific Affairs, broke ground Aug. 18-19 to build the foundation of knowledge the ADA needs to develop educational materials and programs.



**Shop talk:** From left, ergonomist Scott Smith and William Sullivan, M.D., discuss ergonomic implications of hand tool design.



Gingivitis? Discomfort? Inflammation?

Halitosis?

## The Best Therapy for Dry Mouth

**biotene**

Dry Mouth Toothpaste, Gum & Mouthwash

Contains three primary enzymes—Lactoperoxidase, Lysozyme, Glucose Oxidase to restore and boost saliva's own antibacterial action. Helps maintain a healthy balance of oral flora. Naturally sweetened with Xylitol. Contains no Sodium Lauryl Sulfate.



**oralbalance**

Mouth Moisturizing Gel

Soothes and relieves oral dryness and burning mouth sensations up to 6 hours. Non-drying formula also helps promote healing.

The #1 recommended treatment for dry mouth due to: Medications, Cancer Therapy, Sjogren's Syndrome, HIV/AIDS, Auto-Immune Disorders and Diabetes.



In response to the ADA's request, for the first time experts from such varied disciplines as physical therapy, law, epidemiology, dental education, ergonomics, architecture and equipment design convened to provide the kind of objective information related to dentistry and ergonomics the ADA is seeking.

"Our interest in ensuring an ergonomically correct environment for dentists and dental office staff is nothing new," said Dr. Jeffrey Smith, chair of the Council on Dental Practice. "However, suggestions for practice can't be made until more information about ergonomics in dentistry is gathered. We're taking a significant step toward gathering that information."

Dental-specific, scientifically valid and objective information is in short supply with regard to ergonomics. A 1997 report of the National Institute of Occupational and Safety Health—which the Occupational Safety and Health Administration called the "most comprehensive to date"—mentioned only one study of dental workers, and this study failed to meet even one of the four NIOSH research criteria.

But summit presentations suggested that a

**■ "Suggestions for practice can't be made until more information about ergonomics in dentistry is gathered. We're taking a significant step toward gathering that information."**

fair amount of ergonomic research in other industries could be applicable to dental workers, and that basic ergonomic principles are common to many occupations.

"Dental professionals aren't built differently than other people," noted Barbara Silverstein, Ph.D. Dr. Silverstein, an internationally known expert on ergonomics, has worked on ergonomics-related issues at OSHA and various health organizations. "Many of the ergonomic conditions that dental professionals experience are common to people in other industries," she said. Dr. Silverstein is currently the research director, safety and health assessment and research for prevention program at the Washington State Department of Labor and Industries.

Although OSHA has neither established a need to regulate the dental workplace nor given assurance that a standard would improve dental worker safety, the ADA Council on Dental Practice included consideration of ergonomic issues in the charge to the Ergonomics and

See *ERGONOMICS*, page 18

www.laclede.com


**Laclede, Inc.**  
HEALTHCARE PRODUCTS

For additional product information and samples, please call:

**1-800-922-5856**



## *Systems for Esthetic Excellence*



### **> *Brasseler USA Diamonds***

Working closely with the world's leading clinicians and investing heavily in research and development, we have engineered a patented diamond manufacturing process. This process enables us to produce the procedure specific shapes, sizes, and grits demanded by you.

A classic example is the KR series developed to meet the unique requirements associated with all ceramic anterior crowns. This controlled aggressive cutting, super coarse diamond is designed to produce a modified shoulder during axial wall reduction.

Employing these instruments in systematic procedure kits provides a logical step-by-step approach and when combined with your hands, produces the very best clinical results.

***Consistently. Rationally. Systematically.***

Invest a few minutes with a Brasseler USA representative and save hours in chairtime.

***Buy Direct. Buy Brasseler USA.***

To order Call 800.841.4522 or Fax 888.610.1937 or find us on the web: [www.brasselerusa.com](http://www.brasselerusa.com)

© 2000 BRASSELER USA

See us at the ADA meeting, booth 1230





**Health & Science**

**Ergonomics**

*Continued from page 16*

Disability Support Advisory Committee when it was established in November 1998.

The subcommittee also reviews dentists' disability issues unrelated to ergonomics.

Although injuries due to ergonomic factors in dentistry have not been found to occur on a wide scale, the ADA has chosen to take the lead in responding to potential issues.

"With more information about ergonomics as it relates to dentistry we can better educate our members," noted Dr. Smith, adding that the

ergonomics issue is important to the ADA for many reasons unrelated to OSHA. "It's about increased efficiency, the comfort of patients and staff, and all-around better health care delivery."


His sentiments were echoed by summit participants, such as Dr. Michael Belenky. "We should lead the change in the way we work," he told the summit audience. "We [dentists] must offer the industry clear and precise guidelines for dentistry."

Dr. Belenky is currently the director of the World Health Organization Collaborating Center for Oral Health at the University of Maryland and has been coordinator for performance logic activities at the University of Maryland Dental School since 1983.

He regularly presents internationally on the topic of human-centered ergonomics of occupa-



**Barbara Silverstein, Ph.D.:** 'Dental professionals aren't built differently than other people.'



**Joseph Martin:** 'We want and need information from dentists to better design handpieces to fit dentistry's needs.'



**There's a reason we call it  
Colgate® Total®**

**Your patients deserve all the benefits  
only Colgate® Total® can provide<sup>1,2</sup>**

Clinically proven to help prevent and reduce gingivitis	✓
Clinically proven to help protect against plaque, regardless of eating or drinking	✓
Clinically proven to help protect against calculus buildup	✓
Clinically proven to help protect against caries	✓
Clinically proven to help protect against bad breath	✓
Proven 12-hour protection against gingivitis, plaque, calculus buildup, caries, and bad breath	✓
Removes extrinsic stains	✓
Contains triclosan, an antibacterial ingredient	✓
Contains copolymer that prolongs triclosan retention on hard and soft oral tissues	✓
Proven in more than 20 clinical studies	✓
Accepted by the ADA for protection against gingivitis, plaque, and caries	✓
Approved by the FDA for gingivitis and caries	✓
#1 recommended toothpaste by both dentists and hygienists	✓

**It all adds up to better oral health**



1. Voipe AP, et al. J Clin Dent. 1998;7(suppl):S1-S14.  
2. Data on file, Colgate-Palmolive Company.



tion health and peak performance in dental practice.

All of the panel experts expressed a need for ergonomic guidance in dentistry, and confidence that dentistry is fully capable of addressing that need. They gave their opinions about barriers to ergonomically correct dental environments, methods for resolution and strategies for change.

Dr. Michael Unthank, a registered architect and a dentist, blamed what he called the "my stuff" mentality for a myriad of ergonomic blunders.

"The most functionally appropriate treatment



**Dr. Belenky:** 'The world changes and we can change in dentistry.'

**Summit leaders observed that current dental office and equipment design can easily reflect the dental practice of the past rather than tomorrow's more efficient practice because of the slowly evolving purchase cycle.**

room designs are based on the efficient relationship between the dental equipment, the dentist, patient and staff," he said. "In some instances the dentist ergonomically removes the dental assistant from the entire process."

This mentality often develops in dental schools where more time is spent practicing two-handed dentistry rather than four-handed dentistry with an auxiliary. "In many cases, the dentist positions the hand tool tray for himself and doesn't even use the auxiliary to the fullest extent," said Dr. Unthank.

Dr. Belenky highlighted a program for dental students at the University of British Columbia that implements a simple training process that enables a natural posture when dentists and auxiliaries provide treatment. "The world changes and we can change in dentistry," he commented.

Summit leaders observed that current dental office and equipment design can easily reflect the dental practice of the past rather than tomorrow's more efficient practice because of the slowly evolving purchase cycle—dentists buy what manufacturers produce and manufacturers produce what dentists buy. There





**Dialogue:** From left, Dr. Michael Unthank, Dr. Jeffrey Hutter and Joseph Martin discuss the importance of improving communication between dentists and hand tool and equipment design manufacturers.

needs to be better communication between dentists and manufacturers.

"We want and need information from dentists to better design handpieces to fit dentistry's needs," said Joseph Martin, vice president of Nordent Manufacturing Inc., a dental hand instrument manufacturer.

Mr. Martin noted that standards don't exist for dental instrument design and current studies have been conducted in a way that makes it difficult to understand relationships between instrument design and operator comfort and efficiency.

He noted that one of the easiest ways to



**Dr. Smith:** 'With more information about ergonomics as it relates to dentistry we can better educate our members.'

## Pittsburgh names new dental dean

Pittsburgh—Dr. Thomas W. Braun was named dean of the University of Pittsburgh School of Dental Medicine last month.

Dr. Braun—who has served as the school's interim dean since September 1999—was recommended unanimously by the committee charged with identifying candidates for the position. He replaces Dr. Jon Suzuki, whose tenure as dean spanned 10 years.

Dr. Braun said he plans to work in conjunction with the university's administration to re-establish the school as a dominant force in dental education. "In doing that," he explained, "I plan to examine our current curriculum, our admission standards and our physical plant and logistics to determine how the school may be able to be re-engineered such that it is recognized as a center of excellence."

During Dr. Braun's interim post, the dental school was identified as a pre-eminent center for genetics research in the craniofacial complex and began to establish a tissue engineering component in collaboration with other schools. Plans are also underway for a geriatric dentistry center with emphasis on bone biology research and an informatics program.

Dr. Braun earned four degrees from Pitt: a B.S. in 1969, his dental degree and master's degree in 1973 and his Ph.D. in 1977. His position as dean is effective immediately. ■

decrease the need for more force when using dental instruments is to adequately sharpen instruments and grasp objects with a "power grip" rather than a "pinch grip."

Physical therapists say that ideally a 1½-inch diameter instrument, about the size of a broom handle, creates the least amount of stress on the muscles of the hand and forearm—"hardly an appropriate size to work in a person's mouth and still see what's going on," said Dr. Connie Verhagen, a member of both the Council on Scientific Affairs and the Ergonomics and Disability Support Advisory Committee.

Ms. Marcia Garcia, a registered nurse and an attorney, provided a legal overview of ergonomic-related issues and dispelled misconceptions related to workers' compensation, explaining that it is a no-fault insurance plan regulated by each state.

She emphasized how important it is for dentists to carry disability insurance. She also suggested dentists review a job description with a prospective employee to ensure job requirements are understood. If a prospective employee understands what a position entails, an employer can legally ask if the applicant is capable of completing the described responsibilities.

She followed up with a comprehensive discussion about law and ergonomics with the advice, "Dentists should address ergonomic issues and be sure they are adequately insured. Then they can 'relax' and devote their energy to dentistry."

For more information about Ergonomics Summit 2000 or ergonomics in dentistry, call Dr. Al Guay, ADA Council on Dental Practice, toll-free, Ext. 2882. ■

# Silent Nite®

*Clinician Preference Series*

"Dad's not SNORING anymore, thanks to our den-

**\$ 8**

New EVA material in three colors for bruxing snorers.

"In the three years I have prescribed Silent Nite, I have found it to be a most cost efficient and effective appliance for snoring cessation."

*William K. Salmons, DDS  
Private Practice, Knoxville, TN  
Member - Sleep Disorder Dental Society*

"The Silent Nite has been the most effective appliance I have used to treat severe snoring problems. The patients are very comfortable and are happy to report their spouses now sleep comfortably."

**FREE Patient Education Kit**

Your free kit includes: 1-video, 1-poster (not shown), 30-custom labeled brochures with acrylic display, 100-statement stuffers and 30-patient questionnaires (not shown).

Over 26,130\* dentists offer their patients a Silent Nite's sleep.

\* Number of dentists offering their patients Silent Nite devices as of March, 2000.

800.374.7874


**GLIDEWELL LABORATORIES**

Serving Dentistry Since 1970


See us at the ADA Annual Session, Booth #1903




# Need We Say




MOISTURE FRIENDLY



FLUORIDE RELEASE  
FIGHTS DECAY




DEPENDABLE DELIVERY



EASILY INTEGRATED INTO PRACTICE




FAST,  
SAVES TIME AND EFFORT




FOR MOST RESTORATIONS INCLUDING  
LONG SPAN BRIDGES



STRONG AND STABLE



NO WASHOUT




LONG LASTING & DURABLE

## GC FujiCEM™


New GC Fuji CEM, the world's first paste-paste resin reinforced glass ionomer, lets you final cement indirect restorations - metal, PFM and resin crowns, bridges, inlays and onlays, as well as porcelain inlays. Its unique Paste Pak Dispensing System ensures the proper mixing ratio every time so you get the highest compressive, tensile and bond strengths, the lowest film thickness and maximum fluoride release. And with the Paste Pak, there's no waste - no matter how little or how large a mix you need.



# More?



PRECISE MEASUREMENT



LOWEST FILM THICKNESS  
OF ANY LUTING CEMENT




BLOWS POWDER-LIQUIDS AWAY

## Simple to Use - No Waste



## Perfect Mix Every Time



## 15 Second Mix



## Easy to Remove Excess



Starter Packages include applicator, two Paste Paks of FujiCEM, mixing pad and spatula. Each cartridge contains enough material to cement approximately 43 average crowns.

GC's exclusive Paste Pak System dispenses the exact cement mixing ratio so you'll always get the optimal physical properties - no matter how little or how much material you need. A metering slide on the dispenser regulates volume.

GC America Inc.

Advancing the Art and Science of Dentistry

© 2003 GC America Inc., 3737 West 127th St., Alsip, IL 60803  
<http://www.gcamerica.com>



In one night, feel the heart,  
soul, beat and rhythm of Chicago.

**Colgate** Total



On Monday, Oct. 16, 2000, Colgate Total presents the music that made Chicago famous. Join us for an evening extravaganza at Chicago's Symphony Center featuring a live performance by Bonnie Raitt. Plus the best in blues, swing, jazz and classical music, all in one location.

Tickets are available on a first-come, first-serve basis only, so visit the Colgate Booth during the 2000 ADA Annual Session. A \$10 per ticket donation benefits the ADA Health Foundation. Limit four tickets per dentist, hygienist or ADA member while supplies last.



While you're at the booth play "Colgateland," our interactive virtual reality game. You'll qualify for daily prizes and a chance to win a trip for two to one of the Seven Wonders of the World as shown in the game. Play each day for four chances to win! Then, learn about the latest advances in Colgate technology. Receive free samples of Colgate Total, Colgate Sensitive Maximum Strength toothpaste,

and Colgate 2-in-1 toothpaste. And brush up on the advantages of Colgate Actibrush. Without a doubt, this year's event will be music to your ears.






# Annual Session

## A new district?

This map shows the current configuration of the 16 ADA trustee districts. If the 2000 House of Delegates adopts Res. 91-1999, the state of Florida (now part of the 5th District) would become the 17th trustee district.



## House to decide on new trustee district

### Sunshine State would be 17th for ADA

BY JAMES BERRY

The state of Florida will become the ADA's first new trustee district in 14 years if the 2000 House of Delegates adopts a resolution held over from last year.

Because the measure involves a change in ADA bylaws, passage of Res. 91-1999 would require a two-thirds vote of the delegates to establish Florida as the Association's 17th trustee district, the first new district since 1986.

The Sunshine State is currently part of the 5th District, with Alabama, Georgia and Mississippi. Fifth District leaders say they support the resolution as a way to boost ADA representation for all four states in the current district.

"We've enjoyed having Florida with us in a large, efficient district," said Dr. T. Howard Jones, 5th district trustee. "But [Florida] has been large enough to meet the criteria to become a new district for several years now. We support them. A new district will mean more people involved in the process and better representation for all."

ADA policy entitles any state or group of

states with at least 6,000 active, life and retired members to petition the House either to become a new trustee district or to seek reapportionment of existing districts.

Membership records show that Florida has 6,313 active, life and retired members. The remaining states in the 5th District have 5,171 members, more than enough to meet the minimum requirement of 4,500 members to be a trustee district.

In an interview with the ADA News (see page 12), ADA President-elect Robert M. Anderton said designating Florida as a 17th trustee district would be a "very positive move for the Association as a whole, not just for Florida."

He added, "It will mean greater representation for Florida dentists and greater representation for the other states in the current 5th District. I realize that recently opposition has arisen, but the petition appears to meet all the qualifications to become a trustee district."

The 2000 House of Delegates meets in Chicago, Oct. 14-18. ■

## Annual session reminders

### Budget review Oct. 13

An informational review of the proposed 2001 ADA budget will convene from 4-5 p.m. Oct. 13 in the Regency C North room of the Hyatt Regency Chicago.

ADA members are invited to attend to learn more about the proposed 2001 budget.

### Delegates to bring copies

Members of the 2000 ADA House of Delegates are encouraged to bring their copies of the 2000 Annual Reports and

Resolutions and resolution worksheets to the meetings of the House of Delegates in Chicago. Extra copies of these materials are limited.

### Future of Dentistry hearing

Members and guests attending annual session are welcome to share their thoughts about the Association's Future of Dentistry Project at an open hearing on Oct. 15, 12:30-2:30 p.m., at the Hyatt Regency Chicago, Room Columbus G-L. ■

# An Offer You Shouldn't Refuse.

## Great Composite, Great Price!

**Just 60¢\* Per Dose!**

If you use single dose composite, you're probably paying \$2.00 or more per application. That means, weight for weight, you're paying as much for composite as you are for gold.

Not anymore.

At Jeneric/Pentron, we have automated our filling process to the point where we can offer a single dose of our premium, Sculpt-It® Composite for just 60¢\*!

Sculpt-It Composite just recently won a ++++ review from the Dental Advisor with an 87% favorable rating. Consultants who used Sculpt-It Composite remarked on its good polishability and smooth surface, how well it blended with the tooth and how well the shades matched the Vita®\*\* guide both before and after curing.

Sculpt-It Composite Single Doses are available in all 16 Vita®\*\* shades, plus four specially formulated bleach shades. You can order it in refills of single doses per shade or in a kit that contains the six most popular Vita®\*\* shades plus all the bleach shades.

**Order either the kit or ten refills and we'll throw in a dispenser gun absolutely free\*! Hurry, this offer is valid only until October 31, 2000!**

If you think composite filling materials should cost less than gold, this is an offer you shouldn't refuse – a premium composite at a really, really great price.

**SOURCE CODE 1001**

**CALL 800-551-0283**  
Toll Free Fax: 877-677-8844  
In Canada call Synca at 800-667-9622

**Jeneric®/Pentron®**  
INCORPORATED

ISO 9001 CERTIFIED

We Make Good Products at a Fair Price.

And We Stand Behind Them.

\* Additional shipping and handling charges apply.  
\*\* Vita is a registered trademark of Vita Zahnfabrik.



**Order online: www.jeneric.com**

P. O. BOX 724 • Wallingford, CT U.S.A. 06492 • 203-265-7393  
Offer valid until November 30, 2000. No other offers apply. Offer valid U.S.A. only.  
Subject to change or cancellation without notice. © Jeneric/Pentron Inc. 2000. All rights reserved.



# Maximize your retirement savings

## Learn the latest market news at annual session

Want the latest Wall Street news from some of today's leading investment fund managers? Want to find out if your retirement game plan is a winner?

Then don't miss the Oct. 15 seminar, "Maximize Your Future: Invest for the Long Term," which will highlight 401(k) plans—dentists' primary method for investing for retirement.

The event, scheduled for 9-11:30 a.m. in Room 401A in McCormick Place North, is a special annual session event sponsored by the ADA Council on Insurance for ADA members who want to know more about the tax-advantaged

### Annual Session

retirement programs that are available to dentists today.

Experts from mutual fund groups at INVESCO, Massachusetts Financial Services and Alliance Capital Management Corporation will share investment strategies. They'll discuss why this year was a roller coaster ride for investors and offer insight about where that ride is headed.

Seminar participants will hear from Robert

Marronaro, national accounts manager at the Equitable Life Assurance Society. An expert on retirement program design, Mr. Marronaro will give an overview of the different types of 401(k) arrangements that are available to dentists and the most popular plan designs.

According to Mr. Marronaro, the flexibility of 401(k) plans offer significant advantages to dentists.

"A 401(k) plan can be tailored to the particular circumstances of just about every dental practice," Mr. Marronaro said. "They allow dentists to blend 401(k) plans with other existing defined contribution plans, and that enables dentists to increase the

amount of money they contribute to their account."

To help dentists become better investors, three Wall Street investment managers will share their views on investment choices and answer questions. The funds they manage are included in the eight equity fund choices available to ADA Members Retirement Program participants. The program offers a total of 12 investment choices.

Each speaker will discuss a different aspect of investing, as well as what distinguishes their funds from other funds, the market sectors they favor, how their funds have performed during the past year and how they predict funds will perform for the remainder of the year.

Trent May, vice president INVESCO Funds Group, will talk about large cap funds and companies that are established market leaders in the economy's fastest growing business and market sectors.

Alden Stewart, executive vice president, Alliance Capital Management Corporation, will primarily discuss small cap, mid-cap and large cap stocks, as well as an extensive research process for stock selection.

Susan Hunter, vice president Massachusetts Financial Services, will highlight identifying emerging companies that are on their way to becoming major enterprises.

The seminar is open to all ADA members. ■



Robert Marronaro



Trent May



Alden Stewart



Susan Hunter

## TOOTH TOPOGRAPHY

A Flawless Impression Goes A Long Way

15%  
REBATE!

Let Bosworth's complete line of impression trays and materials point you in the direction of an effortless restoration.

- 100% solid Stainless Steel Impression Trays<sup>®</sup> are available in a full selection of regular, odenulous and pododontic lines for full or partial impressions available in both solid or perforated. Impression material locks into the tray to prevent distortion upon removal. Trays are nickel free preventing allergic reaction and are autoclavable for extensive use and wear.
- Tray-Aways<sup>®</sup> are the #1 disposable impression tray of choice. Best suited for use with Supergel<sup>®</sup> alginate impression material to achieve a consistent impression free of distortion or bite through. Interior retention slots and vertical perforation enhance material retention.
- NEW! Fastray LC<sup>™</sup> — A one component, light cured custom tray material supplied in pre-formed sheets that will not distort or stick to fingers or models. No mixing of powder and liquid reduces procedure time and eliminates odors. Fastray LC provides a firm, stable custom tray that is ready to use immediately after trimming and polishing.

#### 15% REBATE ON THE FOLLOWING FAMILY OF IMPRESSION PRODUCTS:

- Tac<sup>™</sup> - Tray Adhesive Compound available in spray or liquid
- Supergel<sup>®</sup>/Supergel Fresh - Alginate impression material
- Tray Aways<sup>®</sup> - #1 Disposable impression trays
- Big Bite Trays<sup>™</sup> - Bite registration trays
- Re'CORD<sup>™</sup> - Cartridge dispensed V.P.S. improved for best results
- Supersil<sup>™</sup> - Putty or cartridge dispensed
- Superbite Paste<sup>™</sup> - Z.O.E. paste - sets hard, sets fast
- Fastray<sup>™</sup> - Custom tray material
- Fastray LC<sup>™</sup> - Light cure custom tray material
- Stainless Steel Trays - 100% Solid Stainless Steel

\*To take advantage of this special offer a copy of your distributor's invoice to: The Harry J. Bosworth Company, 7227 North Hamilton Avenue, Skokie, Illinois 60076 or fax (847)679-2858. To receive rebate, invoice must be dated between 10/01/00 to 11/31/00. Invoices must be sent by 12/31/00. Offer not valid with any other promotion.

**Bosworth Company**



See us at the ADA meeting, booth 4215

## Expocard tracks dental CE credits

Keeping a tally of your continuing education credits will be a breeze with the Expocard (continuing education attendance verification and exhibit action card).

Provided to all persons at the ADA annual session, the card has a personalized magnetic strip containing registration data, and can record your CE attendance simply by swiping the magnetic bar on your card and entering the code for the course into the computer at any of three ADA Continuing Education Pavilions at McCormick Place.

Codes will be announced during each CE course by the room chairman, and participants can print written documentation of attendance immediately after entering the code or at any time during session.

The main CE pavilion is in the Vista Ballroom lobby, Room S406 in McCormick Place South. Other locations for recording CE credit will be on the Grand Concourse near the North meeting rooms and near the entrance lobby of McCormick Place South at Gate 3. ■



# Claims prevention

## Using facts instead of fiction

Scenario 1: For more than 12 years a patient complains to his general dentist about soreness on the inside of his cheek. When finally referred for a biopsy, the patient is diagnosed with advanced squamous cell carcinoma and dies shortly thereafter.

Scenario 2: Two derma-grafts and a bone graft fail following a laser whitening procedure. The plaintiff alleges that the retractor used during whitening injured the recently treated areas. A jury finds the dentist negligent in his treatment of the patient but finds his negligence did not cause the grafts to fail.

Scenario 3: A general dentist performs endodontic therapy on a patient using a particular technique. An overfill of the canal permanently damages a portion of the patient's mandible including the inferior alveolar nerve. The prognosis is extensive surgery to repair the patient's mandible and a lifetime of chronic pain.

Understanding what causes claims like these is the first step toward preventing them. To learn from actual cases in the annals of two nationally known dental professional liability insurance companies, attend the Oct.15 seminar, "Current Risk Issues in Dentistry: Case Studies and Strategies." The course will run from 1:30-4 p.m. in McCormick Place North, Room 401A.

The Dentists Insurance Company and The Medical Protective Company are teaming up to speak to members about loss prevention. In this interactive seminar, learn about up-to-the-minute issues, case outcomes, pertinent laws, risk management recommendations and documentation strategies.

"We've found presenting actual claims scenarios to be a very effective way to teach dentists how to prevent claims," said Robyn Crimmins, TDIC director of risk management and communications and co-presenter of this seminar. "Fact is a more effective learning tool than fiction," she said.

Co-presenter Kathleen Roman, assistant vice



**Robyn Crimmins**



**Kathleen Roman**

president, Risk Management Education Services for The Medical Protective Company said that listening to the experiences of colleagues really hits home for most dentists.

"Lawsuits are the result of a combination of factors. The dentists often concentrate on clinical excellence, but communication skills and documentation may be equally as important and sometimes are more so," she said.

The presenters hand-selected the cases they will highlight based on their learning value and timeliness. "It's important for us to tackle real-world situations that are relevant to today's dentists," said Crimmins.

Cases to be presented include subjects such as infection, graft failure following a laser whitening procedure, nerve injury, pediatric misadventure, swallowed objects, failure to diagnose oral cancer, retreatment issues and complications following restorative work.

Seminar participants will explore such related topics as patient education and informed consent, referral, documentation, use of auxiliaries, practice transition issues, effective communication with other treaters, responding to patient complaints, withdrawing from care and the importance of proper prescribing and monitoring of pediatric patients.

Collectively, The Dentists Insurance Company and The Medical Protective Company insure more than 36,000 dentists throughout the United States. ■

## Coming to Chicago? You're invited to the ADA's Open House

"Sweet Home, Chicago" offers you an opportunity that will really make you feel at home during annual session.

Attend the Association's Open House, scheduled at ADA Headquarters, for a behind-the-scenes look at the activities your dues support.

Visit the newly renovated laboratories in the Division of Science; browse the shelves of one of the world's largest dental libraries, the ADA Library; and stop by the ADA Call Center, which receives more than 30,000 calls each month from members and consumers.

Tour guides will be on hand to provide brief highlights of divisional activities and answer your questions about ADA programs and services.

The Open House will be held daily, Oct. 13-16 from 2-4 p.m.

Invitations are recommended to attend the Open House. Invitations may be obtained at the following locations at McCormick Place, South Building:

- The ADA Membership Booth 4807, located in the ADA Pavilion on the exhibit floor, dur-



**ADA HQ:** You can tour it during session.

ing exhibit hours;

- On Oct. 13th only, invitations will be available at the session registration area at McCormick Place, South Building.


Shuttle bus service between McCormick Place and the ADA Headquarters Building will be available from 1:45-4 p.m. on Open House days only.

Shuttle schedules may be obtained at ADA hotels and at the session registration area at McCormick Place, South Building. ■

# BUILD-IT! F.R.


## Fiber Reinforced Core Build-up Kit

### ...is stronger



Source: Dr. John M. Powers, Professor, Univ. of Texas-Houston

### ...is more economical



Source: Schrein Spring/Summer Catalog 2000, \* REALITY Vol. 13, 1999

### ...is more convenient

Build-It F.R. Material is available in a dual cure A2 shade and self cure shades of blue and gold - all automixed for your convenience.



Build-It is a registered trademark of Jeneric/Pentron. FR is a trademark of Jeneric/Pentron. Tri-Core is a registered trademark of Integrated Dental Systems. Luxacore is a registered trademark of Foreprost Dental Manufacturing. Fluorocore is a registered trademark of Denstep International. CoreRestore is a trademark of 3D Ker. Core Paste is a trademark of Dae-Illas. Core-Flo is a trademark of Bisco.

and is backed by a money back guarantee  
**SO WHY AREN'T YOU USING IT?**

## SAVE \$30!

Buy the *Build-It F.R. Intro Kit* and the companion *Build-It Core Forms Kit* for

### only \$149.90

(Normal Sugg. Retail \$179.90)



**Jeneric®/Pentron®**  
INCORPORATED

ISO 9001 CERTIFIED

WE MAKE GOOD PRODUCTS AT A FAIR PRICE AND WE STAND BEHIND THEM.

P.O. Box 724 • Wallingford, CT 06492, U.S.A.  
order online: [www.jeneric.com](http://www.jeneric.com)

**800-551-0283 • 203-265-7397**

In Canada call SYNCA at 800-667-9622

P.O. Box 724 • Wallingford, CT 06492 • Fax Your Order Toll Free: 1-877-677-8844 Visit Our Web site at: [www.jeneric.com](http://www.jeneric.com). No other offers apply. Offer valid until November 30, 2000. Offer valid in the U.S.A. and Canada only. Additional shipping charges may apply. Subject to change or cancellation without notice.

© Jeneric/Pentron Inc. 2000. All rights reserved.



# Brought to you by the ADA Seminars aim to aid practitioners

BY CLAYTON LUZ

Wondering how to volunteer your dental skills overseas? How to rev up your dental team? Wondering what the most current guidelines are for evaluating and treating the medically compromised dental patient? How to facilitate the transition from dental school to dental practice?

You can find the solutions to these and other challenges when you attend an ADA-sponsored program during annual session.

Designed to help dental professionals meet the challenges of dentistry, each program will feature leading researchers, consultants and practitioners discussing dentistry's most impor-

## Annual Session

tant and emerging issues.

- Beginning on pre-session Oct. 12, the International Volunteer Symposium is a 1½-day workshop that offers first-time volunteers as well as international veterans a smorgasbord of information on topics related to volunteering overseas, including a dynamic cross-cultural exercise.

The International Volunteer Symposium will convene Oct. 12, 6-9:30 p.m. and Oct. 13, 7:30



**Plenty of space:** Most session programs will be presented in McCormick Place South.

a.m.-5:30 p.m. at the Hillenbrand Auditorium at ADA Headquarters. Ticket cost is \$150.

The symposium, presented in cooperation with the Dentistry Overseas Steering Committee of the Council on ADA Sessions and

International Programs, is partially underwritten by the Pierre Fauchard Academy and the Academy of Dentistry International.

- Team Building Conference V will help your office team up for practice success. This two-day conference includes lectures, interactive sessions, team discussions and lunch with practice management consultants who will help re-energize your team. Sponsored by the ADA Council on Dental Practice, the clinic ticket cost is \$260 for dentists and \$150 for each staff member.

Team Building Conference V will run Oct. 13-14, 8:30 a.m.-4:30 p.m. in Room S501B at McCormick Place, South Building, as will the following ADA-sponsored sessions:

- Oct. 14: "Dental Treatment Considerations for the Older Patient"—Dr. Ken Shay will present a simple procedure for dentists to follow when assessing and planning dental care for senior citizens, Room N427A, 9:30-noon. Presented in cooperation with the ADA Council on Access, Prevention and Interprofessional Relations;

- Oct. 15: "Economic Issues in the Sale of Dental Practices"—Drs. Jackson Brown, Howard Bailit and Tryfon Beazoglou, along with Brian Hufford, C.P.A., and Paul Consani will discuss issues associated with the entry and exit from dental practice that practitioners are likely to experience in the future, Room N226, 9-11:30 a.m. Presented in cooperation with the ADA Health Policy Resources Center;

- Oct. 16: "Create a Practice for 2001 Today"—Dr. Randolph Shoup will explore the key elements of outstanding practices and how to apply them to your practice, Room S403A, 8:30-11 a.m. Presented in cooperation with the ADA Council on Dental Practice;

- Oct. 16: "Medically Complex Patients, Assessment and Treatment Protocols"—Dr. Michael Glick will explain and provide clinical protocols for the dental care of patients who have complex medical conditions, Room N427A, 9:30-noon. Repeat 2-4:30 p.m. Presented in cooperation with the ADA Council on Access, Prevention and Interprofessional Relations.

The following ADA-sponsored sessions also are scheduled at McCormick Place North:

- Oct. 15: "Maximizing Your Future: Invest for the Long Term"—Robert Marronaro, Trent May, Susan Hunter, M.B.A., and Alden Stewart, M.B.A., will discuss the benefits of establishing a retirement plan, including the new investment option in the ADA Members Retirement Program, Room N231, 9-11:30 a.m. Presented in cooperation with the ADA Council on Insurance; (*See story, page 24.*)

- Oct. 15: "Current Risk Issues in Dentistry: Case Studies and Strategies"—Robyn Crimmins and Kathleen Roman will discuss current claims scenarios, their outcomes, pertinent laws, risk management recommendations and documentation strategies, Room N231, 1:30-4 p.m. Presented in cooperation with the ADA Council on Insurance. (*See story, page 25.*)

Sessions are open to all registrants, but seating is available on a first-come first-served basis. The American Dental Association is an ADA/CERP provider of continuing dental education. Up to 32 hours of courses are offered for continuing dental education credit. (One clock hour equals one credit hour.) ■

### The Only Drug Reference Dentists Need

Every day your patients rely on you for sound advice on prescription and over-the-counter drugs. Now the completely updated ADA Guide to Dental Therapeutics is the one source for quick, accurate information to help guide your drug treatment decisions.

Edited by Sebastian G. Ciancio, D.D.S., in cooperation with the ADA Council on Scientific

Buy the all-new revised edition with completely updated chapters and more than 30 new easy-reference tables. No other book has so much thorough and reliable drug information in one easy-access reference ...

- accurate information on over 3,000 generic and brand-name drugs used in dentistry and medicine
- nearly 500 concise tables giving rapid access to drug characteristics, indications, contraindications and interactions
- listing of products bearing the ADA Seal of Acceptance, an assurance of safety and efficacy you won't find in any other book

2nd Edition  
Newly Revised & Expanded

ADA PUBLISHING  
A Division of ADA Business Enterprises, Inc.

Expert Advice From  
Experts You Trust

**Yes! Please send me \_\_\_\_\_ copies of the ADA Guide to Dental Therapeutics (Item # K063)**

To order, just call 1-800-947-4746, visit our web site at [www.ada.org](http://www.ada.org) or fax sales, completed form to 630-443-9970, or mail it to:

P.O. Box 776,  
St. Charles, IL 60174

Please print all information

Name \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_ Stat \_\_\_\_\_ Zip \_\_\_\_\_  
Country \_\_\_\_\_  
Phone \_\_\_\_\_  
Fax \_\_\_\_\_

Payment must accompany order. Rates subject to change.

Members	Membership	\$44.95	QTY	=	
Non-Members (U.S. and foreign)		x	QTY	=	
		\$64.95	Tax	\$	
		x	(IL Residents add 7% sales tax.)		
	<input type="checkbox"/> Check enclosed (payable to ADA Publishing)		Shipping and Handling	\$	
	<input type="checkbox"/> Charge to: <input type="checkbox"/> Visa <input type="checkbox"/> MasterCard		U.S. (per book)	\$ 5.95	
			Foreign/Air Mail (per book—calculated according to destination)		
			<b>Total</b>	\$	
	Card # _____ Exp _____				
	Signature _____				



# CAPIR names community, geriatric award winners

## School, nursing home programs cited

An oral health program that invites students inside a larger-than-life human mouth and a Washington, D.C., dental fraternity that provides care for nursing home residents have received this year's Community Preventive Dentistry and Geriatric Oral Health Care awards, respectively.

The awards will be presented at the Special Recognition Luncheon scheduled Oct. 14 during the 141st Annual Session of the American Dental Association.

The Livingston County (Illinois) Body Walk is a hands-on educational program offered to fourth-grade students in the county's 19 elementary schools.

The program offers students a walking tour of the human body via a series of stations representing various aspects of anatomy, such as the mouth, head and brain. Organized so that each station leads to the next, the program demonstrates the interactions between the parts of the body and provides students an opportunity to interact with health professionals.

Dr. James Day, one of the creators of Body Walk, says the Oral Health Program component uses a basic mouth model comprised of a tent whose entrance is framed by a large pair of lips, a wooden board representing the tongue and molar "seats" which can be painted to show fillings and sealants.

The mouth station is designed to provide an intimate setting in which students can learn about the oral cavity. Some molar seats may offer a cut-away view of a tooth, showing pulp, dentin and enamel, enabling students to interactively visualize the tooth structure.

In recognition of Body Walk's Oral Health Program, the ADA Health Foundation on Access, Prevention and Interprofessional Relations designated the program to receive the 2000 Community Preventive Dentistry Award.

The Body Walk, which started in 1996, receives funding from the United Way, the local dental society and individual donors.

The Community Preventive Dentistry Award was established in 1972 and is sponsored by CAPIR through the ADA Health Foundation, with support from Johnson & Johnson Consumer Products Inc.

The first-place program will be awarded \$2,500 and a wall plaque during this year's annual session.

Meritorious awards of \$500 will be made to three other programs:

- "Springhouse Dental Program" is a day rehabilitation program that serves 250 members diagnosed with serious mental illness. Springhouse contracted with St. Francis House, a community health clinic, to provide its members with dental services which are paid for on a sliding fee scale with the help of grant funds, private donations and fundraising events. Springhouse members and staff conduct free community education programs to increase awareness about people with mental illness and the need to improve access to dental care for people unable to afford them;

- "Kern County Children's Dental Health Program" (Calif.) is a partnership comprising the Kern County Dental Society; Kern County Dental Hygienists Society; the Kern County Superintendent of Schools; the Kern County School Nurses' Organization; Taft College Dental Hygiene Program; Community Connection for

Child Care; and private child development centers and county school districts.

Participation in the program is based on a family's difficulty or inability to obtain access to dental services within its community.

- "SMILES, a School-Based Preventive Dental Program" is a preventive dental program created by Dental Health for Arlington. Sealing Molars Improves the Life of Every Student began in 1994 as a pilot project in two low-income elementary schools. The program provides local elementary school students with a visual screening by a volunteer dentist, oral health education, new toothbrush, and oral hygiene and nutritional instruction. Sealants are also provided.

Volunteer dentists from the Arlington Dental Student Club and the Texas Department of Public Health conduct oral screenings in Spanish, Vietnamese and English.

Families who are unable to afford needed treatment are referred to DHA's Allan Saxe Dental Clinic for complimentary care.

The Geriatric Oral Health Care Award, established in 1984, is sponsored by CAPIR through the ADAHF with the support of a generous grant from Warner-Lambert Co. Consumer Health Products Group.

The Alpha Omega Dental Fraternity, Washington chapter, will receive this year's 2000 Geriatric Oral Health Care Award during annual session, along with a \$2,500 check and wall plaque. The chapter provides comprehensive oral health care to the residents of

the Hebrew Home of Greater Washington, a 558 bed not-for-profit nursing home in Rockville, Md. Each of the Home's two buildings contains a dental clinic furnished primarily through the generosity of a local family of dentists.

Said Dr. Michael Barnett, senior director of dental affairs at Warner-Lambert Consumer Healthcare,

"It is critical that we recognize the valuable contribution of projects such as this to the overall well being of a growing segment of our population. We are pleased to work with the ADAHF Health Foundation in supporting this prestigious award program."

In January 1999 the Alpha Omega Dental Fraternity organized itself to form a volunteer dental panel, so that oral health care could be offered on a consistent basis to all the residents at Hebrew Home.


Thirty-five general and specialty dentists, assisted by a full-time dental assistant employed by the Home, provide the residents with a full range of dental services, encompassing all areas of dentistry, including examining, diagnosis, treatment and treatment planning.

The panel has also provided continuing education lectures to the nursing staff on daily oral care maintenance.

A meritorious award will also be made to the Washington State Dental Association for its video, "Oral Care for the Alzheimer's Patient—Video and Brochure."

Designed to meet the oral health care needs of individuals with early-stage Alzheimer's disease, the video demonstrates for caregivers of Alzheimer's patients how to provide daily oral hygiene and care, teaches the importance of regular dental examinations and suggests appropriate oral care products.

A companion brochure featuring additional information was also produced. The WSDA Seattle-based central office distributes the video and brochure. ■



# Proven.



Alert Condensable Composite offers exceptional clinical performance. But don't take our word for it.

A recent 12 month clinical report from the University of Texas-Houston Health Science Center shows that Alert Condensable Composite has excellent resistance to wear and to marginal discoloration. The report also showed that, after one year, Alert restorations had no recurrent caries, no sensitivity and 100% retention.

Another one year clinical study by the independent review journal *The Dental Advisor* gave Alert Condensable Composite a 96%, +++++ rating – their highest. 95 restorations were evaluated and none showed any fracture or chipping, 94% were rated excellent for marginal discoloration and 96% were rated excellent for wear resistance. Clinicians were pleased with Alert Composite's "good resistance to packing" and 5mm depth of cure.

To celebrate these results, we are offering Alert Condensable Composite at a very special price – just \$99 for a complete kit with four 4 gm. syringes plus Bond-1® Primer/Adhesive single step bonding agent and all the accessories you need. Gram for gram, that's about half the price of other composites. Because we manufacture Alert Condensable Composite and sell it to you directly, you save – as you do any time you order from Jeneric/Pentron.

Alert Condensable Composite offers proven clinical performance. Prove it in your office today.



Clinical photos courtesy of RoseMarie Fay, D.D.S.



# \$99

per kit\*

KIT CONTENTS: 4 gm. syringes • Alert Condensable Composite Matrix A2, A2.5, B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B14, B15, B16, B17, B18, B19, B20, B21, B22, B23, B24, B25, B26, B27, B28, B29, B30, B31, B32, B33, B34, B35, B36, B37, B38, B39, B40, B41, B42, B43, B44, B45, B46, B47, B48, B49, B50, B51, B52, B53, B54, B55, B56, B57, B58, B59, B60, B61, B62, B63, B64, B65, B66, B67, B68, B69, B70, B71, B72, B73, B74, B75, B76, B77, B78, B79, B80, B81, B82, B83, B84, B85, B86, B87, B88, B89, B90, B91, B92, B93, B94, B95, B96, B97, B98, B99, B100, B101, B102, B103, B104, B105, B106, B107, B108, B109, B110, B111, B112, B113, B114, B115, B116, B117, B118, B119, B120, B121, B122, B123, B124, B125, B126, B127, B128, B129, B130, B131, B132, B133, B134, B135, B136, B137, B138, B139, B140, B141, B142, B143, B144, B145, B146, B147, B148, B149, B150, B151, B152, B153, B154, B155, B156, B157, B158, B159, B160, B161, B162, B163, B164, B165, B166, B167, B168, B169, B170, B171, B172, B173, B174, B175, B176, B177, B178, B179, B180, B181, B182, B183, B184, B185, B186, B187, B188, B189, B190, B191, B192, B193, B194, B195, B196, B197, B198, B199, B200, B201, B202, B203, B204, B205, B206, B207, B208, B209, B210, B211, B212, B213, B214, B215, B216, B217, B218, B219, B220, B221, B222, B223, B224, B225, B226, B227, B228, B229, B230, B231, B232, B233, B234, B235, B236, B237, B238, B239, B240, B241, B242, B243, B244, B245, B246, B247, B248, B249, B250, B251, B252, B253, B254, B255, B256, B257, B258, B259, B260, B261, B262, B263, B264, B265, B266, B267, B268, B269, B270, B271, B272, B273, B274, B275, B276, B277, B278, B279, B280, B281, B282, B283, B284, B285, B286, B287, B288, B289, B290, B291, B292, B293, B294, B295, B296, B297, B298, B299, B300, B301, B302, B303, B304, B305, B306, B307, B308, B309, B310, B311, B312, B313, B314, B315, B316, B317, B318, B319, B320, B321, B322, B323, B324, B325, B326, B327, B328, B329, B330, B331, B332, B333, B334, B335, B336, B337, B338, B339, B340, B341, B342, B343, B344, B345, B346, B347, B348, B349, B350, B351, B352, B353, B354, B355, B356, B357, B358, B359, B360, B361, B362, B363, B364, B365, B366, B367, B368, B369, B370, B371, B372, B373, B374, B375, B376, B377, B378, B379, B380, B381, B382, B383, B384, B385, B386, B387, B388, B389, B390, B391, B392, B393, B394, B395, B396, B397, B398, B399, B400, B401, B402, B403, B404, B405, B406, B407, B408, B409, B410, B411, B412, B413, B414, B415, B416, B417, B418, B419, B420, B421, B422, B423, B424, B425, B426, B427, B428, B429, B430, B431, B432, B433, B434, B435, B436, B437, B438, B439, B440, B441, B442, B443, B444, B445, B446, B447, B448, B449, B450, B451, B452, B453, B454, B455, B456, B457, B458, B459, B460, B461, B462, B463, B464, B465, B466, B467, B468, B469, B470, B471, B472, B473, B474, B475, B476, B477, B478, B479, B480, B481, B482, B483, B484, B485, B486, B487, B488, B489, B490, B491, B492, B493, B494, B495, B496, B497, B498, B499, B500, B501, B502, B503, B504, B505, B506, B507, B508, B509, B510, B511, B512, B513, B514, B515, B516, B517, B518, B519, B520, B521, B522, B523, B524, B525, B526, B527, B528, B529, B530, B531, B532, B533, B534, B535, B536, B537, B538, B539, B540, B541, B542, B543, B544, B545, B546, B547, B548, B549, B550, B551, B552, B553, B554, B555, B556, B557, B558, B559, B560, B561, B562, B563, B564, B565, B566, B567, B568, B569, B570, B571, B572, B573, B574, B575, B576, B577, B578, B579, B580, B581, B582, B583, B584, B585, B586, B587, B588, B589, B590, B591, B592, B593, B594, B595, B596, B597, B598, B599, B600, B601, B602, B603, B604, B605, B606, B607, B608, B609, B610, B611, B612, B613, B614, B615, B616, B617, B618, B619, B620, B621, B622, B623, B624, B625, B626, B627, B628, B629, B630, B631, B632, B633, B634, B635, B636, B637, B638, B639, B640, B641, B642, B643, B644, B645, B646, B647, B648, B649, B650, B651, B652, B653, B654, B655, B656, B657, B658, B659, B660, B661, B662, B663, B664, B665, B666, B667, B668, B669, B670, B671, B672, B673, B674, B675, B676, B677, B678, B679, B680, B681, B682, B683, B684, B685, B686, B687, B688, B689, B690, B691, B692, B693, B694, B695, B696, B697, B698, B699, B700, B701, B702, B703, B704, B705, B706, B707, B708, B709, B710, B711, B712, B713, B714, B715, B716, B717, B718, B719, B720, B721, B722, B723, B724, B725, B726, B727, B728, B729, B730, B731, B732, B733, B734, B735, B736, B737, B738, B739, B740, B741, B742, B743, B744, B745, B746, B747, B748, B749, B750, B751, B752, B753, B754, B755, B756, B757, B758, B759, B760, B761, B762, B763, B764, B765, B766, B767, B768, B769, B770, B771, B772, B773, B774, B775, B776, B777, B778, B779, B780, B781, B782, B783, B784, B785, B786, B787, B788, B789, B790, B791, B792, B793, B794, B795, B796, B797, B798, B799, B800, B801, B802, B803, B804, B805, B806, B807, B808, B809, B810, B811, B812, B813, B814, B815, B816, B817, B818, B819, B820, B821, B822, B823, B824, B825, B826, B827, B828, B829, B830, B831, B832, B833, B834, B835, B836, B837, B838, B839, B840, B841, B842, B843, B844, B845, B846, B847, B848, B849, B850, B851, B852, B853, B854, B855, B856, B857, B858, B859, B860, B861, B862, B863, B864, B865, B866, B867, B868, B869, B870, B871, B872, B873, B874, B875, B876, B877, B878, B879, B880, B881, B882, B883, B884, B885, B886, B887, B888, B889, B890, B891, B892, B893, B894, B895, B896, B897, B898, B899, B900, B901, B902, B903, B904, B905, B906, B907, B908, B909, B910, B911, B912, B913, B914, B915, B916, B917, B918, B919, B920, B921, B922, B923, B924, B925, B926, B927, B928, B929, B930, B931, B932, B933, B934, B935, B936, B937, B938, B939, B940, B941, B942, B943, B944, B945, B946, B947, B948, B949, B950, B951, B952, B953, B954, B955, B956, B957, B958, B959, B960, B961, B962, B963, B964, B965, B966, B967, B968, B969, B970, B971, B972, B973, B974, B975, B976, B977, B978, B979, B980, B981, B982, B983, B984, B985, B986, B987, B988, B989, B990, B991, B992, B993, B994, B995, B996, B997, B998, B999, B1000.

**Toll Free 800-551-0283**

203-265-7397 • Toll Free Fax 877-677-8844

Order Online: [www.jeneric.com](http://www.jeneric.com)

FREE shipping when you order online

SOURCE CODE 1501



In Canada call SYMCA at 1-800-687-9622

**Jeneric®/Pentron®**  
INCORPORATED

Proudly manufactured in Wallingford, CT U.S.A.

We make good products at a fair price. And we stand behind them.

53 North Plains Industrial Road • P. O. Box 724 • Wallingford, CT USA 06492

Offer valid until November 30, 2000. No other offers apply. Offer valid U.S.A. only. Additional shipping charges may apply. Subject to change or cancellation without notice. © Jeneric/Pentron Inc. 2000. All rights reserved.



# Students ready table clinics for competition

Outstanding student table clinicians will represent their dental schools and showcase their accomplishments in clinical and research dentistry as they present their clinics Oct. 16 for judging in the 42nd ADA/Dentsply Student Table Clinic Competition at the ADA annual session.

Judging will be held in a closed session the morning of Oct. 16, and all clinics will be open for viewing from 2-4 p.m. in McCormick Place South (table clinic area in the exhibit hall).

Competition winners will present their clinics Oct. 17 to session goes from 9:30 a.m.-noon. Two hours of continuing education credit can be earned by attending the Oct. 16 clinics and one hour for the Oct. 17 clinics.

The program, which is financially underwritten by Dentsply International Inc., invites the table clinic winners from every dental school in the United States and Puerto Rico accredited by the ADA Commission on Dental Accreditation.

## Category I: Clinical Application and Technique

Judges for Category 1 are Drs. John Olmsted, Greensboro, N.C., chairman; Shirley Austin, Dearborn, Mich.; Cordell Fisher, Newport Beach, Calif.; Peter Guevara, Pittsburgh; Brenda J. Harman, Dallas; Arthur Hunger Jr., York, Pa.; Keith Krell, West Des Moines, Iowa; Dan Middaugh, Seattle; Jack Penhall, Greensburg, Pa.; John S. Rutkauskas, Hinsdale, Ill.

Category 1 entrants:

- E1, "Detection of Mandibular Fractures Using Tuned Aperture Computed Tomography," University of Pittsburgh School of Dental Medicine, Michael P. Johnson;
- E2, "Biocompatibility of Bone Cement, Mineral Trioxide Aggregate," and "Ethoxy Benzoic Acid in Ferret Canines," University of Maryland at Baltimore College of Dental Surgery, Gary M. Holt;
- E3, "Evaluation of Composite Repair Strength," Loma Linda University School of Dentistry, Scott W. Steedman;

## Annual Session

- E4, "In Vitro Effects of Daily Topical Fluorides on TMA Orthodontic Wires," University of Missouri School of Dentistry, Richard J. White;
- E5, "Digital Analysis of Trabecular Pattern in Jaws of Patients with Sickle Cell Anemia," University of California at Los Angeles School of Dentistry, Jason M. Cohen;
- E6, "Controlling DUWL Bacterial Contamination and Biofilm Through Chemical Biocides," University of North Carolina School of Dentistry, Natalie D. Tart;
- E7, "Accuracy of Various Diagnostic Methods in Detecting Fissure Caries Lesions, a Pilot Study," The University of Texas at San Antonio Health Science Center, Greg K. Gor;
- E8, "Quantitative and SEM Evaluation of Bond Performance Utilizing Three Chairside Hard Reline Systems on Three Denture Surface Preparations," State University of New York at Stony Brook School of Dental Medicine, Mouhab Z. Rizkallah;
- E9, "Shear Bond Strength to Wet and Dry Dentin," Louisiana State University School of Dentistry, Marlon D. Henderson;
- E10, "Comparison of a Plasma-arc and Conventional Halogen Light-curing Units," University of Mississippi School of Dentistry-Medical Center, Steven B. Roberts;
- E11, "Endosseous Implants in Patients with a History of Head and Neck Cancers," University of Detroit Mercy School of Dentistry, Steven Z. Edlund;
- E12, "Maximum and Intuitive Forces that Inexperienced Clinicians will Apply to an Implant Abutment Screw," Medical University of South Carolina College of Dental Medicine, Andrew G. Gambrell;
- E13, "Drug Reference Comparison," The



**Tall story:** The Sears Tower dominates Chicago's famous lakefront skyline.

Oregon Health Science University School of Dentistry, Michael D. Payne;

- E14, "Surgical and Radiotherapy Management of Synovial Sarcoma: A Case Report," Southern Illinois University School of Dental Medicine, Steven J. Hyten;
- E15, "Mechanical and Corrosion Properties of a New Beta-Titanium Orthodontic Wire," University of Alabama School of Dentistry, Murray D. Dickson;
- E16, "Save the Pulp—The Partial Pulpotomy: A Review," University of Texas at Houston, Azie M. Atang;
- E17, "Cementation of Indirect Restorations with Composite Resin Cement Utilizing an Ultrasonic Insertion Technique," Northwestern University, Gerald F. Johnson;
- E18, "An Evaluation of a Resin System as an Alternative to Porcelain Restoration using CAD-CAM Technique," University of Puerto Rico, Ramon Ortiz;
- E19, "Comparing Polishing Systems on Microhybrid Composite Resin Utilizing Profilometry," Tufts University, Bruce M. Nghiem;
- E20, "Comparisons of D and E-Plus Speed Films with CCD" and "CMOS-APS Digital Sensors for Evaluation of Diagnostic Efficacy," University of Pennsylvania, James Tsau;

● E21, "Stainless-Steel versus Nickel-Titanium Files," University of Southern California, Rozita Nosratabadi;

- E22, "Mechanical Properties of Glass Ionomer Cements," University of Illinois, Christine Gadia;
- E23, "Porcelain Repair Using Current Dental Bonding Systems," Nova Southeastern University, Paul D. Anderson;
- E24, "Simulated Smile Design as an Adjunct to Esthetic Treatment Planning," University of the Pacific, William Worden;
- E25, "Rapid Curing Orthodontic Bracket Adhesive with a Xenon Plasma Arc Light," University of Colorado, Stacy A. Henderson.

## Category II: Basic Science and Research

Judges for Category 2 are Drs. Richard Tatum, Columbia, Md.; Stephen Abel, New York City; Robert Augsburger, Tulsa, Okla.; Gordon Christensen, Provo, Utah; Thomas Emmering, Bloomington, Ill.; Pamela S. Herrera, Bloomfield Hills, Mich.; Joseph V. Levy, Burlingame, Calif.; Mirdza E. Neiders, Amherst, N.Y.; Linda C. Niessen, Dallas; Rahele Rezai, Washington, D.C.; Richard G. Shaffer, Potomac, Md.; Guy S. Champagne, Annapolis, Md.; Roger Stambaugh, Santa Monica, Calif.; Rada Sumareva, Brooklyn, N.Y.; Dr. Jon B. Suzuki, Pittsburgh; Thomas Van Dyke, Boston; Joel White, San Francisco; Dr. Hans J. Wenz, Germany.

Category 2 entrants:

- F1, "Congenital Cardiac Disease (CCD) and the Oral Microflora: Is There a Correlation?" West Virginia University School of Dentistry, Lori L. Gochenour;
- F2, "Post-operative Pain Processing in the Human Brain: A Dento-alveolar Surgery Pain Model," New York University College of Dentistry, Michael J. Spink;
- F3, "Intra-oral Appliances and Collagen Fiber Anisotropy in the TMJ Disc," University of Washington School of Dentistry, Stan E. Edwards;
- F4, "Gene Transfer of Platelet-derived Growth Factor to Periodontal Cells," The University of Michigan School of Dentistry, Marjon B. Jahromi;
- F5, "The Development of a Model to Study Migration of Osteoblasts on Type I Collagen," The University of Connecticut School of Dental Medicine, Sophie Markovic;
- F6, "THP-1 Monocytes vs. Human Peripheral Monocytes for Biocompatibility Testing," Medical College of Georgia School of Dentistry, Tina L. Heil;
- F7, "Multiple Single Unit Electrophysiological Recording in the Behaving Rat: A Testable Behavioral Paradigm," Columbia University School of Dental and Oral Surgery, Stephen T. Connelly;
- F8, "Inherited Non-syndromic Cleft Palate in Mice: Phenotypic and Molecular Studies," Indiana University School of Dentistry, Robert E. Blau;
- F9, "Hearing Loss in Dentistry," Marquette University School of Dentistry, Robb A. Warren;

See STUDENTS, page 31

## Great Savings at Your Fingertips!

**ADA**  
ELECTRONIC COMMERCE  
**Marketplace**

The ADA Electronic Commerce Marketplace offers safe, secure online shopping from your home or office. Register today to begin shopping and start saving!


- GREAT SAVINGS - Discounts up to 50% off.
- OVER 80 LEADING MERCHANTS - barnesandnoble.com, babygear.com, garden.com and many more.
- SHOP BY CATEGORY - books, computers, toys and more.
- 24-HOUR ONLINE CUSTOMER SERVICE

The ADA Electronic Commerce Marketplace makes shopping easy!

1. Log on at [www.ada.org/ecco](http://www.ada.org/ecco)
2. Click on the ADA Electronic Commerce Marketplace.
3. Register with your ADA number, your e-mail address and create a password.

[www.ada.org/ecco](http://www.ada.org/ecco)





**Has a patient of yours ever gotten this excited about dental hygiene?**

Probably not. But with its combination of 31,000 brush strokes per minute and gentle sonic waves, **sonicare**® can remove even hidden plaque, giving your patients a clean feeling so unique, it will turn just about anyone into a dental hygiene fanatic. In fact, we'll even guarantee your patients better checkups after just 90 days, or we'll give them their money back. For a sampling of the more than 40 published studies on **sonicare**, please call 1-800-676-SONIC.



It's not just a better toothbrush. It's a better checkup. **sonicare**®  
the sonic toothbrush



# EMERGENCY INSURANCE

THE HEALTHFIRST LINE OF MEDICAL EMERGENCY PRODUCTS

## emergent-ez "e-cart" system

**CART SYSTEM 4000** with.....**SM1 KIT**.....OR.....**HM1000 KIT**.....



**GROUP A:**



The HealthFirst emergent-ez "e-cart" system is a mobile oxygen supply unit complete with a demand and resuscitation valve. The "e-cart" system, when combined with a basic emergency kit, prepares your office for common emergencies.

The oxygen supply, on a wheeled cart, can be quickly moved to an emergency.

The demand and resuscitation valve will provide either positive pressure or demand oxygen applications (Group A, pictured lower left.)

The basic color-coded emergency kit, either model SM1 or model HM1000 (pictured above) is accessible in the easy-to-reach bracket on the cart.

**PROTECT YOURSELF... BE PREPARED!**



**HealthFirst Corp.**

22316 70th Ave. W., #A  
Mountlake Terrace, WA 98043

**1-800-331-1984**

website: [www.healthfirstcorp.com](http://www.healthfirstcorp.com)



## Annual Session

### Students

*Continued from page 28*

- F10, "Salivary Flow, Medication Use, and Xerostomia Among a 79+ year old Cohort," The University of Iowa College of Dentistry, Scott D. Thompson;
- F11, "Changes in Soft Tissue Measurements for Three Randomly Placed Implant Types," Ohio State University College of Dentistry, Jonathan J. Eaton;
- F12, "Macro-Indentation Load Damage of Selected Resin Composites," University of Oklahoma Health Science Center, Rocky D. Cullens;
- F13, "Interocclusal Distance in Subjects with Normal Occlusion and Malocclusion," Texas A&M University System Baylor College of Dentistry, Shannon E. Owens;
- F14, "Preventing the Induction of Oral and Maxillofacial Clefting by Understanding the

Effects of Some Common Teratogens on Gene Pathways, Including the Sonic Hedgehog and Others," Howard University College of Dentistry, Brandon M. Wainwright;

- F15, "Infection of Human Bone Marrow Stromal Cells with Replication Deficient Adenovirus: Dose-Dependent Infectivity and Protein Synthesis," Virginia Commonwealth University School of Dentistry, Tricia T. Tran;
- F16, "Marginal Fit of Shoulder Porcelain Fused to Metal Restorations Fabricated with Gypsum and Epoxy Die Materials," University of Nebraska, Medical Center College of Dentistry, Denise D. Claridge;
- F17, "Low Neutrophil-Priming Activity of Lipopolysaccharide from *Fusobacterium Nucleatum*," University of Tennessee College of Dentistry, Richard H. Gentzler;
- F18, "Periodontitis as a Risk Factor for

Cardiovascular Disease," State University of New York at Buffalo, Jonathan E. Adam;

- F19, "Induced Osteogenesis by Periosteal Distraction," University of California at San Francisco, Laski M. Kung;
- F20, "Expression of Zfphep Transcription Factor During Development of Meckel's Cartilage," University of Louisville, Michael G. Lecheminant;
- F21, "Prevalence of the Mandibular Lingual Foramen and its Review," Creighton University, Brian J. Gribble;
- F22, "The Development of a Polymer Based Chlorhexidine Delivery Device for the Treatment of Periodontal Disease," Harvard School of Dental Medicine, Isaac C. Yue;
- F23, "Arylsulfatase A Activity in Human Saliva: Stimulation by Ethanol," University of Medicine and Dentistry New Jersey, Neha P. Shah;

● F24, "Chitin Hydrolases of the Oral Pathogen," Boston University, Charlie Hong;

- F25, "Fracture Patterns for Bonded Composite—Empress II Chevron Notched Specimens," University of Florida, Joseph H. Farag;
- F26, "The Effect of Short-course Administration of Non-Steroidal Anti-Inflammatory Agents (NSAIDs) on Prostaglandin E2 Production during Orthodontic Tooth Movement," University of Minnesota, Jim R. Miller;
- F27, "Single Nucleotide Polymorphisms in the Human B-defensin 2 Gene," Case Western Reserve University, Rob Armstrong;
- F28, "Stress Enhanced HSV-1 Immediate Early (ELa) Gene Activity in PC-12 Cells," University of Kentucky, Chris Freeman. ■

### International students to present clinics

The winners of the 2000 DENTSPLY student table clinic competitions in Canada, France, Germany, India, Japan, Scandinavia, South Africa, South Korea, Taiwan, Thailand and the United Kingdom will also present their clinics from 2-4 p.m. Oct. 16, and again with the winning U.S. clinicians on the morning of Oct. 12 from 9:30 a.m. to noon.

At press time, table clinic titles were available for the following international students:

- D1, "A non-RGD Recognition Peptide Inhibits Spreading of Keratinocytes on Fibronectin," Phoebe Tsang, University of British Columbia, Canada;
- D2, "Contribution to the Study of the Buccal Mucous Membrane Microcirculation by Capillaroscopy," Grégoire Kuhn, Paris VII University, France;
- D3, "Carrier Materials for Recombinant Human Osteogenic Protein-1 in Sinus-augmentation with Simultaneous Insertion of Dental Implants—An Experimental Study in Miniature Pigs," Heide Müller, University of Kiel, Germany;
- D4, "Modification in the Dental Office for the Handicapped Patient," Rahul Rehani, Maulana Azad Medical College, India;
- D5, "A Study on the Setting Reaction and Heat Evolution of Dental Cements Using Differential Scanning Calorimeter," Nam Sejin, Seoul National University, Korea;
- D6, "An Identical Mutans Streptococci Genotypes be Found in Dating Individuals," Even Nisja, University of Malmö, Sweden;
- D7, "An Application of Lead Foil from used Periapical Films for Radiation Protection Purposes," Lalisa Yaowaratana, Chiang-Mai University, Thailand;
- D8, "Dental Masks—Little More Than a Cover Up," Nicholas Fabbri, University of Liverpool, United Kingdom;
- D9, "Advancements in Dental Mirrors to Assist Tooth Preparation for Students," Masahi Nakajim, Osaka University, Japan;
- D10, "Interproximal Thickness of Six Bonding Agents Utilizing Different Prescribed Techniques," Dannhe Thorsten, University of Pretoria, South Africa;
- D11, "An Analysis of Surface Alteration on Human Dentin after the Application of The Nd: YAG Laser," Yu Chi Wei, National Taiwan University, Taiwan. ■

# SRP + PERIOSTAT®

## THE WHOLE MOUTH TREATMENT FOR ADULT PERIODONTITIS.



**SRP**



**Periostat**  
(doxycycline hyclate) 20mg capsules

### NOW YOU CAN TREAT THE PROBLEM FROM THE INSIDE AND OUT.

By combining the antimicrobial effects of SRP (scaling and root planing) with the systemic benefits of Periostat, you can help give your patients with adult periodontitis a healthier mouth, inside and out. Periostat is the first oral enzyme-suppressing agent proven to slow the progression of disease.\* Prescribe one capsule twice a day for your SRP patients and you'll be helping them get the most out of their SRP treatment.

When used in combination with SRP, Periostat is proven to:<sup>1,2</sup>

- Significantly enhance the results of SRP
- Treat the whole mouth at once, not just one area at a time
- Provide efficacy with convenient oral, bid dosing
- Have an antimicrobial susceptibility profile similar to placebo for up to 18 months
- Have a safety profile comparable to placebo

THE WHOLE MOUTH TREATMENT FOR ADULT PERIODONTITIS



**COLLAGENEX**  
pharmaceuticals

www.collagenex.com  
For more information, visit the CollaGenex Web site, or call CollaGenex Professional Affairs at 1-888-339-5678.



**Periostat**  
(doxycycline hyclate) 20mg capsules

Periostat is a 20 mg form of doxycycline. Traditional tetracycline contraindications, precautions, and warnings must be considered prior to use of Periostat. This drug is contraindicated in people who have shown hypersensitivity to any of the tetracyclines. Tetracycline drugs should not be used in infants, children less than 8 years old, or pregnant or nursing women unless potential benefits outweigh potential risks. Patients exposed to direct sunlight or ultraviolet light should be advised that an exaggerated sunburn reaction can occur with tetracycline drugs.

Please see Contraindications, Warnings, Precautions, and Adverse Reactions in the Brief Summary of Prescribing Information on next page.  
\*Clinical studies show that doxycycline reduces the elevated collagenase activity in the gingival crevicular fluid of patients with adult periodontitis. The clinical significance of these findings is not known. Please see accompanying Brief Summary of Prescribing Information for further reference.



# Annual Session Delegates

Continued from page one  
as of press time. Each resolution is submitted to a House reference committee based on subject matter and is listed by reference committee here.

## Budget and Business Matters

**Res. 6** calls for an amendment to change the name of the Council on Insurance to the Council on Insurance and Retirement Programs to better reflect the council's duties in both the insurance and retirement investment arenas.

**Res. 25** proposes a Bylaws change that will

decrease membership dues \$3 to reflect a reduction for one-time activities that were authorized for 2000 but not recurring, partially offset by funding for the proposed 2001 budget. The dues amount can be amended during the course of the annual session to coincide with House actions that would impact the budget. If approved, the dues change becomes effective Jan. 1, 2001.

**Res. 40** proposes a special assessment of \$45 a year for six years (2001-2006) for the purpose of funding the renovation of the ADA-occupied floors in the Chicago headquarters building. All funds from this assessment will be maintained in a segregated account.

## Dental Benefits, Practice and Health

**Res. 10** addresses the ADA's position on health literacy, a national health issue. Statistics show that those patients with the

greatest need for health care may have the least ability to access and understand the information they need to function successfully as a patient.

The resolution proposes a specific health literacy policy that will strengthen the ADA's position as it encourages health care organizations considering health literacy campaigns to recognize the importance of oral health literacy and include oral health literacy as a component of their efforts.

**Res. 10** states that:

- functional health illiteracy—the inability to read and understand essential health-related materials required to successfully function as a patient—is a barrier to access to effective oral health care that affects more than one-third of the adult U.S. population;

- the ADA, through the appropriate agencies,

communicate with health care organizations that have or are developing health literacy awareness and advocacy programs the ADA's concern that limited health literacy affects all aspects of health care, including oral health care;

- the ADA encourage patient advocacy organizations and government agencies such as the National Institute of Dental and Craniofacial Research to develop appropriate patient resources and professional educational programs that can assist oral health care providers in communicating with patients who have limited literacy skills;

- that appropriate ADA agencies offer technical advice and assistance relating to oral health care to organizations that are developing health literacy resources and programs.

**Res. 20** and **Res. 21** deal with existing Association policy statements on dental benefit programs. **Res. 20** amends the Statement for Dental Benefit Plans by adding:

- "Fee schedules should be based on procedures performed by the dentist and not on the specialty status of the dentist performing them."

- "The database used by plan administrators to set fee schedules, percentiles or for UCR determinations should be current, geographically relevant and readily available to the public."

- "Profiling to establish a different rate of reimbursement for the provider should not be used as a means of cost control by the plan administrators."

- "The data, calculations and methodology used for practice profiling of individual dentists should be made available to those dentists upon request."

**Res. 21** calls for an amendment to the Requirements for Managed Care Programs—section on Legislative/Regulatory issues—with the addition of the following: "All plans should have the ability to report every treatment service provided to each patient. These data should be made available to enrollees, plan purchasers, appropriate regulatory agencies and any other entity that is responsible for evaluating the plan."

**Res. 23** states the ADA's opposition—as a leader in the promotion of good oral health—to the practice of marketing soft drinks in elementary and secondary schools.

## Dental Education and Related Matters

**Res. 13** proposes that the American Academy of Orofacial Pain's request for recognition of orofacial pain as a dental specialty be denied because AAOP has failed to demonstrate compliance with all requirements for recognition as contained in the Requirement for Recognition of Dental Specialties and the National Certifying Board for Dental Specialists.

**Res. 14** affirms the ADA's support for the right of appropriately trained dentists to administer anesthesia services to dental patients. The language in **Res. 14** is consistent with the language contained in the Association's policy statement: The Use of Conscious Sedation, Deep Sedation and General Anesthesia in Dentistry.

**Res. 16**—a policy statement drafted by the Council on Dental Education and Licensure—addresses the dentist's responsibility to pursue life-long learning throughout his or her professional career through a variety of educational methods. **Res. 16** encourages members to identify individual needs and calls for the development of a plan to meet those needs. If adopted, the CDEL expects to implement long-term goals associated with this policy including development of a curriculum model for life-long learning.

**Res. 30** and **Res. 31** propose revisions to the ADA's Guidelines for Teaching the Comprehensive Control of Anxiety and Pain in Dentistry and the Guidelines for the Use of Conscious Sedation, Deep Sedation and General Anesthesia. The proposed changes incorporate content into both documents related

# Periostat<sup>®</sup>

(doxycycline hyclate) **CD 20mg capsules**

## THE WHOLE MOUTH TREATMENT FOR ADULT PERIODONTITIS

**PERIOSTAT<sup>®</sup>**  
(doxycycline hyclate capsules USP)

### BRIEF SUMMARY INDICATIONS AND USAGE

Periostat<sup>®</sup> is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.

### CONTRAINDICATIONS

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

### INERT INGREDIENTS

Hard gelatin capsules, magnesium stearate, microcrystalline cellulose.

### MECHANISM OF ACTION

Studies have shown that doxycycline reduces elevated collagenase activity in the gingival crevicular fluid of patients with adult periodontitis. The clinical significance of these findings is not known.

### MICROBIOLOGY

The dosage of doxycycline achieved with this product during administration is well below the concentration required to inhibit microorganisms associated with adult periodontitis. This product **should not** be used for reducing the numbers of or eliminating those microorganisms associated with periodontitis.

### WARNINGS

THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP AND IN PREGNANT OR NURSING MOTHERS UNLESS THE POTENTIAL BENEFITS MAY BE ACCEPTABLE DESPITE THE POTENTIAL RISKS.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fetal growth rate has been observed in premature infants given oral tetracyclines in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.

Doxycycline can cause fetal harm when administered to a pregnant woman. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracyclines are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

The catabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

### PRECAUTIONS

While no overgrowth by opportunistic microorganisms such as yeast were noted during clinical studies, as with other antimicrobials, Periostat<sup>®</sup> therapy may result in overgrowth of non-susceptible microorganisms including fungi.

The use of tetracyclines may increase the incidence of vaginal candidiasis.

Periostat<sup>®</sup> should be used with caution in patients with a history or predisposition to oral candidiasis. The safety and effectiveness of Periostat<sup>®</sup> has not been established for the treatment of periodontitis in patients with coexistent oral candidiasis.

If superinfection is suspected, appropriate measures should be taken.

**Laboratory Tests:** In long-term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed.

**Drug Interactions:** Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacterial antibiotics, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of members of the  $\beta$ -lactam (e.g. penicillin) class of antibiotics, it is not advisable to administer these antibiotics concomitantly.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. Absorption is also impaired by bismuth subsalicylate.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and Penthrane (methoxy-fluorane) has been reported to result in fatal renal toxicity.

Concurrent use of tetracycline may render oral contraceptives less effective.

**Drug/Laboratory Test Interactions:** False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Doxycycline hyclate has not been evaluated for carcinogenic potential in long-term animal studies. Evidence of oncogenic activity was obtained in studies with related compounds (i.e., oxytetracycline [adrenal and pituitary tumors] and minocycline [thyroid tumors]).

Doxycycline hyclate demonstrated no potential to cause genetic toxicity in an *in vitro* point mutation study with mammalian cells (CHO/HGPRT forward mutation assay) or in an *in vivo* micronucleus assay conducted in CD-1 mice. However, data from an *in vitro* assay with CHO cells for potential to cause chromosomal aberrations suggest that doxycycline hyclate is a weak clastogen.

Oral administration of doxycycline hyclate to male and female Sprague-Dawley rats adversely affected fertility and reproductive performance, as evidenced by increased time for mating to occur, reduced sperm motility, velocity, and concentration, abnormal sperm morphology, and increased pre- and postimplantation losses. Doxycycline hyclate induced reproductive toxicity at all dosages that were examined in this study, as even the lowest dosage tested (50 mg/kg/day) induced a statistically significant reduction in sperm velocity. Note that 50 mg/kg/day is approximately 10 times the amount of doxycycline hyclate contained in the recommended daily dose of Periostat<sup>®</sup> for a 60 kg human when compared on the basis of body surface area estimates (mg/m<sup>2</sup>). Although doxycycline impairs the fertility of rats when administered at sufficient dosage, the effect of Periostat<sup>®</sup> on human fertility is unknown.

**Pregnancy: Teratogenic Effects:** Pregnancy Category D. (See WARNINGS.) Results from animal studies indicate that doxycycline crosses the placenta and is found in fetal tissues.

**Nonteratogenic effects:** (See WARNINGS.)

**Labor and Delivery:** The effect of tetracyclines on labor and delivery is unknown.

**Nursing Mothers:** Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from doxycycline, the use of Periostat<sup>®</sup> in nursing mothers is contraindicated. (See WARNINGS.)

**Pediatric Use:** The use of Periostat<sup>®</sup> in infancy and childhood is contraindicated. (See WARNINGS.)

### ADVERSE REACTIONS

**Adverse Reactions in Clinical Trials of Periostat<sup>®</sup>:** In clinical trials of adult patients with periodontal disease 213 patients received Periostat<sup>®</sup> 20 mg BID over a 9 - 12 month period. The most frequent adverse reactions occurring in studies involving treatment with Periostat<sup>®</sup> or placebo are listed below:

Incidence (%) of Adverse Reactions in Periostat<sup>®</sup> Clinical Trials

	Periostat <sup>®</sup> 20 mg BID (n=213)	Placebo (n=215)
Headache	55 (26%)	56 (26%)
Common Cold	47 (22%)	46 (21%)
Flu Symptoms	24 (11%)	40 (19%)
Tooth Ache	14 (7%)	28 (13%)
Periodontal Abscess	8 (4%)	21 (10%)
Tooth Disorder	13 (6%)	19 (9%)
Nausea	17 (8%)	12 (6%)
Sinusitis	7 (3%)	18 (8%)
Injury	11 (5%)	18 (8%)
Dyspepsia	13 (6%)	5 (2%)
Sore Throat	11 (5%)	13 (6%)
Joint Pain	12 (6%)	8 (4%)
Diarrhea	12 (6%)	8 (4%)
Sinus Congestion	11 (5%)	11 (5%)
Coughing	9 (4%)	11 (5%)
Sinus Headache	8 (4%)	8 (4%)
Rash	8 (4%)	6 (3%)
Back Pain	7 (3%)	8 (4%)
Back Ache	4 (2%)	9 (4%)
Menstrual Cramp	9 (4%)	5 (2%)
Acid Indigestion	8 (4%)	7 (3%)
Pain	8 (4%)	5 (2%)
Infection	4 (2%)	6 (3%)
Gum Pain	1 (1%)	6 (3%)
Bronchitis	7 (3%)	5 (2%)
Muscle Pain	2 (1%)	6 (3%)

Note: Percentages are based on total number of study participants in each treatment group.

**Adverse Reactions for Tetracyclines:** The following adverse reactions have been observed in patients receiving tetracyclines:

Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with vaginal candidiasis) in the anogenital region. Hepatotoxicity has been reported rarely. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving the capsule forms of the drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (SEE DOSAGE AND ADMINISTRATION.)

Skin: maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See WARNINGS.)

Renal toxicity: Rise in BUN has been reported and is apparently dose-related. (See WARNINGS.)

Hypersensitivity reactions: urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.

Blood: hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia have been reported.

### OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Doxycycline is eliminated with a half-life of approximately 18 hours by renal and fecal excretion of unchanged drug. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdose.

### DOSAGE AND ADMINISTRATION

THE DOSAGE OF PERIOSTAT<sup>®</sup> DIFFERS FROM THAT OF DOXYCYCLINE USED TO TREAT INFECTIONS. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS INCLUDING THE DEVELOPMENT OF RESISTANT MICROORGANISMS.

Periostat<sup>®</sup> 20 mg twice daily as an adjunct following scaling and root planing may be administered for up to 9 months. Safety beyond 12 months and efficacy beyond 9 months have not been established.

Periostat<sup>®</sup> should be administered at least one hour prior to morning and evening meals.

Administration of adequate amounts of fluid along with the capsules is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration. (SEE ADVERSE REACTIONS.)

### CAUTION

Federal law prohibits dispensing without a prescription.

PERIOSTAT<sup>®</sup> is a trademark of ColLAGENEX Pharmaceuticals, Inc., Newtown, PA 18940

Manufactured by Applied Analytical Inc.

Wilmington, NC 28403

Marketed by ColLAGENEX Pharmaceuticals, Inc., Newtown, PA 18940



### References:

1. Golub LM, Ryan ME, Williams FC. Modulation of the host response in the treatment of periodontitis. *Dentistry Today*. 1998;17(10):1-6. 2. Data on file. ColLAGENEX Pharmaceuticals, Inc.



to the use and administration of oral sedation and ensure that the documents remain current.

**Res. 35** requests funding for the Council on Dental Education and Licensure to implement long-term goals associated with allied personnel recruitment and retention initiatives. If adopted, resource materials for use by constituent and component dental societies and member dentists would be developed.

**Res. 42** was developed in response to a 1999 House of Delegates directive that proposed a career guidance program to recruit students into dentistry. The program, as proposed, includes both short- and long-term recruitment goals that will build on the strength of past SELECT Program initiatives. The proposal also calls for the establishment of a network of state- and local-level coordinators to serve as career guidance partners.

**Legal and Legislative Matters**

**Res. 1** seeks to amend the duties of the Council on Ethics, Bylaws and Judicial Affairs with regard to the Bylaws, with the intent of streamlining the process of making editorial changes in the Bylaws. Currently, CEBJA is authorized to propose editorial changes to the House of Delegates, which means the House must review and approve all changes—even spelling, grammar errors and misplaced punctuation marks.

Res. 1 will authorize the Council to recommend to the House editorial changes in the Bylaws to improve their consistency, clarity and style, but grants CEBJA the authority to make Bylaws corrections that do not alter the Bylaws' context or meaning—such as punctuation, grammar and spelling—through unanimous vote of CEBJA members present and voting.



Chicago fun: Navy Pier's Ferris wheel.

**Scientific Matters**

**Res. 33** calls for the ADA to develop laboratory protocols and capabilities to replicate ISO 11143—an international standard for dental equipment—for amalgam separators, evaluate the standards for its applicability and appropriateness, and develop the laboratory and other evaluation protocols to test the performance of amalgam separators as wastewater amalgam/mercury reduction devices.

**1999 resolutions**

**Res. 91**—held over for further study from the 1999 House—calls for the formation of a 17th Trustee District composed of the state of Florida. The substitute resolution by the ADA Board of Trustees modifies the resultant council assignments proposed to accommodate the fact that the Council on Scientific Affairs membership is not district based. (See story, page 23.) ■

**It's easy to build your Web site**  
Netopia offers ADA members the know-how

Do you ever feel like technology is passing you by?

Catch up—in less than an hour—with Netopia, the Web-creation company endorsed by ADA Business Enterprises, Inc.

By using a content package specifically designed for ADA members, Netopia will create and customize dental practice Web sites for ADA members.

"It wasn't a big investment to get in on the ground floor," said Dr. Frank Egan, an orthodontist practicing in East Patchogue, N.Y. "Now I have a Web site I can continue to work with in the future."

Netopia's team of skilled design specialists will build an entire Web site using information and graphics a dentist chooses to provide.

Typical dental practice sites consist of eight customized pages, including medical history forms, patient education pages, a link to the



ADA and links to other dental related sites.

Dr. Michael Montalbano, Baton Rouge, La., distinguished his site by hosting a "no cavity" club for children. Children who receive cavity-free check-ups get their pictures posted on the site.

"The photos look great," said Kim Thomas, the dental hygienist at Dr. John Benedetto's, Olympia Fields, Ill., dental practice. "We provide a lot of cosmetic dentistry services so it's great to show patients before and after photos."

Most dentists choose Netopia's Premium Service, which includes software, site building and hosting of sample content and graphics.

Dentists also have the option of customizing their own Web site. They begin with a basic hosting package with telephone and/or e-mail support, then follow the simple steps to build a site using Netopia's powerful design software.

Visit Netopia Booth 4711 in the ADA Resource Center at annual session and enter to win the daily drawing.

For more information, call Netopia Inc., 1-800-513-9062, or go to "adaecco.netopia.com" to learn more. ■

# KaVo

**PRESENTS A MATCHED SET OF HIGH- AND LOW-SPEED HANDPIECES THAT PROVIDE...**

**CONSISTENT FEEL.  
PRECISION BALANCE.  
RELIABLE PERFORMANCE.**

The Signet System combines KaVo's advanced handpiece technology into a single, affordable system for all your restorative clinical needs.



FOR DENTISTS WHO INSIST ON THE BEST

KaVo America Corporation | 340 East Main Street, Lake Zurich, IL 60047 | 1.888.KaVo.USA (528.6872)  
Fax 1.847.550.6825 | www.kavousa.com



**IN ADDITION, THE SIGNET SYSTEM OFFERS THESE EXCLUSIVE BENEFITS:**

**2 YEAR WARRANTY**  
Peace of mind from an extended two year factory warranty. . .double the length of any other comprehensive warranty.

**PERSONALIZATION**  
Immediate handpiece identification with your laser etched initials.

**SPECIAL PACKAGE PRICING**  
Three Cellular Optic High Speed Handpieces Plus One Coupler  
PLUS  
Any One of these Two Low Speed Systems:  
Signet System L-Package (optic w/ spray)  
Signet K-Package (non-optic)

Now, you can own the most reliable, highest quality handpieces available at special prices. Contact your local authorized KaVo dealer or KaVo, but do not delay.

See us at the ADA meeting booth 2011



## Get ready for the new ADA.org

Log on and find a wealth of information on the profession

At a time when most of the gold medals are being awarded offshore, one sure-fire winner is debuting here at home.

This month, ADA.org will re-emerge on the World Wide Web as the premier source of oral health information.

The redesigned ADA Web site offers the dental profession and the public more of the reliable news and information they've become accustomed to from the ADA—but with faster and easier access.

"The ADA.org site is moving into the next generation," said Dr. John S. Zapp, ADA executive director. "Its redesign marks the beginning of a new era in the delivery of oral health information."

### Learning Center showcases ADA.org, page 38

To many, it may come as no surprise that the world's most prominent oral health organization would build a Web site that surpasses all other commercial oral health sites in providing such service.

But ADA.org didn't become the best because it was created by the biggest. Instead, the American Dental Association crafted a one-stop resource that is broad in scope, yet easy to use.

A new navigation scheme puts all resources available on ADA.org (on the Internet at "www.ada.org") at your fingertips. Finding specific information is now easier and quicker with an overhauled search function that provides advanced search capabilities and a user-friendly interface.

On the Profession page, several content areas, including Dental Education Programs



and ADA Meetings and Events, have been reorganized into searchable databases to provide fast access to these popular offerings.

Careers and Classifieds brings the ADA's online resources on careers in dentistry together in one easy-to-use reference. The classified advertising from the Journal of the American Dental Association, widely recognized as the most comprehensive collection of classified ads in dentistry, is now online in a searchable database format.

You can also search a database of articles on legal and ethical issues of relevance to the dental profession or access specific legal information through new links on a new Law, Ethics and Risk Management content area, which also includes information on the protocol for secur-

ing legal assistance from the ADA on matters of national significance for dentistry.

The Public page provides answers to patients' oral health questions and connects patients to an ADA-member dentist in their neighborhood.

Dentists can go to the ADA page to access key ADA officers and trustees or even to enjoy some recreational reading, such as an ADA timeline that captures a glimpse of the history of organized dentistry.

Resources on the Products and Services page provide links to consumer products and financial services that can help dentists develop their own Web site, expedite reimbursement by filing electronic claims or sign on with an ADA-endorsed discount Internet service provider. ■

## Annual Session

### Pre-session ready to roll in Chicago Team Building, Tech Day Oct. 13

Last year after Team Building Conference IV, departing participants' comments included:

- "We gained a lot of good, applicable insight";

- "I found a lot of answers to a lot our practice's problems."

Success begets success.

For the fifth consecutive year at annual session, Team Building Conference V will show you how to create a motivating climate, minimize conflict, improve problem-solving ability and instill a "can do" spirit in your dental team.

Scheduled Oct. 13-14 from 8:30 a.m.-4:30 p.m. at McCormick Place, South Building, the popular two-day program includes lectures, interactive sessions, team discussion and lunch.

Annual session also offers for the third straight year the popular Technology Day III, which will demonstrate Oct. 13 from 8 a.m.-5 p.m. how you can integrate the latest developments in dental technology to improve patient care and your bottom line.

Located in the Vista Room at McCormick Place, South Building, this program will feature more than 30 courses designed for dentists, assistants, business assistants and hygienists.

For registration information about the 141st annual session, including scientific sessions, exhibits, Technology Day, Team Building Conference, hotel reservations, travel and child care, you have four convenient options:

- Visit ADA.org at "www.ada.org/session";
- See the Aug. 21 issue of ADA News;
- See the July issue of the Journal of the American Dental Association;
- Get an official Preview by calling 1-800-232-1432 or 1-312-440-2388; or by e-mailing your request to "annualsession@ada.org". ■

## Syllabus of Prosthetics for Osseointegrated Implants

By Douglas P. Clepper, DMD

**Plus** Prosthetic Notebook containing several Implant System catalogs updating prosthetic components.

This is the most popular implant prosthetic textbook in the country, with over 715 pages and 1,000 color illustrations. Includes treatment planning, case design, and "cookbook style" prosthetic technique and separate chapters for Paragon™, Brånemark®, Calcitek®, Steri-Oss®, 3i®, and BioHorizons®.

**Only \$188.00 + Shipping & Handling for book and notebook**

Contact: OMEGA PUBLICATIONS  
3553 Wheeler Road, Augusta, GA 30909

Order Toll Free: 1-800-521-8913 or call (706) 738-8070

Return for refund in 10 days if not completely satisfied.

## ADA Business Enterprises partners with Xerox Corp. Also learn what Trojan offers

New to ADA Business Enterprises, Inc., is an alliance with the Xerox Corp. which enables ADA members to save up to 35 percent off the purchase or lease price of Xerox products and services.

The alliance and availability of the products at a reduced price will launch at annual session in Chicago.

As an added bonus, a free copy of the Physicians Desk Reference Electronic Library on CD-ROM accompanies purchases from a product line specifically designed to meet the needs of a dental office—Xerox's Small Office/Home Office.

For more information customers can go to "www.ada.org/ecco" or call 1-800-ASK-XEROX, Ext. ADA, for personalized customer service.

Visit Xerox, Booth 4705 in the ADA Resource Center, at annual session to learn more about how to save money and increase produc-

tivity using these new ADA member benefits. **Trojan**

As the Internet changes the way the world does business, electronic health claims change the way dentists are reimbursed.

"I estimate that use of electronic transactions with all my insurance companies will save me \$200 per week," said Dr. Scott Trapp. "The big savings are in the staff time spent on the telephone and posting statements."

The ADA has actively encouraged ADA members to use electronic transactions. As one of its earliest ventures, the ADA Electronic Commerce Division endorsed Trojan Professional Services Inc. to provide software that allows dentists to file claims electronically.

Learn about saving time and money through Trojan by visiting "www.ada.org/ecco" or calling 1-800-451-9723. Or, visit Trojan Professional Services Inc., Booth 4914 in the ADA Resource Center, at annual session. ■





1. APPLY (twice)



2. CURE



3. BUILD

Presenting Touch&Bond™ ... Just one bottle and a pledget

# NO ETCHING. NO RINSING. NO PRIMING. NO MIXING.

## Effortless composite bonding. No post-op sensitivity.

Let's say you've finished prepping the tooth, so now you're ready to bond.

Using the special pledget that comes with the kit, simply apply Touch&Bond to the dentin and enamel surfaces you're bonding to. (By the way, the surfaces can be damp or dry.)

There's no acid-etching. No rinsing. No priming. No mixing. And there's no need to change soggy cotton rolls.

Let Touch&Bond sit on the tooth for 20 seconds. Then gently blow it with your air syringe for 3-5 seconds.

Use the same sponge to apply another coat. Dry it with your syringe immediately, and light cure for 10 seconds.

That's it. You're done. The tooth is now ready for composite build-up. The entire procedure takes maybe a minute.

### The secret in the sponges

Actually, we don't call them "sponges." "Pledget activators" sounds more impressive. And besides, they're not mere sponges. They're small polyurethane applica-

tors impregnated with a special co-initiator (sodium p-toluenesulfonate, 4-H<sub>2</sub>O.)

The instant the pledget touches the 4-META-based liquid, it triggers a complex penetration-and-polymerization reaction. The adhesive's 4-META molecules infiltrate the smear-layer left by your bur to grab the sound tooth structure below. Your curing light then completes polymerization.

The result is the kind of 4-META hybrid-layer bond and tooth-protecting biological seal that once required complex etching, rinsing and priming.

Frankly, advertisers spend way too much time touting results of their latest bond strength tests. Most researchers admit that nobody knows how these numbers relate to clinical performance. Nevertheless, for those of you who care, Touch&Bond does very well in the research lab with published microtensile bond strengths of 22.4 MPa (3250 psi) to dentin.<sup>1,2</sup>

More significant, is this fact: *In all clinical trials conducted on two continents, there wasn't a single case reported of post-op sensitivity. Not one.*

### Less than a buck per application

At \$96, the kit includes a bottle of Touch&Bond (about 175 drops) plus 175 pledgets in a nifty little plastic organizer that keeps everything together, ready for the next procedure.

Of course the precise cost-per-application will vary according to the size of your restoration. A large posterior composite may require a

full drop of Touch&Bond. On the other hand, if you're restoring a series of cervicals, a single drop and one pledget will probably handle two or three Class V's.

### And of course, there's Parkell's risk-free trial

Like all of Parkell's 4-META-based adhesives, Touch&Bond comes with a 3-month money-back trial. Simply pay within a month, and if you decide it's not what you're looking for, call us anytime during the trial. We'll have the remaining material picked up at our expense and we'll give you all your money back ... including the shipping charges.

1. Iishiya M. et al. Application of sealed restoration to root caries. *Journal of Japanese Adhesive Dentistry*. 17(4), 320 1999  
2. Nakaki Y. et al. Micro-shear bond strength of single step adhesives to bovine dentin. *Shikuzairo-KIKAI 19 (Special Issue 35)*. 73 2000

PRIORITY NO. 1532-D

ORDER TOLL-FREE USA & CANADA  
**1-800-243-7446**  
(Outside USA & Canada, 631-249-1134 • Fax: 631-249-1242)



E-Mail info@parkell.com • www.parkell.com

PRIORITY NO. 1532-D

Mail or fax coupon to:  
Parkell, Box 376  
Farmingdale, NY 11735  
Fax: 631-249-1242

Please send me a kit of Touch&Bond™ (S280AD) and bill me \$96 plus shipping. Includes Touch&Bond liquid (5.5ml) plus 175 activator pledgets.

Name \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_  
Zip \_\_\_\_\_ Telephone \_\_\_\_\_

U.S. Patent No. 6,071,983 and patents pending



# The ADA Resource Center is your information source

Learn about the ADA's latest programs and services in the ADA Resource Center—flanked by blue and green banners on the exhibit floor.

Formerly called the ADA Pavilion, the plaza of booths was renamed The ADA Resource Center to reflect its role as the one-stop shopping resource for the dental community.

**Booth 4703:** The ADA Business Enterprises Publishing division, which brings you the ADA News and The Journal of the American Dental Association, will feature these and other publications and products. The newly revised and expanded Second Edition of the ADA Guide to Dental Therapeutics, dentistry's most comprehensive drug reference, will be available at the ADA Store for the ADA member price of \$44.95. This authoritative guide is the profession's source for adverse effects, clinical considerations and interactions among dentist- and physician-prescribed drugs.

During annual session, the recently updated version of JADA CD-ROM is available for \$119. The CD-ROM, which includes all JADA articles published from 1990-98, may be purchased at the ADA Store located near the registration area or ordered at the booth.

**Booth 4704:** The ADA Health Foundation has recently been hailed as "one of the most positive forces in dentistry." As the charitable arm of the ADA, the ADAHF is the nation's leading charitable organization dedicated to enhancing clinical dentistry.

Receive news and updates on research conducted at the ADAHF Paffenbarger Research Center and the ADAHF Research Institute, Health Screening Program, the Harris Fund for Children's Dental Health and much more. Learn how you can make clinical dentistry better through the ADA Health Foundation.

**Booth 4705:** Xerox Corporation is offering

## Annual Session

ADA members 35 percent off the purchase or lease price of Xerox products and services. Visit their booth to learn more about how these new member benefits can save money and increase productivity.

**Booth 4706:** The ADA Membership Retirement Program helps you to save for the future. You'll learn how the right retirement plan can reduce your taxable income significantly and defer taxes on your contributions and any investment earnings until you retire. The program offers a wide array of investment options that allow you to diversify your retirement assets. The ADA Program charges you a fraction of what many other retirement programs charge for everything from enrollment to recordkeeping fees. Stop by for a free personal consultation.

**Booth 4708:** Great West Life and Annuity Insurance Company (underwriter and administrator of the ADA insurance plans), is giving away 50,000 pennies—\$500, to a winning ADA member during annual session. Stop by the Great-West Booth to learn more about the various ADA-sponsored member insurance plans. These plans include term life, universal life, income protection, office overhead expense and family hospital income.

Plan representatives will be available to discuss members' insurance needs and answer questions about the cost and scope of coverage offered. Great-West will also be collecting pennies, along with any other donations, for the National Foundation of Dentistry for the Handicapped in a specially marked "penny jar."

**Booth 4711:** Netopia, premier provider of custom Web sites and endorsed by ADA Business Enterprises, Inc., creates and customizes dental practice Web sites specifically designed for ADA members. Each day, Netopia will give away five Web sites. Stop by the booth and enter to win the daily drawing.

**Booth 4713:** WebMD/ENVOY representatives will demonstrate how dentists can make their practices run more efficiently and improve cash flow with new practice management software. Endorsed by ADA Business Enterprises, Inc., WebMD/Envoy is a leader in electronic claims that can provide you with cutting-edge information about online eligibility, electronic attachments and processing.

**Booth 4803:** The Learning Center will provide interactive demonstrations each day during annual session to help ADA members use ADA.org to its fullest potential and to introduce the redesigned Web site to the dental profession.

**Booth 4805:** The Dentist Well-Being Programs will offer Words of Wisdom or a Cup of Kindness or some information about some of the challenges dentists and their families can face. There are great pamphlets about stress management, family relationships, anxiety, depression, substance abuse and more. We've got local AA meeting schedules, too. Some friendly volunteers have signed on to help, so come on by and say "Hi!"

**Booth 4806:** The ADA Office of Student Affairs will display ADA resources available to students and new dentists, such as the very popular ADA InfoPaks—packaged libraries on 13 different "hot topics," from associateships to licensing to practice management. Look for publications such as Dental Licensure and the New Graduate,

Financial Planning Issues for Dental Students, ADA Lifeline and information for dentists in the Federal Dental Services and women dentists.

**Booth 4807:** The ADA Membership Resources Booth will offer free ADA key chains and information about the wide array of programs and services available to members of organized dentistry. You'll find dozens of helpful resources—from details on library services to the ADA's Calendar of National Dental Meetings.

In addition, ADA staff will be on hand to answer any questions you may have about benefits and provide details on how to make the most of your membership in organized dentistry. A directory of all ADA members will also be on hand so that you may verify your address and look up your colleagues.

**Booth 4811:** Citibank USA and Citimortgage Inc. will discuss credit card services, residential mortgages and home equity loans—all special offerings from the ADA 1 Plan. Stop by the booth to apply for the ADA Platinum Visa card.

**Booth 4814:** The ADA Electronic Commerce Marketplace, hosted by BATNET1, offers a safe and secure way to do online shopping with brand name retailers at special discounts to ADA members. Stop by the booth and find out how to make purchases through the Marketplace and sign up for the discounted Internet Service now available to ADA members.

**Booth 4905:** The ADA Library is conducting its first-ever ADA Library Dental History and Trivia Contest. Do you think you know a lot about dentistry and its past? Do you know G.V. Black from A.D. Black? Why is Pierre Fauchard so important to dentistry? Is that your final answer?

Well, now you have the chance to test your knowledge at annual session. There's also a children's edition for anyone 12 and under. All entries must be turned in by 4 p.m. Oct. 16, and answers and winners will be posted at the Library booth by 11 a.m. Oct. 17.

**Booth 4906:** The Survey Center offers reports that focus on all aspects of dentistry, from private dental practice, such as the Survey of Dental Practice, to all facets of dental education, such as the Survey of Predoctoral Dental Educational Institutions. Recent surveys delve into topics of current interest to dentists, including dental management service organizations, capitated and preferred provider organization dental plans, and legal provisions for delegating functions to dental team members.

**Booth 4907:** American Dental Political Action Committee and ADA Grassroots staff and volunteers will be on hand to provide information and answers about political involvement, ADPAC membership and the grassroots network.

**Booth 4914:** Trojan Professional Services Inc. representatives will explain how Trojan's software can assist dentists with filing electronic insurance claims. Additional information about their services and enrollment will also be available.

**Booth 5003:** The ADA Commission on Relief Fund Activities will be providing brochures and other written material on the charitable activities of the ADA Relief Fund and those of The ADA Endowment and Assistance Fund Inc. and ADA Emergency Fund Inc. Staff and commission members will be present to answer any questions members have regarding these agencies and their programs.

**Booth 5004:** The Council on Scientific Affairs will highlight safe and effective dental products that are part of the Seal of Acceptance Program. The backdrop of the booth will be a map of the convention floor with a guide to the booths of dental product manufacturers that participate in

**Enter.....**

Step into the digital office.

There is a good chance that your next client will want to visit your Web site before visiting your office. Make sure it's a professional, state-of-the-art place to be. The Internet delivers clients. Netopia delivers the Internet.

- Reach prospective clients
- Strengthen existing client relations
- Provide practice information
- Answer frequently asked questions
- Leverage existing marketing efforts
- Present a leading-edge image

Custom Web  
premium ser-

**Click.**  
<http://adaecco.netopia.com/ada/we>

**Call.**  
1-800-513-

**netopia**

**ADA**  
ELECTRONIC COMMERCE  
A Division of ADA Business Enterprises, Inc.





**Contrasts:** Chicago's parks and skylines join to create dramatic views around the city.

the Seal of Acceptance Program. The booth will have a hands-on display of the ADA's interactive Web-based Seal Program site with information on accepted Seal products.

For dentists, the booth will be stocked with useful laminated cards summarizing endocarditis and prosthetic joint prophylaxis recommendations, as well as booklets listing accepted over-the-counter dental products that can be copied for patients. Manufacturers can pick up packages of information that detail the steps involved in earning an ADA Seal and see how accepted product information is displayed on the ADA Web page.

**Booth 5005:** The ADA Council on Dental Practice provides many resources to help members develop their practices. Samples of all of the practice management publications, including the new books, Basic Training for New Dental Office Staff and Increasing Your Bottom Line with Effective Marketing, will be available for you to browse at your leisure. Receive a 10 percent discount on all salable publications and a 15-minute phone card with any order of \$100 or more. Stop by the booth and pick up free publications and directories for your office.

**Booth 5006:** The ADA Council on Dental Benefit Programs staff will be available to answer questions you may have about the ADA's Direct Reimbursement promotional campaign. If you are interested in learning more about the DR campaign, how your constituent society can get involved or for an update on available DR educational and promotional resources, just ask at the booth.

**Booth 5007:** ADA Salable Materials will have free samples of the latest and most popular patient education brochures. Stop by and check out the new practice management titles. Catalog sales staff will be on hand to answer any questions and take your orders. Order during annual session and receive 10 percent off member prices. Also, if you order \$100 or more during annual session you will receive a free 15-minute phone card.

**Booth 5011:** Matsco Companies—which specialize in practice financing for dentists through a consultative approach—will discuss practice financing options for ADA members, including practice acquisition and new practice financing, equipment leasing and commercial real estate, and business loan consolidation.

**Booth 5013:** Paymentech—the nation's third largest credit card processing provider—will have representatives on hand to explain low discount rates offered to ADA members for electronic payment transactions in the dental office.

**Booth 5767:** ADA Health Volunteers Overseas is a private voluntary organization dedicated to improving the quality of health care in developing countries through training and education. Dentistry Overseas, a division of HVO sponsored by the ADA, currently has programs in Bangladesh,

Brazil, Haiti, India, Jamaica, St. Lucia, Vietnam and Zimbabwe. Volunteer assignments range from one to four weeks and housing is usually provided.

Former volunteers and committee members will answer your questions and provide information about each site and how you can support Dentistry Overseas by becoming an HVO member.

**Booth 5768:** USA Section of the FDI World Dental Federation offers information about the FDI and future FDI meetings and sites. Representatives will answer questions about U.S. travel to FDI meetings and explain organization benefits for those interested in becoming FDI members.

**Booth 5769:** The Council on Access, Prevention and Interprofessional Relations is dedicated to broadening the scope of oral

health care within the health system, promoting preventive dentistry as a cornerstone of oral health care and advancing delivery to the public. Learn about CAPIR's relationship with other health care organizations, wide-ranging programs and other resources and services.

**Booth 5770:** The Dr. Samuel D. Harris National Museum of Dentistry celebrates the great heritage of dentistry, its present and its future. Find out about the museum's latest exhibitions—Watch your Mouth, Sports and Dentistry.

**Booth 5771:** The Alliance of the American Dental Association will offer information on the activities of dental Volunteers will be available each day during annual session to answer questions focusing on membership recruitment. ■


PUT THE PROOF IN YOUR PRACTICE

# Significant remineralization at 3 months and 6 months



NEW STUDY REVEALS<sup>1</sup>

Significant reversal of root caries



<sup>1</sup>PRCL = Primary Root Carious Lesions  
<sup>2</sup>Lesion hardness comparable in texture to surrounding healthy dentin

- Results at 3 months: 38.2% of patients had 1 or more carious lesions harden
- Even more impressive at 6 months: 56.9%

**Colgate**  
**PreviDent 5000 Plus**  
 (1.1% SODIUM FLUORIDE) Prescription Dental Cream  
 The only Rx dentifrice with clinical proof

Worldwide leader in oral care.



1-800-2-COLGATE



# Family feeling

## Incoming AADA president leads dental clans in health education

BY CLAYTON LUZ

Susan Martindale's notion of the dental family is quite encompassing.

"Well, there's the children in my dental family at home. That's my main dental family," she says, referring to her husband, Dan, their four daughters and one grandson. "Then there's my dental family whom I meet at dental health fairs around the country. Another dental family is my

husband's office staff. And, of course, my dental family through the friends I've made during my association with the Alliance."

Must be a big table setting for the holidays.

Since joining the Alliance of the American Dental Association 22 years ago as Dental Health Chair in Monticello, Miss., Mrs. Martindale has helped lead her dental families to promote dental health education among the general public, especially children, at all levels of her participation in dentistry.

She soon will realize the pinnacle of her association participation on Oct. 16 when she is installed as AADA's 46th president during its annual meeting, which will convene in Ballroom D at the Chicago Marriott downtown.

Considering her definition of dental family, Mrs. Martindale's presidency theme, "2000 and Beyond, Celebrating the Dental Family," makes sense. She believes the family, however you may define it, must be involved to "make dentistry the best profession it can be."

Key issues for the Alliance, says the president-elect, will include increasing membership through recruitment and retention, encouraging mentoring for membership development and a continuation of one of the profession's most respected and successful anti-spit tobacco campaigns.

According to Mrs. Martindale, the campaign, a joint effort with the Foundation for Dental Health Education, features an anti-tobacco message delivered by baseball hero Mark McGwire. A grand slam since its inception three years ago, to date the campaign has sold more than 3 million cards and 7,000 posters.

The message "hits close to home for me," says the president-elect. Sadly, Mrs. Martindale relates she recently lost her mother to an emphysema-related illness.

Her personal mission to promote dental education has led this recipient of a master's degree in special education from Mississippi State University through terms as president-elect,



**Susan Martindale:** 'We must ensure that our children have proper dental health care.'

vice president, comptroller (two terms), District 3 trustee, dental health chair (two terms) and as a student spouse chair. She also has served two terms as president in her home state of Mississippi.

Mrs. Martindale brings considerable legislative experience to her presidential post. Currently Mrs. Martindale serves on the American Cancer Society Mid-South Division Advocacy Committee. Her lobbying efforts include having lobbied in the Mississippi House and Senate for issues related to children and youth and stronger regulation for tobacco products. She has also lobbied for insurance coverage for all Mississippi children and senior adults.

"We're here to promote legislative issues," says Mrs. Martindale, now marking her 11th year of involvement with the AADA at the national level. "Also, we must ensure that our children have proper dental health care. Part of this involves working closely with the ADA to accomplish its own goals. We want to be involved in our community." ■

## Annual Session

### ADA Learning Center debuts

#### Want to know about ADA.org? This is the place

To help ADA members use ADA.org to its potential and to introduce the redesigned site to the dental profession, the Learning Center, located in Booth 4803 within the ADA Resource Center, will provide interactive demonstrations each day during annual session.

ADA and ADA Business Enterprises, Inc. staff will present demonstrations to familiarize ADA members with key areas of the site.

"For the first time, the ADA is bringing the Association and its resources together to educate members on what is available to them," said Dr. John S. Zapp, in describing Learning Center activities.

Demonstrations will begin at 9 a.m. each of the four days of session. Question-and-answer sessions will follow.

After attending a demonstration, participants may fill out an evaluation form and enter for a chance to win a new desktop computer, computer software, a leather computer bag, a digital camera or an H/P Jornada 420 personal digital assistant. Those visiting early in the day may receive an ADA.org T-shirt. Contest rules are available at Booth 4803. ■

## FDI lunch set for Oct. 16 in Chicago

The USA Section of the FDI World Dental Federation will convene its annual luncheon Oct. 16 at the Asian restaurant Vong, 6 W. Hubbard St., beginning at noon.

Dentists who attend the luncheon become eligible to win a door prize valued at more than \$450. The prize, which will be awarded at the luncheon, is one free dental registration for the winning dentist and accompanying person to the 2001 FDI World Dental Congress.

The luncheon will celebrate Malaysia, site of the 2001 FDI World Dental Congress, which will convene Sept. 27-Oct. 1 in Kuala Lumpur, the country's capital.

Vong's chef Jean-Georges Vongerichten has garnered industry acclaim for his intriguing blend of French technique and Far East flavors.

These menu delights await your palate: the Black Plate (crab spring rolls/prawn satay/lobster); Daikon rolls/tuna rolls/quail rubbed with Thai spices; warm asparagus salad; spiced halibut with curried artichokes; sorbet tasting.

Complimentary red and white wine, soft drinks, mineral water, teas and coffee will be available.

Tickets cost \$40 each and are available through the FDI/USA Section by calling the ADA's toll-free number, Ext. 2727.

Round-trip shuttle transportation will be provided between McCormick Place South and the restaurant. ■

## ADA Seal in spotlight

### Follow the giant map at session to find participating companies

Some of the 1,300 products bearing the ADA Seal of Acceptance will be on display at this year's annual session. Want to know where?

The ADA Resource Center will feature an enlarged roadmap of technical exhibits, and the map will highlight the location of every company participating in the Seal program.

- For dental products that meet ADA criteria for safety and effectiveness, check out the floor plan of the convention's technical exhibits at the Council on Scientific Affairs, Seal of Acceptance Program (Booth 5004 in the ADA Resource Center in McCormick Place South). The map will highlight Seal participants.

- The CSA booth also features the ADA Web site with information on the Seal program. CSA staff will answer questions on accepted products and the rigorous scientific review procedures required to obtain the seal.

- Manufacturers can pick up information packages about submitting their products for the Seal, and make an appointment to talk with CSA staff involved with the Seal program.



• New this year are laminated cards summarizing current ADA co-sponsored antibiotic prophylactic recommendations for preventing both bacterial endocarditis and prosthetic joint infections—in convenient table format for members to use in the operator.

- Members can also pick up patient-friendly lists of accepted dental products to photocopy and distribute to patients.

- Lists are available for dentifrices, toothbrushes, mouthrinses, dental floss, oral irrigators and whitening products. They are designed to respond to patient inquiries about which products to use. ■

#### PrevDent 5000 Plus® brand of 1.1% Sodium Fluoride prescription dental cream Rx only.

**DESCRIPTION:** Self-topical enamel fluoride dentifrice containing 1.1% (w/w) sodium fluoride for use as a dental cavity preventive in adults and pediatric patients.

**Active Ingredient:** Sodium Fluoride 1.1% (w/w).  
**Other Ingredients:** Purified Water, Sorbitol, Hydrated Silica, PEG-12, Tripotassium Pyrophosphate, Sodium Lauryl Sulfate, Mint Flavor (Spectrum flavor only), Xanthan Gum, Sodium Benzoate, Fruit Flavor (Fruitease™ flavor only), Sodium Saccharin, Titanium Dioxide (Fruitease™ flavor only), FD&C Blue #1 (Spectrum flavor only), D&C Red #33 (Fruitease™ flavor only).

**CLINICAL PHARMACOLOGY:** Frequent topical applications to the teeth with preparations having a relatively high fluoride content increase tooth resistance to acid dissolution and enhance penetration of the fluoride ion into tooth enamel.  
**INDICATIONS AND USAGE:** A dental cavity preventive, for once daily self-applied topical use. It is well established that 1.1% sodium fluoride is safe and extraordinarily effective as a cavity preventive when applied frequently with insulating applicators. PrevDent 5000 Plus brand of 1.1% sodium fluoride in a squeeze-tube is easily applied onto a toothbrush. This prescription dental cream should be used once daily in place of your regular toothpaste unless otherwise instructed by your dental professional. (See WARNINGS for exception.)

**CONTRAINDICATIONS:** Do not use in pediatric patients under age 6 years unless recommended by a dentist or physician.

**WARNINGS:** Prolonged daily excessive ingestion of fluoride may result in various degrees of dental fluorosis in pediatric patients under age 6 years, especially in the areas with high fluoride concentration in drinking water. Use in pediatric patients under age 6 years requires special supervision to prevent repeated swallowing of dental cream which could cause dental fluorosis. Read directions carefully before using. Keep out of reach of infants and children.

**PRECAUTIONS:**

**General:** Not for systemic treatment. DO NOT SWALLOW.  
**Carcinogenesis, Mutagenesis, Impairment of Fertility:** In a study conducted in rodents, no carcinogenesis was found in male and female mice and female rats treated with fluoride at dose levels ranging from 4.1 to 9.3 mg/kg of body weight. Equivocal evidence of carcinogenesis was reported in male rats treated with 2.5 and 4.1 mg/kg of body weight. In a second study, no carcinogenesis was observed in rats, males or females, treated with fluoride up to 11.3 mg/kg of body weight. Epidemiological data provide no credible evidence for an association between fluoride, either naturally occurring or added to drinking water and risk of human cancer.

Fluoride ion is not mutagenic in standard bacterial systems. It has been shown that fluoride ion has potential to induce chromosome aberrations in cultured human and rodent cells at doses much higher than those to which humans are exposed. *In vivo* data are conflicting. Some studies report chromosome damage in rodents, while other studies using similar protocols report negative results. Potential adverse reproductive effects of fluoride exposure in humans has not been adequately evaluated. Adverse effects on reproduction were reported for rats, mice, fox, and cattle exposed to 100 ppm or greater concentrations of fluoride in their diet or drinking water. Other studies conducted in rats demonstrated that lower concentrations of fluoride (5 mg/kg of body weight) did not result in impaired fertility and reproductive capabilities.

**Pregnancy:** Pregnancy Category B. It has been shown that fluoride crosses the placenta of rats, but only 0.01% of the amount administered is incorporated in fetal tissue. Animal studies (rats, mice, rabbits) have shown that fluoride is not a teratogen.

Maternal exposure to 12.2 mg fluoride/kg of body weight (rats) or 13.1 mg/kg of body weight (rabbits) did not affect the litter size or fetal weight and did not increase the frequency of skeletal or visceral malformations. There are no adequate and well-controlled studies in pregnant women. However, epidemiological studies conducted in areas with high levels of naturally fluoridated water showed no increase in birth defects. Heavy exposure to fluoride during in utero development may result in skeletal fluorosis which becomes evident in childhood.

**Nursing Mothers:** It is not known if fluoride is excreted in human milk. However, many drugs are excreted in milk, and caution should be exercised when products containing fluoride are administered to a nursing woman. Reduced milk production was reported in breast-feeding fox when the animals were fed a diet containing a high concentration of fluoride (95-137 mg/kg of body weight). No adverse effects on parturition, lactation, or offspring were seen in rats administered fluoride up to 5 mg/kg of body weight.

**Pediatric Use:** The use of PrevDent 5000 Plus in pediatric age groups 6 to 16 years as a cavity preventive is supported by pioneering clinical studies with 1.1% sodium fluoride gels in mouth trays in students age 11-14 years conducted by Englander, et al.<sup>1,2</sup> Safety and effectiveness in pediatric patients below the age of 6 years have not been established. Please refer to the CONTRAINDICATIONS and WARNINGS sections.

**ADVERSE REACTIONS:** Allergic reactions and other idiosyncrasies have been rarely reported.

**OVERDOSSAGE:** Accidental ingestion of large amounts of fluoride may result in acute burning in the mouth and sore tongue, nausea, vomiting, and diarrhea. If it occurs soon after ingestion (within 30 minutes) and is accompanied by salivation, hematemesis, and epigastric cramping abdominal pain. These symptoms may persist for 24 hours. If less than 5 mg fluoride/kg body weight (i.e., less than 2.3 mg fluoride/kg body weight) have been ingested, give calcium (e.g., milk) orally to reduce gastrointestinal symptoms and observe for a few hours. If more than 5 mg fluoride/kg body weight (i.e., more than 2.3 mg fluoride/kg body weight) have been ingested, induce vomiting, give orally soluble calcium (e.g., milk, 5% calcium gluconate or calcium lactate solution) and immediately seek medical assistance. For accidental ingestion of more than 15 mg fluoride/kg of body weight (i.e., more than 6.9 mg fluoride/kg body weight), induce vomiting and admit immediately to a hospital facility.

A treatment dose (a thin ribbon) of PrevDent 5000 Plus® contains 2.5 mg fluoride. A 1.8 oz. tube contains 255 mg fluoride.

**DOSE AND ADMINISTRATION:** Follow these instructions unless otherwise instructed by your dental professional: 1. Adults and pediatric patients 6 years of age or older, apply a thin ribbon of PrevDent 5000 Plus to a toothbrush. Brush thoroughly once daily for two minutes, preferably at bedtime. 2. After use, adults expectorate. For best results, do not eat, drink, or rinse for 30 minutes. Pediatric patients, age 6-16, expectorate after use and rinse mouth thoroughly.

**HOW SUPPLIED:**

Spectrum	Fruitease
1.8 oz. (51g) net wt. tubes	NDC# 0126-0287-66
Tube Pack (two 1.8 oz. (51g) net wt. tubes)	NDC# 0126-0287-33

**STORAGE:** Store at Controlled Room Temperature, 20-25°C (68-77°F).

**REFERENCES:** 1. Accepted Dental Therapeutics, Ed. 40, ADA, Chicago, P-405-407, 1984. 2. Englander HC, Keys et al. JADA 75:618-644, 1967. 3. Englander HC, et al. JADA 78:703-707, 1968. 4. Englander HC, et al. JADA 83:354-358, 1971.

Fruitease is a licensed trademark of National Fruit Products Co., Inc.

Reference: 1. Data on file, Colgate Oral Pharmaceuticals.





Are you practicing your 21st century skills with a 19th century device?  
Inject yourself into the 21st century!



Introducing the newly enhanced  
**Wand<sup>®</sup> Plus**



**Advanced technology for improved efficiency and better patient care**

- Build your practice with procedural efficiencies and referrals
- Reduce operator and patient stress and anxiety
- Proven in practice. OVER 5.0 MILLION INJECTIONS GIVEN
- Often perform more dentistry in the same visit using fewer injections and less anesthetic
- Anesthetize multiple teeth from single, very comfortable, newly defined palatal injections without numbing lips and face (AMSA<sup>®</sup>, P-ASA<sup>®</sup>)
- Modified PDL injections so comfortable & effective they can often be used as the primary injection
- Can be used for all injections on all patients
- **Technology that takes you beyond what you can do with a syringe!**

1. The AMSA injection: A new concept for local anesthesia of maxillary teeth using a computer-controlled injection system; Friedman, Mark J., DDS; Hochman, Mark N., DDS; *Quintessence Int.* 1998;29:297-303.  
2. P-ASA Block Injection: A New Palatal Technique to Anesthetize Maxillary Anterior Teeth; Friedman, Mark J., DDS; Hochman, Mark N., DDS; *Journal of Esthetic Dentistry*, Vol. 11, Number 3.

Dr. Hochman is a clinical consultant to Milestone Scientific.

**New WAND Plus enhancements:**

- NEW "Cruise Control" locks in the flow rate
- NEW Audible tones indicate volume of anesthetic delivered
- NEW optional voice prompts and sound tones ("beeps") to select from
- Standard premium foot control

**Experience The WAND for yourself!**

*Ask about our 90-day trial offer!*


**Order one today!**

**Call 1-800-862-1125.**

**MILESTONE**  
SCIENTIFIC

Dental Division,  
Deerfield, IL 60015  
Visit our Web site: [www.thewand.com](http://www.thewand.com)  
E-mail: [milestone@milesci.com](mailto:milestone@milesci.com)

© Milestone Scientific 2000. All Rights Reserved



The WAND is accepted as a device that has been shown to safely and effectively deliver anesthetic solution when used by an appropriately qualified professional. Council on Scientific Affairs, American Dental Association.



Editorial Excerpts: Dr. Lawrence H. Meskin

# Words of wisdom

Since he was named JADA editor in October 1990, Dr. Lawrence H. Meskin has penned roughly 120 editorials—with about another dozen to go before he steps down as editor at the end of next year.

What follows are excerpts of his observations on a wide range of topics published over the last decade.

## Scope of dental practice

Dentistry's mandate as a health profession is to advance the public's oral health status. As the sole purveyors of dental care, dentistry has the obligation to continually seek new knowledge that will enhance its mission. If offering medical tests previously in the domain of other health professionals assists in accomplishing this goal, then arguments against such procedures are spurious.

*"Expanding the scope of dental practice"*  
March 1992

## Reporting cases of abuse

Dentists, as the first and perhaps only health service contact for many of the abused, often represent the sole opportunity for abused individuals to escape the cycle of violence. Because a large proportion of abusive injuries occur in body regions open to direct observations, dentists should ensure that they are competent to recognize the most subtle signs of abuse.

*"If not us, then who?"*  
January 1994



## Dental benefits

The marketplace should remain the arena for ultimate decision making. Let all payment methods be judged against each other. Examine and compare cost, quality and provider remuneration. But before the assessment begins, all participants must agree that the primary standard for judgment must be the placement of patient welfare ahead of any other consideration.

*"To dream the impossible dream ..."*  
November 1996

## Quality of care

Unfortunately, the concept of quality does not lend itself to simple measures. The variables that affect quality of health are numerous and often obscure. Anyone attempting to measure quality of health care must be aware that this is a highly

complex venture not amenable to "shake-and-bake" solutions.

*"A gentle touch is not enough"*  
February 1998

## Patient protection

Eventually, some form of legislation will pass—that's a given. Additional legislative actions will follow and will continue until patient rights are fully acknowledged and protected. The American Dental Association—its Washington Office and its grassroots supporters—should take pride in bringing this issue to national prominence. Others, far better positioned, were unwilling to do so.

*"I think I can ... I thought I could"*  
April 1998

## Unsupervised hygiene practice

Those pursuing this course should remember that oral health care is not elective health care. It is an integral component of health care and must be viewed in that dimension. Just consider the emerging relationships between oral infection, low birth weight and cardiovascular disease. Show me the training that qualifies the nondentists to manage these conditions.

*"Who's in charge? You are"*  
August 1998

## Continuing competency

Few issues in dental practice are so contentious. Most dentists face only one competency assessment in their entire professional lives:

their entry licensing exam. That, most dentists would agree, is the way it should be, offering as evidence the extremely small percentage of dentists (1 to 3 percent) who actually face some form of punitive action for practice violations.

*"Pew!"*  
January 1999

## Cost of education

This is not just an educator's issue. Practitioners also have a vested interest. Without the understanding and input of the practicing profession, the issue of dental school financing will languish. Collective solutions need to be advanced and supported. Action starts with knowledge.

*"A debt service"*  
April 1999

## Conflicts of interest in publishing

Peer review itself offers no defense against undisclosed conflicts of interest. The review process also is vulnerable to the accuracy of the submitted data. Omissions or distortions, either by accident or purposeful, are almost impossible to detect. Ultimately, it will be the patients who suffer if practitioners do not have all the facts necessary to make a best judgment of a product's true effectiveness.

*"Foxes in the hen house"*  
May 1999

## The 21st century

With a new millennium approaching, dentistry is positioned between what was and what will be. We can anticipate a future that will be even better than the past. I am confident that, with a past so superb, the profession of dentistry and the public it serves will witness a 21st century of even greater progress.

*"Great expectations"*  
December 1999

## Retirement

For many dentists who have made dentistry the total focus of their lives, the prospect of closing the office door for the last time fills them with trepidation, even if they're financially secure. Imagine the retirement anxiety of those dentists whose finances are insufficient. Some dentists may even be pushed to practice long after their physical abilities have been compromised.

*"Ready or not"*  
March 2000

## Teaching

The opportunities and benefits of an academic career should have greater appeal. Far more than 20 recent grads should be interested in sharing knowledge, influencing students, savoring the joys of satisfying their intellectual curiosity through research, having the opportunity to travel, and meeting and collaborating with colleagues throughout the world.

*"Those who can, do"*  
April 2000

3 days...

23 credit hours...

71 speakers...

Serious C.E.

**SOUTHWEST™**  
Dental Conference  
at Dallas  
*Knowledge in the Age of Information*

February 1-3, 2001  
Dallas Convention Center  
Dallas, Texas

FOR MORE INFORMATION  
CALL TOLL-FREE

866-THE-SWDC  
(866-843-7932)

OR

972-386-5741

REGISTER ON-LINE AT  
[www.swdentalconf.org](http://www.swdentalconf.org)

Sponsored by Dallas County Dental Society



# Dr. Meskin

*Continued from page one*

receive the news of his departure.

Dr. Meskin will step down as editor of dentistry's flagship professional journal on Dec. 31, 2001, leaving ample time for a farewell party or two.

"I guess that makes me a lame duck," he said, a bit downcast after going public with his decision at a Sept. 11 meeting of the Board of Directors, ADA Business Enterprises, Inc., the ADA subsidiary that includes the publishing division.

The Journal editor seemed heartened by a gentle reminder that more than a dozen issues of JADA must be put to bed before he's allowed to leave, though the search for a successor has already commenced. More about that soon.

In a report to the ADABEI Board, Publisher Laura A. Kosden credited Dr. Meskin with updating a journal that some would argue once fit Mark Twain's definition of a classic: a book often praised but rarely read.

"Within a decade," she wrote, "Dr. Meskin has repositioned JADA as a publication that speaks directly to the needs of the dental clinician, offering practical information that dentists can use to improve patient care. As a result, JADA's appeal with readers has never been higher in its 87-year history."

Latest readership scores confirm that

**■ "I'm a big advocate of term limits. I think 10 years is a good amount of time to achieve certain goals, and now it's time to give someone else a chance."**

fact. PERQ/HCI Corp., an independent research firm that conducts a yearly survey of dental publications, found that JADA has entered the 21st century as dentistry's best-read, peer-reviewed journal. JADA trails the industry-leading ADA News by just one percentage point and is a full 10 points ahead of its nearest competitor.

But the most stunning news from the survey is JADA's standing with newer dentists—those in practice 15 years or less—who say they prize it above all others, including the ADA News. It's this achievement that Dr. Meskin counts as his most satisfying.


"They're the future," he said of new dentists. "Of course, all of our readers are important to us, but the fact that young dentists are interested in The Journal is very rewarding."

So with all this success and no end in sight, why leave? And why now?

"I'm a big advocate of term limits," said Dr. Meskin. "I've never done any one thing this long. I think 10 years is a good amount of time to achieve certain goals, and now it's time to give someone else a chance. JADA will benefit from some new thoughts and ideas."

Though formal by today's MTV standards (he routinely shows up on Casual Friday's in jacket and tie), Larry Meskin insists that people call him Larry, despite the string of initials behind his name.

*See DR. MESKIN, page 42*



**Honored:** Dr. Meskin accepts the 1998 Thomas Jefferson Award from James Shore, M.D., chancellor of the University of Colorado Health Sciences Center. The departing JADA editor serves as director of the Colorado dental school's continuing education program. The Jefferson Award is the university's highest honor.

**FROM MERCK  
FOR THE TREATMENT OF  
BOTH ACUTE PAIN IN ADULTS  
AND OSTEOARTHRITIS  
AN AGENT THAT INHIBITS  
ONLY COX-2**

ONCE DAILY  
**VIOXX**<sup>®</sup>  
(rofecoxib)

**ONCE-DAILY  
POWER**

**STRENGTH.  
SAFETY.  
QD SIMPLICITY.**

**LEARN ABOUT VIOXX  
AT COLLAGENEX  
PHARMACEUTICALS  
BOOTH #5726 AT  
ADA 2000 IN CHICAGO**

**FOR BOTH ACUTE PAIN IN ADULTS  
AND OSTEOARTHRITIS**

VIOXX is contraindicated in patients with known hypersensitivity to rofecoxib or any other component of VIOXX. VIOXX should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.

The management of acute pain beyond five days has not been studied; acute-pain studies were designed to last up to five days.

Common adverse events included upper respiratory infection (8.5%), diarrhea (6.5%), nausea (5.2%), and hypertension (3.5%).

Serious gastrointestinal (GI) toxicity can occur with or without warning symptoms with NSAIDs.

No sulfonamide contraindication.

**STUDIED IN POSTOPERATIVE DENTAL PAIN**

Please read Brief Summary of Prescribing Information on adjacent page.

[www.vioxx.com](http://www.vioxx.com)

© 2000 Merck & Co., Inc. All rights reserved. 005716(2)(805)-VIO



# Dr. Meskin

Continued from page 41

He earned his dental degree from the University of Detroit in 1961. From there, he moved to the University of Minnesota where he picked up three more degrees: master of science in oral pathology, master of public health, doctorate in epidemiology.

In 1981, he, wife, Estelle; and their two children headed for Denver and the University of Colorado School of Dentistry where Dr. Meskin served as dean through 1987.

He's been there ever since, occupying a number of different staff positions, including vice president for academic affairs and research. Today, he directs the dental school's continuing education program and is a professor in the med-



**On the town:** Dr. Meskin and his wife, Estelle, at a recent dinner with the Board of Trustees. The couple has two grown children: Scott, 37, a physician; and Sarah, 34, an architect.

## VIOXX® (rofecoxib tablets and oral suspension)

**INDICATIONS AND USAGE:** VIOXX is indicated for relief of the signs and symptoms of osteoarthritis (OA); management of acute pain in adults; treatment of primary dysmenorrhea.

**CONTRAINDICATIONS:** VIOXX is contraindicated in patients with known hypersensitivity to rofecoxib or any other component of VIOXX.

VIOXX should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Severe, rarely fatal, anaphylactoid reactions to NSAIDs have been reported in such patients (see WARNINGS, Anaphylactoid Reactions and PRECAUTIONS, Preexisting Asthma).

**WARNINGS:** Gastrointestinal (GI) Effects—Risk of GI ulceration, bleeding, and perforation: Serious GI toxicity, such as bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, can occur at any time with or without warning symptoms. In patients treated with NSAIDs, minor upper GI problems, such as dyspepsia, are common and may also occur at any time during NSAID therapy. Therefore, physicians and patients should remain alert for ulceration and bleeding, even in the absence of previous GI tract symptoms. Patients should be informed about the signs and/or symptoms of serious GI toxicity and the steps to take if they occur. The ability of periodic laboratory monitoring has not been demonstrated, nor has it been adequately assessed. Only in 5 patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. It has been demonstrated that upper GI ulcers, gross bleeding, or perforation caused by NSAIDs, appear to occur in approximately 1% of patients treated for 3-6 months, and in about 2%-4% of patients treated for 1 year. These trends continue throughout the treatment of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.

It is unclear, at the present time, how the above rates apply to VIOXX. Among 3,527 patients who received VIOXX in controlled clinical trials of 6 weeks to 1 year in duration (most were enrolled in 6-month or longer studies) at a daily dose of 12.5 mg (50 mg oral, a total of 4 patients experienced a serious upper GI event, using protocol-derived criteria. Two patients experienced an upper GI bleed within 3 months (at Days 62 and 97, respectively) (0.08%). One additional patient experienced an obstruction within 6 months (Day 130) and the remaining patient developed an upper GI bleed within 12 months (Day 322) (0.12%). Approximately 23% of these 3,527 patients were in studies that required them to be alert for GI toxicity. It is unclear if this study population is representative of the general population. Prospective, long-term studies are required to compare the incidence of serious, clinically significant upper GI adverse events in patients taking VIOXX vs. comparator NSAID products. However, not been performed.

NSAIDs should be prescribed with extreme caution in patients with a prior history of ulcer disease or GI bleeding. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.

Studies have shown that patients with a prior history of peptic ulcer disease and/or GI bleeding and who use NSAIDs, have a greater than 10-fold higher risk for developing a GI bleed than patients with neither of these risk factors. In addition to a past history of ulcer disease, pharmacokinetic studies have identified several other factors that increase the risk for developing a GI bleed for NSAIDs, such as: treatment with oral corticosteroids; treatment with anticoagulants; longer duration of NSAID therapy; smoking; alcoholism; older age; and poor general health status.

**Anaphylactoid Reactions:** As with NSAIDs in general, anaphylactoid reactions have occurred in patients without known prior exposure to VIOXX. In postmarketing experience, rare cases of anaphylactoid reactions and angioedema have been reported in patients receiving VIOXX. VIOXX should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS, Preexisting Asthma). Emergency help should be sought in cases where an anaphylactoid reaction occurs.

**Adverse Renal Disease:** No safety information is available regarding the use of VIOXX in patients with advanced kidney disease. Therefore, treatment with VIOXX is not recommended in these patients. If VIOXX therapy must be initiated, close monitoring of the patient's kidney function is advisable (see PRECAUTIONS, Renal Effects).

**Pregnancy:** In late pregnancy, VIOXX should be avoided because it may cause premature closure of the ductus arteriosus.

**PRECAUTIONS:** General: VIOXX cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.

The pharmacologic activity of VIOXX in reducing inflammation, and possibly fever, may diminish the utility of these diagnostic signs in detecting infectious complications of presumed rheumatoid, painful conditions.

**Hepatic Effects:** Borderline elevations of 1 or more liver tests may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST (3 or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. These laboratory abnormalities may regress, may remain unchanged, or may be transient with continuing therapy. Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis, and hepatic failure (some with fatal outcome) have been reported with NSAIDs. In controlled clinical trials of VIOXX, the incidence of borderline elevations of liver tests at doses of 12.5 mg and 25 mg daily was comparable to the incidence observed with ibuprofen and lower than that observed with diclofenac. In placebo-controlled trials, approximately 0.5% of patients taking rofecoxib (12.5 mg or 25 mg q.d.) and 0.1% of patients taking placebo had notable elevations of ALT or AST.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with VIOXX. Use of VIOXX is not recommended in patients with moderate or severe hepatic insufficiency. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), VIOXX should be discontinued.

**Renal Effects:** Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and angiotensin-converting enzyme (ACE) inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. Clinical trials with VIOXX at daily doses of 12.5 mg and 25 mg have shown renal effects (e.g., hypotension, azotemia) similar to those observed with comparator NSAIDs; these occur with an increased frequency with chronic use of VIOXX at doses above the 12.5 mg to 25 mg range (see ADVERSE REACTIONS). Caution should be used when initiating therapy with VIOXX in patients with considerable dehydration. It is advisable to rehydrate patients first and then start therapy with VIOXX. Caution is also recommended in patients with preexisting kidney disease (see WARNINGS, Advanced Renal Disease).

**Hematologic Effects:** Anemia is sometimes seen in patients receiving VIOXX. In placebo-controlled trials, there were no significant differences observed between VIOXX and placebo in clinical reports of anemia. Patients on long-term treatment with VIOXX should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia or blood loss. VIOXX does not generally affect platelet counts, prothrombin time, or partial thromboplastin time, and does not inhibit platelet aggregation at indicated dosages.

**Fluid Retention and Edema:** Fluid retention and edema have been observed in some patients taking VIOXX (rofecoxib tablets and oral suspension) (see ADVERSE REACTIONS). VIOXX should be used with caution and should be discontinued at the lowest recommended dose in patients with fluid retention, hypotension, or heart failure.

**Preexisting Asthma:** Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal. Since cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, VIOXX should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.

**Information for Patients:** VIOXX can cause discomfort and, rarely, more serious side effects, such as GI bleeding, which may result in hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should seek medical advice when observing any indicative signs or symptoms. Patients should be advised of the importance of this follow-up (see WARNINGS, Gastrointestinal (GI) Effects—Risk of GI Ulceration, Bleeding, and Perforation).

Patients should promptly report signs or symptoms of GI ulceration or bleeding, such as: black, tarry stools; unexplained weight gain, or edema to their physicians.

Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, anorexia, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.

Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction (see WARNINGS).

In late pregnancy, VIOXX should be avoided because it may cause premature closure of the ductus arteriosus.

**Laboratory Tests:** Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding.

**Drug Interactions:** ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. In patients with moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mmHg compared to ACE inhibitor alone. This interaction should be given consideration in patients taking VIOXX concurrently with ACE inhibitors. Aspirin: Concurrent administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone. At steady state, VIOXX 50 mg once daily had no effect on the anticoagulant activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB<sub>2</sub> generation in fasting blood. VIOXX in a 2 x 2 factorial trial superior for cardiovascular morbidity. Cardiovascular: Concomitant use with high doses of warfarin (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as well as pharmacokinetic observations, have shown that NSAIDs can reduce the analgesic effect of fluorocaine and triacetin in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. Acetaminophen: Rofecoxib 400 mg daily did not have any clinically significant effect on the pharmacokinetics of acetaminophen. Cyclosporin: Cyclosporin with high doses of rofecoxib (80 mg twice daily) increased the Coombs of rofecoxib by 21%, the AUC<sub>0-24h</sub> by 33%, and the t<sub>1/2</sub> by 15%. These small changes are not clinically significant and no dose adjustment is necessary. Digoxin: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5-mg oral dose. Fluorocaine: Clinical studies, as



## Come and Explore

Your American Dental Association  
at the Annual Session!

# THE 2000

Your one-stop resource  
at the 2000 Annual Session,  
brought to you by the  
ADA.

Everything Dental . . .

Virtually!

The ADA Pavilion located on Aisle 4700-5000 is an exciting, user-friendly plaza of booths providing helpful information about the ADA, its affiliated agencies, and their products and services.

Visit ADA staff, the ADA Learning Center and learn how to access critical information on ADA.org<sup>SM</sup>.

The ADA Catalog booth will have the latest patient education

and practice management materials available to order at 10% off already low member prices!

Learn about the latest programs and strategies, and about our valuable member services. Don't miss this

ADA Headquarters Open House,  
Friday, October 13 through Monday October  
16 from 2:00-4:00 p.m. each day

chance to become

better acquainted with the ADA's many programs and services that will help keep organized dentistry prospering through the next millennium.

Don't forget while in Chicago for Annual Session you will have an opportunity to attend the Association's Open House for a behind-the-scenes look at the activities your dues support.

- Visit the newly renovated laboratories in the Division of Science
- Browse the shelves of one of the world's largest dental libraries, the ADA library
- Stop by the ADA Call Center, which receives more than 30,000 call each month from members and the public.

Tour guides will provide brief highlights of divisional activities and answer your questions about ADA programs and services.

Invitations are recommended to attend the open house. You may pick up your free invitations during exhibit hours at the ADA Membership Resource booth (no.4807) located in the ADA Pavilion. On Friday, October 13, invitations will be available at the session registration area in McCormick Place, South building.

### The ADA Store

In a world-class shopping city like Chicago, we can't forget to include the ADA Store. Stop by, just steps from the convention floor in McCormick Place, and find a wide array of one-of-a-kind items such as ADA apparel and scrubs, dental themed jewelry and all sorts of unique gift items you can't find anywhere else!

**ADA**<sup>®</sup>



# Assembly Inspired.

Easier Loading. Greater Compliance.

Now changing interdental brush refills is a snap... with Proxabrush® Snap-Ons, from Butler GUM®.

- ▶ Snap-Ons **load directly** from their dispenser—no fumbling with refill packaging or threading a tiny wire through a tiny hole.
- ▶ **More comfortable handle** with soft grip, for better control.
- ▶ **More sanitary** - because the brush is never touched while loading.
- ▶ **Airborne bacteria** in the bathroom, not to mention bacteria in the mouth, can contaminate a brush. Proxabrush® Snap-Ons bristles are coated with an anti-bacterial ingredient, to keep them cleaner for up to two weeks of normal use.\*

Proxabrush®  
Interdental Brush  
Snap-Ons



HEALTHY GUMS. HEALTHY LIFE.™

\* Antiseptic coating of chlorhexidine does NOT deliver chlorhexidine into the mouth. Proxabrush® Snap-Ons are NOT a delivery system for chlorhexidine.

©2008 John O. Butler Company, A Sunstar Company. P00079